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An astonishing number of patients are admitted to hospitals in the United States 
each year with musculoskeletal injuries. Of the 6.3 million fractures that occur annually 
in the U.S., approximately 1 million result in more complicated skeletal defects that 
require additional intervention to achieve normal healing [1]. Skeletal autografts and 
allografts remain the current gold standard for treating large bone defects, with over 
500,000 being performed in the United States annually at a cost of $2.5 billion/year to the 
medical system [2]. However, bone grafting techniques suffer from a number of 
limitations, including low tissue availability, donor site morbidity, insufficient 
engraftment, and host immune rejection – all of which contribute to the need for multiple 
revision surgeries in as many as 15% of bone grafting procedures annually [1].  
The discovery and pharmaceutical production of osteogenic proteins such as bone 
morphogenetic protein-2 (BMP-2) has revolutionized the treatment of large bone defects 
by providing a means to stimulate endogenous repair mechanisms to regenerate damaged 
bone [3-5]. Despite the promise of this approach, clinical approval for BMP-2 treatment 
using a collagen sponge delivery vehicle has thus far been limited to a few select 
applications. Furthermore, the widespread off-label use of BMP-2 coupled with poor 
dose control in the clinic has contributed to an increase in adverse events, eventually 
leading to a number of lawsuits being filed again Medtronic for its INFUSE® BMP-2 
delivery vehicle between 2006-2012. The side effects associated with BMP-2 have been 
attributed to both the suprahysiological BMP-2 doses required to initiate healing (≥0.2 
mg BMP-2/kg body weight) [6] and use of a collagen sponge delivery vehicle that 
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demonstrates low affinity for BMP-2. Thus, there is a clear need to develop biomaterials 
to improve the efficacy of BMP-2 delivery while minimizing the negative side effects 
associated with rapid growth factor release. 
The goal of this work was to address the shortcomings of current growth factor 
treatment strategies for large bone defects by creating a versatile biomaterial delivery 
vehicle that could (1) improve current delivery strategies for clinical BMP-2 treatment, 
and (2) integrate novel approaches for the delivery of multiple growth factors for better 
targeting bone repair. We harnessed the high growth factor binding capacity of the 
glycosaminoglycan heparin to fabricate an affinity-based biomaterial delivery vehicle 
capable of accomplishing both aspects of this goal.  
First, we developed a method to fabricate pure heparin microparticles from a 
modified cross-linkable heparin species and demonstrated the ability of these 
microparticles to retain bioactive BMP-2 (Chapter 3). Following in vitro success, we 
incorporated these microparticles into a previously characterized tissue engineering 
construct consisting of an RGD-functionalized alginate hydrogel and polycaprolactone 
nanofiber mesh tube for investigation of both ectopic mineralization and orthotopic bone 
healing at low BMP-2 doses (Chapter 4). We next developed a computational model to 
provide insight into the effect of heparin microparticles on BMP-2 release in vivo and 
help inform future experiments in the femoral defect model (Chapter 5). Taken together, 
this work revealed that the high affinity of heparin microparticles for BMP-2 resulted in 
attenuated BMP-2 release in vivo, resulting in reduced bone formation in the femoral 
defect when low BMP-2 doses were used.  
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Consequently, in Chapters 6 and 7, we shifted our focus to evaluating heparin 
microparticles for high dose BMP-2 delivery, as a method to improve spatial localization 
of bone formation at clinical BMP-2 doses. We demonstrated that, when high doses of 
BMP-2 were delivered in vivo using heparin microparticles mixed into the alginate 
hydrogel, bone formation could be better localized within the defect space and the 
incidence of heterotopic bone could be reduced (Chapter 6). However, when we 
incorporated empty heparin microparticles into the PCL nanofiber mesh as a barrier to 
BMP-2 diffusion, we found that this method was ineffective for reducing heterotopic 
bone formation (Chapter 7). This led to further in vitro investigation into the effects of 
competitive binding of serum components on BMP-2-heparin interactions.  
Finally, we conducted a series of experiments to evaluate the efficacy of heparin 
microparticles as a biomaterial vehicle to sequester and deliver multiple proteins from a 
complex solution (Chapter 8). Since previous studies have demonstrated that embryonic 
stem cell conditioned media contain a variety of potent biomolecules capable of 
influencing cell fate [7, 8], we investigated the in vitro delivery of stem cell morphogens 
as a first step in developing morphogen-laden microparticles as a novel approach to tissue 
regeneration. The promising effects observed on cell growth and differentiation 
suggested that the delivery of stem cell morphogens could one day be explored as an 
alternative method for tissue regeneration. Overall, the studies completed within this 
thesis broadened current understanding of bone tissue engineering, affinity-based 
biomaterials, and stem cell-based therapeutics, and provided valuable information that 








Musculoskeletal injuries resulting in significant bone loss affect thousands of 
people each year. Given the limited success of current bone grafting treatments, the 
delivery of osteoinductive growth factors, such as bone morphogenetic protein-2 (BMP-
2), offers a promising means of stimulating endogenous repair mechanisms to heal 
injured bone. However, clinical application of growth factor therapy is hindered by the 
lack of adequate biomaterial delivery vehicles to provide the sustained growth factor 
presentation necessary to induce repair. Current growth factor delivery approaches using 
a collagen sponge scaffold often rely on supraphysiological concentrations of BMP-2 
(≥0.2 mg BMP-2/kg body weight) [6] to stimulate bone healing. Such high 
concentrations of a single growth factor do not recapitulate the natural bone healing 
cascade, and, when rapidly released from the defect site, can result in excessive 
inflammation and heterotopic ossification [9]. Thus, there is a clear need to develop 
biomaterials to improve the efficacy of growth factor delivery while minimizing the 
negative side effects associated with rapid growth factor release. 
Affinity-based growth factor delivery systems have demonstrated promise in a 
number of tissue regeneration applications due to their tunable ability to noncovalently 
immobilize and present proteins of interest [1, 10, 11]. Glycosaminoglycans (GAGs), 
such as heparin, have a natural binding capacity for a number of growth factors 
influential in tissue development and repair and can be incorporated into a variety of 
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biomaterial scaffolds to create affinity-based delivery vehicles. Growth factor binding to 
heparin is mediated by reversible electrostatic interactions, resulting in promiscuous 
protein binding that can be harnessed for the delivery of single or multiple growth 
factors, including biological cues to initiate and resolve the stages of bone healing. 
Consequently, heparin-based delivery systems can be utilized for both (1) improving 
current delivery strategies for clinical BMP-2 treatment, and (2) developing novel 
approaches for the delivery of multiple growth factors for better targeting bone repair.  
The therapeutic delivery of combinations of growth factors may improve tissue 
regeneration outcomes by providing several, specific biological cues to endogenous cell 
populations at different stages of repair. Therefore, the second major focus of this project 
was to evaluate the efficacy of pluripotent stem cell morphogens as a source of potent 
growth factors for tissue regeneration. Pluripotent stem cells (PSCs) secrete many 
heparin-binding growth factors during differentiation, which have been implicated in 
tissue regeneration following stem cell transplantation and may provide essential 
biological cues [11]. Thus, heparin-based delivery systems could also be used to 
concentrate and deliver PSC-derived morphogens to tissue injury sites, thereby 
overcoming challenges associated with stem cell transplantation, such as low cell 
engraftment, immune rejection, and tumorigenicity. 
Ultimately, the long term goal of this work is to engineer affinity-based strategies 
to improve single and multiple growth factor delivery for bone repair. The overall 
objective of this project was to develop heparin-based microparticles for the enhanced 
delivery and presentation of growth factors to regenerate and spatially localize bone in a 
critically sized femoral defect. The central hypothesis of this project was that growth 
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factor-loaded heparin microparticles would increase retention of bioactive growth factors 
both in vitro and within the tissue injury site, leading to enhanced cellular responses and 
improved bone repair. This hypothesis was based upon the well-documented ability of 
heparin to bind and retain various growth factors without hindering bioactivity; it was 
tested through the following specific aims: 
 
1.2 Specific Aims 
 
Specific Aim 1: Engineer heparin-based microparticles for growth factor delivery. The 
working hypothesis of this aim was that heparin microparticles would enhance stable 
retention and controlled presentation of bioactive growth factors – specifically BMP-2. 
Heparin microparticles were fabricated via thermal cross-linking of methacrylamide-
modified heparin. BMP-2 retention capacity was determined by loading heparin 
microparticles with increasing BMP-2 concentrations and measuring subsequent release. 
Bioactivity of microparticle-bound BMP-2 was evaluated via alkaline phosphatase (ALP) 
activity of skeletal myoblasts. The outcome of this aim was the establishment of a 
reproducible protocol for fabricating heparin-based microparticles with the ability to 
retain large amounts of bioactive BMP-2. These results are presented in Chapter 3. 
 
Specific Aim 2: Evaluate the ability of heparin microparticles to deliver low and high 
doses of BMP-2 to a critically sized femoral defect to promote bone healing. The 
working hypothesis of this aim was that loading BMP-2 onto heparin microparticles prior 
to incorporation into a bulk tissue engineering construct (alginate hydrogel + 
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polycaprolactone nanofiber mesh) would increase growth factor retention within the 
defect site, resulting in higher volumes of spatially localized bone formation. 
Microparticle and BMP-2 retention in tissue engineering constructs were evaluated in 
vivo using fluorescently tagged heparin and BMP-2. BMP-2-mediated bone formation 
was investigated initially in an ectopic site, using 5 µg of BMP-2, followed by evaluation 
in an orthotopic bone defect site, using both a low dose (2.5 µg) and a high, clinically 
relevant dose (30 µg) of BMP-2. Through this aim, the enhanced in vivo presentation of 
BMP-2 achieved using heparin microparticles was determined to have utility in localizing 
bone formation at high BMP-2 doses, despite reducing bone formation at low BMP-2 
doses in comparison to BMP-2 delivery without microparticles. These results are 
presented in Chapters 4 and 6. We also investigated the incorporation of unloaded 
microparticles into the PCL nanofiber mesh as an alternative method to spatially limit 
BMP-2 diffusion and localize bone formation. These results are presented in Chapter 7. 
 
Specific Aim 3: Develop a computational model describing in vivo BMP-2 release from 
tissue engineering constructs containing heparin microparticles. The working 
hypothesis of this aim was that a computational model based on experimental and 
theoretical parameters for alginate diffusion and microparticle-BMP-2 interactions could 
predict BMP-2 release in experimental conditions and explain in vivo bone regeneration 
results observed. First, BMP-2 diffusion through alginate hydrogels was measured using 
a capillary tube diffusion method. A COMSOL computational model was then developed 
to simulate the delivery of various amounts of BMP-2 and heparin microparticles, as well 
as different heparin microparticle loading regimes. A sensitivity analysis was also 
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conducted to determine the impact of key parameters on BMP-2 diffusion in this model. 
The outcomes of this aim were the development of a novel method of analyzing protein 
diffusion through hydrogels and the creation of a computational model describing 
affinity-based BMP-2 release in vivo. These results are presented in Chapter 5. 
 
Specific Aim 4: Evaluate the ability of heparin microparticles to sequester and 
concentrate PSC-derived morphogens for in vitro analysis and delivery to other cell 
populations. The working hypothesis of this aim was that the high growth factor loading 
capacity of heparin microparticles could also be used to concentrate and deliver a 
complex mixture of heparin binding proteins from PSC conditioned media, while 
minimizing the delivery of cellular metabolites and wastes. PSC aggregates were 
differentiated in suspension culture over 14 days, allowing for the collection of PSC 
conditioned media from various stages of differentiation. PSC conditioned media was 
then loaded onto heparin microparticles for proteomic analysis and delivered to other 
somatic cell populations in vitro, such as fibroblasts and skeletal myoblasts. PSC-derived 
proteins bound to heparin microparticles were found to differ based on stage of stem cell 
differentiation, and could influence fibroblast and myoblast growth, differentiation, and 
morphology. The outcome of this aim was the characterization of PSC conditioned media 
as a source of potent morphogens that could be harnessed and concentrated via heparin 







This work presents significant contributions to bone tissue engineering, affinity-
based biomaterial design, and the translation of stem cell-based therapeutics. The 
development of a heparin-based biomaterial delivery vehicle addresses current limitations 
in BMP-2 delivery strategies in an attempt to solve the clinical problem of bone 
regeneration in complex injury environments requiring surgical intervention. This 
innovative two-fold approach aimed to improve current growth factor delivery strategies 
by both creating a novel affinity-based biomaterial for clinically approved BMP-2 
delivery and investigating PSC morphogens as a source of growth factors for the 
treatment of bone injuries. The heparin-based microparticles developed through this work 
have been studied herein as a BMP-2 delivery vehicle, but can also be used to facilitate 
the in vitro and in vivo delivery of a number of potent heparin-binding growth factors for 
alternative applications. Furthermore, the computational model developed to describe 
BMP-2 release from a tissue engineering construct, as well as the capillary tube method 
of determining protein diffusion through hydrogels, are both versatile tools that can 
benefit the design of numerous other affinity-based protein delivery vehicles, by 
simplifying the experimental space that must be investigated to develop a new material. 
Finally, the use of heparin microparticles to concentrate PSC-derived morphogens from 
conditioned media presents a novel approach to utilizing the paracrine effects of PSCs, 
while circumventing some of the typical challenges of stem cell-based therapies. This 
work provided new insight into the synergistic effects of PSC-derived proteins on 
somatic cell types in vitro, which may one day lead to use of this strategy for in vivo 
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tissue regeneration. Overall, this investigation of both single and multiple growth factor 
delivery from a single biomaterial delivery vehicle clearly demonstrates the versatility of 
this platform, which may be further developed for other applications in the future.  
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW1 
 
2.1 Bone Tissue Engineering 
	
2.1.1 Bone Structure and Function 
 
Bone is a unique organ of the body that serves several functions, including the 
protection of soft organs, stabilization and load bearing capabilities of the 
musculoskeletal system, storage of minerals such as calcium and phosphate, and 
production of hematopoietic and mesenchymal stem cells from the bone marrow niche 
[12]. It is composed of an inorganic hydroxyapatite (Ca10(PO4)6(OH)2) fraction (70-90%) 
and organic collagen I fraction (10-30%) [13, 14]. Bone can be broadly categorized into 
two main groups based on its structure: cortical or compact bone, which forms the dense 
outer shell of many bones, and trabecular or cancellous bone, which has a lattice structure 
and is often found in the interior of many musculoskeletal structures, such as long bones 
and the vertebrae [15]. While the properties of these two types of bone can vary with age, 
disease, and mechanical environment, cortical bone is denser and ranges in porosity from 
5-10%, while trabecular bone is typically more porous (75-95%) [16, 17]. 
The development and maintenance of bone is a dynamic process, which involves 
complex interplay between a variety of cell populations and soluble molecular cues. 
During development, long bones typically form via endochondral ossification, in which 
mesenchymal condensations gives way to chondrocyte-mediated cartilage formation and 
																																																								
1  Modified from Hettiaratchi MH, Guldberg RE, McDevitt TC. (2016). Biomaterial strategies for 
controlling stem cell fate via morphogen sequestration. Journal of Materials Chemistry B. DOI: 
10.1039/c5tb02575c 
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finally chondrocyte hypertrophy and bone formation [18, 19]. Alternatively, flat bones 
develop via intramembranous ossification, in which mesenchymal condensations 
differentiate directly into osteoblasts that produce mineral, bypassing the cartilage phase 
[18, 19]. In order to maintain established bone, mesenchymal stem cells (MSCs) from the 
bone marrow and osteoprogenitor cells from the endosteal and periosteal layers 
differentiate into mature osteoblasts and osteocytes, which secrete organic bone matrix 
that eventually undergoes mineralization [15]. Osteoblasts also regulate the 
differentiation of hematopoietic stem cells (HSCs) in the bone marrow compartment into 
osteoclasts, which are responsible for bone breakdown and resorption, resulting in release 
of minerals and bone remodeling [15, 20]. 
 
2.1.2 Bone Healing Cascade 
	
Adult bone healing typically occurs via endochondral ossification and involves 
several key stages, which are broadly described as hematoma formation, inflammation, 
revascularization, cartilage formation and mineralization, woven bone formation, and 
remodeling (Figure 2.1) [1]. Immediately following a fracture, damage to the vasculature 
results in the formation of a blood clot (hematoma), triggering the onset of the 
inflammatory response and temporarily elevating levels of interleukins (ILs), tumor 
necrosis factor (TNF-α), and stromal cell-derived factor-1 (SDF-1) [21]. These cytokines 
recruit necessary mesenchymal stem cells (MSCs), inflammatory cells, and macrophages 
to the injury site from the periosteum, bone marrow, and circulating blood, and contribute 
to the revascularization of the bone defect, promoting secretion of angiogenic factors, 
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such as hypoxia-inducible factor 1-α (HIF-1α), angiopoietin 1 (Ang 1), and vascular 
endothelial growth factor (VEGF) [22-24]. During the intermediate stage of cartilage 
formation, the growth and calcification of cartilage within the defect site are mediated by 
differentiating and proliferating chondrocytes that become hypertrophic in response to 
VEGF and several growth factors of the transforming growth factor beta (TGF-β) family 
[25]. Finally, in the terminal stages of bone formation and remodeling, MSCs that have 
differentiated into osteoblasts deposit mineral in the presence of mitogenic and 
osteogenic factors, such as bone morphogenetic protein-2 (BMP-2), TGF-β3, and insulin-
like growth factor-1 (IGF-1) [26, 27]. These osteoblasts also secrete cytokines such as a 
TNF-α, IL-1, IL-6, and IL-11, promoting the proliferation of osteoclasts, which organize 
the woven bone into mature, lamellar structures [27, 28]. Ultimately, the bone healing 
cascade is characterized by a dynamic profile of cell phenotypes and biomolecules within 
the bone injury site. Although the stages of bone healing are inherently different, there is 
significant overlap in the cellular and molecular profiles at the injury site between 
consecutive stages, with several growth factors being constitutively expressed at varying 
levels, including BMP-2, Ang 1, VEGF, TGF-β3, and IGF-1 [1, 26, 29].  
 
 
Figure 2.1. Stages of the Bone Healing Cascade. [1] 
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2.1.3 Incidence of Musculoskeletal Injuries and Current Treatments 
 
Given that the bone healing cascade involves complex interplay between a variety 
of cell populations and signaling molecules, a mechanically challenged injury 
environment or imbalances in biological cues can easily disrupt the healing process and 
result in delayed healing and/or nonunion. Of the 6.3 million fractures that occur annually 
in the United States, approximately 1 million result in more complicated skeletal defects 
that require additional intervention to achieve normal healing [1]. Furthermore, large 
bone defects are not only the result of traumatic injury; they may also be caused by tumor 
resection, osteonecrosis, infection, and skeletal deformities – all of which result in 
significant loss of quality of life for the patient. Musculoskeletal injuries are also a 
leading cause of death and long term disability among military personnel, accounting for 
50-60% of all combat injuries [30].  
Despite the prevalence of severe bone loss, treatment methods to effectively 
regenerate damaged bone tissue and fully restore function to the affected limbs have not 
yet been developed. The current gold standard for treating large bone defects is the use of 
skeletal autografts and allografts, with over 500,000 being performed in the United States 
annually at a cost of $2.5 billion/year to the medical system [2]. Bone autografts are most 
commonly harvested from a patient’s iliac crest, while allografts are often obtained from 
cadavers. However, these bone grafting techniques suffer from a number of limitations, 
including low tissue availability, donor site morbidity in the case of live bone grafts, 
insufficient engraftment of the tissue, and host immune rejection – all of which contribute 
to the need for multiple revision surgeries in as many as 15% of bone grafting procedures 
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annually [1]. Thus, there is a clear need to develop more effective bone repair strategies 
that can more reliably restore bone function and quality of life for injured individuals. 
 
2.1.4 Clinical Recombinant Growth Factor Delivery Strategies 
	
The identification of several key osteoinductive growth factors in the bone 
extracellular matrix has led to the investigation of recombinant growth factor delivery to 
stimulate endogenous repair mechanisms to heal injured bone [31-33]. Two recombinant 
human bone morphogenetic proteins (rhBMP-2 and rhBMP-7) are currently available for 
clinical use within absorbable collagen sponge delivery systems (Medtronic’s INFUSE, 
Stryker’s OP-1 Putty) [4]. Several successful clinical trials for anterior lumbar spinal 
fusions, open tibial fractures, and sinus augmentations have been completed using 
rhBMP-2 and have demonstrated comparable efficacy to bone grafting treatments, 
leading to FDA approval of BMP-2 delivery for these three specific applications [34-38].  
The absorbable collagen sponge scaffold entraps rhBMP-2 through weak 
electrostatic interactions, resulting in a burst release of molecular cargo upon 
implantation in the tissue defect and low retention of BMP-2 at the site of interest [39-
42]. This has led to the use of supraphysiological BMP-2 doses (≥0.2 mg/kg body 
weight) clinically [6] in order to ensure that an effective dose of BMP-2 remains 
bioactive at the site of interest. Rapid diffusion of high concentrations of BMP-2 away 
from the implantation site not only reduces the efficacy of orthopic bone formation 
within the defect site, but has also been associated with excessive vascular permeability, 
soft tissue inflammation, and heterotopic ossification when used “off-label” for other 
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bone regeneration applications, including cervical, posterior lumbar, and transforaminal 
lumbar spinal fusions [9, 43-45]. These detrimental effects are a combined result of both 
high BMP-2 concentrations and the use of biomaterial delivery vehicles that cannot 
effectively retain a sufficient local concentration of BMP-2 within the bone defect site. 
Consequently, biomaterials that provide better control over the spatiotemporal 
presentation of growth factors may enable the more widespread use of BMP-2 for other 
bone healing applications, while minimizing the negative side effects associated with 
rapid growth factor release. 
	
2.2 Stem Cells and Stem Cell Morphogens 
	
2.2.1 Pluripotent Stem Cells and PSC Secretomes 
	
Stem cell potency defines the ability of a stem cell population to differentiate into 
other cell phenotypes, and ranges from pluripotent stem cells (PSCs), such as embryonic 
stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which can differentiate into 
all cells of an organism, to multipotent stem cells, such as mesenchymal stem cells 
(MSCs), neural stem cells (NSCs), and hematopoietic stem cells (HSCs), which exhibit a 
more limited capacity for differentiation. ESCs are derived from the inner cell mass of a 
pre-implantation blastocyst and can differentiate into cells of all three germ layers, much 
like a developing embryo [46, 47]. Embryogenesis is a tightly regulated process, 
consisting of numerous cell-secreted biomolecular cues that orchestrate the complex and 
overlapping series of cell proliferation, differentiation, migration, and organization events 
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that ultimately give rise to the functioning tissues and organs of a complete organism. 
Considering the numerous cell fate decisions that ESCs undergo, directing ESC 
differentiation towards particular cell phenotypes requires the expression of many 
morphogens in concert and is highly dependent on cell state and the coordinated presence 
of other signals. As such, ESCs retain the potential to secrete a variety of potent 
morphogens responsible for maintaining pluripotency or promoting differentiation, and 
thus contribute to both embryonic and mature tissue development. 
Mass spectrometry and/or antibody-based assays have been used to identify 
secreted proteins in ESC cultures, demonstrating the presence of many potent 
biomolecules, including fibroblast growth factors (FGFs), transforming growth factors 
(TGF-βs), insulin-like growth factors (IGFs), insulin-like growth factor binding proteins 
(IGFBPs), bone morphogenetic proteins (BMPs), vascular endothelial growth factor 
(VEGF), growth differentiation factors (GDFs), stromal cell-derived factor-1 (SDF-1), 
and stem cell factor (SCF) [48-52]. The signaling pathways in which these growth factors 
are involved play key roles in defining ESC fate, and can promote or inhibit numerous 
cell processes depending on stage of differentiation. For example, BMP is known to exert 
differential temporal effects on ESC differentiation. Early BMP signaling is required for 
specification towards the mesoderm germ layer and eventual mesenchymal 
morphogenesis [53-55]; conversely, the inhibition of BMP signaling promotes 
pluripotency [56, 57]. Later BMP signaling also influences the differentiation of 
primitive ESC-derived mesoderm towards cardiac phenotypes, as studies have 
demonstrated that both temporary inhibition and stage-specific activation of this pathway 
can promote cardiomyocyte generation [58-60]. FGF and IGF signaling pathways play 
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essential roles in supporting human ESC self-renewal and maintenance of pluripotency 
[56, 57, 61], while mouse ESCs undergo differentiation in the presence of FGFs [62]. 
Stable gradients of growth factors also serve important functions in ESC differentiation 
and embryogenesis. Gradients of VEGF in the developing embryo guide vessel 
development and promote endothelial cell differentiation [63], while spatially regulated 
FGF signaling is involved in gross embryonic patterning [64]. Taken together, these 
examples demonstrate the importance of ESC secreted morphogens in determining ESC 
fate, emphasize the conserved and divergent effects of individual morphogens on mouse 
and human ESC fate, and highlight the precise temporal and spatial control of morphogen 
presentation required to effectively maintain ESC pluripotency or activate differentiation 
and morphogenesis. 
Similar to ESCs, iPSCs possess comparable abilities to self renew and 
differentiate into cells of the three embryonic germ layers and rely on many of the same 
signaling molecules to maintain pluripotency and direct differentiation [65, 66]. 
However, unlike ESCs, iPSCs are derived by reprogramming terminally differentiated, 
somatic cells with the overexpression of several key transcription factors [65, 66]. 
Although less information exists on the profiles of morphogens secreted by iPSCs in 
comparison to ESCs, recent studies that highlight potential benefits of iPSC secreted 
morphogens on other cell types may lead to further investigation in this area [67, 68]. 
 
	
2.2.2 Paracrine Effects of Stem Cell Morphogens 
	
 
The diverse profiles of morphogens secreted by stem cell populations can 
influence the cell fate decisions of not only the stem cells that secrete the morphogens, 
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but often other cell populations within and outside of their respective stem cell niches. 
Morphogens such as FGFs, BMPs, IGFs, SCF, VEGF, SDF-1, and TGF-βs have far-
reaching effects on basic cellular processes required by many cell types. Consequently, 
recent research has delved further into the use of stem cells as reservoirs of soluble 
factors that can act through paracrine mechanisms to influence other cell populations 
[69]. Delivery of ESC conditioned media containing secreted factors can stimulate the 
survival, proliferation, and/or migration of a variety of differentiated cell types, including 
muscle satellite cells, neural progenitor cells, fibroblasts, endothelial cells, and 
hematopoietic progenitor cells [7, 8, 51, 52]. Such effects on other cell types have been 
observed with conditioned media obtained from ESCs in various stages of differentiation, 
including undifferentiated ESCs, ESCs differentiated as adherent monolayer cells, and 
ESC differentiated as suspension aggregates (embryoid bodies) [7, 8, 51, 52]. Several 
studies have also demonstrated correlations between growth factor content and paracrine 
effects; for example, conditioned media collected from spontaneously differentiating 
embryoid bodies at later time points contained higher levels of IGF-2 and VEGF-A and 
induced greater endothelial cell proliferation and migration than conditioned media 
obtained from earlier time points [7]. 
Similar studies have also been conducted with MSC-conditioned media. Chen, et 
al. demonstrated that conditioned media collected from MSCs cultured under hypoxic 
conditions stimulated the proliferation of keratinocytes and endothelial cells and 
migration of keratinocytes, endothelial cells, and macrophages [70]. MSC conditioned 
media has also been used to successfully maintain the self renewal abilities and 
pluripotency of ESC cultures in the absence of feeder cells [71]. Furthermore, a number 
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of other studies have utilized MSC conditioned media or MSC co-cultures to expand and 
maintain the multipotency of HSC populations in vitro, hence mimicking the native 
MSC/HSC relationship of the bone marrow niche [72-74].  
 
2.2.3 Stem Cell Approaches to Tissue Regeneration 
 
Stem cells possess significant potential to cure degenerative diseases caused by 
cellular deficiencies and replace damaged tissues resulting from traumatic injuries. The 
promise of stem cell research has been further fueled by a large number of studies that 
have documented positive results following stem cell transplantation for various 
applications. However, the translation of stem cell research into viable cell 
transplantation technologies has been thwarted by the difficulty of obtaining large 
quantities of stem cells, low cell engraftment post-implantation, immune rejection, and, 
in the case of PSCs, the propensity to form teratomas [75]. Interestingly, despite the low 
persistence of transplanted stem cells within tissue injury sites, several studies have 
demonstrated improvements in tissue/organ function following stem cell transplantation 
in cardiac, neural, and bone defect environments [60, 76-78].  
As such, researchers now believe that the beneficial effects of stem cell 
transplantation may be largely attributed to the presence of stem cell-secreted 
morphogens within the damaged tissue and the ability of stem cells to recruit and direct 
endogenous cell populations through the secretion of various soluble factors at the tissue 
defect site [79]. Transplanted stem cells may serve as reservoirs of secreted factors in 
vivo that can influence endogenous cell populations to repair and regenerate damaged 
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tissues through a variety of mechanisms. This is contrary to the traditional notion that 
transplanted stem cells directly contributed to tissue repair through stable engraftment 
and differentiation and represents a paradigm shift in the way researchers consider 
applying stem cells for regenerative medicine, placing emphasis on both the viability of 
the cells themselves and duration, amount, and efficacy of soluble factors they secrete. 
Further investigation into the paracrine actions of transplanted stem cells in vivo 
has revealed improvements in heart function following myocardial infarction due to ESC-
secreted VEGF, IGF-1, and IL-10 [80], axonal regeneration following spinal cord injury 
due to NSC-secreted NGF, BDNF, GDNF [81], and bone healing induced by the delivery 
of MSC conditioned media containing VEGF and IGF-1 [82]. Despite the plethora of 
musculoskeletal-related growth factors secreted by ESCs, such as BMPs, IGFs, TGF-βs, 
and VEGF, the tumorigenicity of ESCs has prevented their widespread use in animal 
models of bone injury without pre-differentiation into MSCs or osteoblasts [83, 84], 
further motivating the development of strategies employing stem cell paracrine factors. 
However, perhaps the most extensive research regarding stem cell paracrine effects has 
been conducted with MSCs transplanted for cardiac regeneration following myocardial 
infarction [85]. Numerous studies have demonstrated improvement in cardiac function 
following MSC transplantation, prompting investigation into whether these effects are 
paracrine-mediated. Although the mechanisms by which MSCs exert cardioprotective 
effects are still somewhat unknown, both in vitro and in vivo studies have revealed a role 






2.3.1 Structure and Function 
 
The extracellular matrix (ECM) contains a variety of molecules responsible for 
providing structural integrity, mechanical cues, cell adhesion sites, and protein binding 
domains within the cellular microenvironment [90, 91].  Glycosaminoglycans (GAGs) 
are a class of ECM molecules composed of linear polysaccharide chains that exist both as 
free chains and covalently-linked components of glycosylated proteins known as 
proteoglycans [92, 93]. When attached to proteoglycan protein cores, the presence of 
multiple GAG chains in close proximity provides the dense negative charges that 
promote endogenous protein sequestration. Interactions between GAGs and various 
proteins have been extensively studied in the past, revealing that GAG–protein binding is 
primarily electrostatic and relies heavily on negatively charged sulfate groups within the 
disaccharide chains [91, 94]. Heparin, heparan sulfate, and chondroitin sulfate are all 
highly sulfated GAGs, and thus have a strong affinity for number of potent, positively 
charged morphogens, known collectively as ‘‘heparin binding proteins [93].’’ While 
heparan sulfate and chondroitin sulfate are somewhat less sulfated and almost exclusively 
found covalently attached to proteoglycans on cell membranes and in the ECM, heparin 
has the highest sulfation density of all naturally occurring GAGs and typically exists as 




2.3.2 Affinity Interactions with Proteins 
 
While many proteins interact with GAGs in a purely electrostatic manner, specific 
carbohydrate sequences have been identified within heparin and heparan sulfate that 
mediate binding with known domains on certain heparin binding proteins. Thus, the 
sulfation patterns displayed on different GAG species may play a significant role in 
determining protein binding affinity. For example, a specific pentasaccharide sequence is 
required for heparin binding to antithrombin III to inhibit coagulation, while a 
tetrasaccharide sequence is necessary for FGF-1 and FGF-2 binding [95, 96]. Likewise, 
specific protein sequences on FGF-1, FGF-2, and BMP-2 molecules have also been 
identified as being necessary for heparin binding [3, 97]. 
Although GAG interactions with FGFs and BMPs are the most extensively 
characterized, GAGs can also strongly and reversibly bind other morphogens influential 
in stem cell maintenance and developmental processes, including VEGF, Wnt3a, TGF-βs, 
IGFs, and IGFBPs [94, 98-100]. GAG binding to proteins can increase protein half-lives 
in in vitro cell cultures and in vivo tissues, by protecting them from enzymatic 
degradation and denaturing environmental agents [101-103]. Furthermore, interactions 
between GAGs and various growth factors have been previously shown to either enhance 
or inhibit a wide range of biological effects, depending on the relative concentrations of 
GAG and growth factor and context of interaction. This has been thoroughly investigated 
in the context of BMP-2-mediated osteogenesis, in which heparin has been specifically 
shown to extend BMP-2 half-life and enhance BMP-2/BMP receptor dimerization in 
some cases [101, 104], while interfering with BMP-2/BMP receptor binding and 
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downstream signaling pathway in others [105]. In general, higher concentrations of 
heparin over shorter periods of time tend to inhibit BMP-2 activity, while lower 
concentrations of heparin over longer periods of time promote BMP-2 signaling [105, 
106]. Moreover, although soluble heparin can sequester BMP-2 away from cells to 
interfere with BMP-2-mediated alkaline phosphatase (ALP) activity, BMP-2 bound to 
similar amounts of heparin-based materials, such as microparticles, can directly interact 
with cell surface receptors to promote ALP activity [107]. 
 
2.4 Biomaterial Strategies for Protein Delivery and Sequestration 
 
The natural capacity of the ECM to strongly and reversibly bind bioactive 
morphogens provides an attractive template for designing effective biomaterials. ECM-
based, ECM-containing, and ECM-mimetic materials harness the protein sequestering 
qualities of the native ECM to provide biomimetic strategies for improving 
microenvironments for stem cell regulation and methods of morphogen delivery. 
Consequently, a variety of materials have been developed using this strategy and are 




Figure 2.2. Methods of morphogen sequestration demonstrated in the cellular 
microenvironment (left) and employed in biomaterials for protein delivery (right). The 
cellular microenvironment displays soluble, ECM-bound, and GAG-bound morphogens that are 
typically secreted by other supporting cell types. Biomimetic materials make use of natural cell–
material interactions, including both covalent morphogen presentation strategies (morphogen 


















Table 2.1. Summary of biomaterial strategies for growth factor delivery and sequestration. 






In vivo delivery for bone regeneration 
 
[40] 
VEGF HUVEC proliferation [108] 
TGF-β2 In vivo delivery for cell proliferation [109] 









Mesoderm differentiation of ESC aggregates 
 
[112] 
BMP-4, TPO Hematopoietic differentiation of ESC aggregates [113] 
BMP-4, FGF-2 
 













BMP-2 In vivo delivery for bone regeneration [116] 
FGF-2 HUVEC proliferation [117] 
BMP-4, TPO Mesoderm/hematopoietic differentiation of ESCs [112, 113] 
VEGF 
 
























IGF, TGF- β3 
 









In vivo delivery for bone regeneration 
 
[122] 
BMP-2 MSC osteogenic differentiation [123] 
FGF-2 MSC proliferation [124] 
TGF-β1 Cardiac progenitor cell proliferation,  
differentiation, and soluble factor secretion 
[125, 126] 
No exogenous GF 
 








C2C12 proliferation and myogenic differentiation 
 
[129] 
VEGF, FGF-2 HUVEC tube formation [130, 131] 
NGF Neurite extension from neural crest cells [130] 
No exogenous GF MSC proliferation, migration, and differentiation [132] 











HUVEC, MSC, and smooth muscle cell migration, 
proliferation, and differentiation 
 
[134, 135] 
BMP-2 MSC osteogenic differentiation [135, 136] 
 BMP-2, VEGF, 
PDGF-BB 





Sulfated Chitosan  
 
No exogenous GF 
 













No exogenous GF 
 




2.4.1 Extracellular Matrix-based Materials 
 
Both fibrillar ECM proteins, such as collagens, and glycoproteins, such as 
fibronectin, have been used to create biomimetic materials for growth factor delivery and 
cell culture. Collagens, with their self-assembling network structure, biodegradability, 
and ability to interact with cells and biomolecules, have frequently been used in a variety 
of applications. Perhaps the most common clinical application of collagens is as a 
delivery vehicle for BMP-2 and BMP-7 in the context of bone healing [40]. Porous 
sponges made of lyophilized Type I collagen networks are soaked in a concentrated BMP 
solution immediately prior to implantation, and growth factor loading occurs via 
electrostatic interactions between negatively charged residues on the collagen fibers and 
positively charged residues on BMP. When delivered in vivo, the porous network of the 
collagen sponge facilitates robust cell infiltration and degradation, while the sequestered 
BMP is rapidly released to promote osteogenesis. Collagen materials have also been used 
for protein delivery in vitro. The use of collagen I and collagen II hydrogels for delivery 
of TGF-β1 to MSC cultures has been shown to enhance chondrogenic differentiation 
[110]. Gelatin, which is simply denatured collagen, has been previously used as a 
delivery vehicle for BMP-4, thrombopoietin (TPO), and the BMP-4 antagonist noggin in 
ESC culture [112, 113]. Robust mesoderm differentiation was achieved with 
microparticle delivery of BMP-4 concentrations that were 12-fold lower than that 
required for soluble BMP-4 delivery, demonstrating the efficacy of this material-based 
protein delivery strategy [112]. 
As mentioned previously, collagens do not contain specific binding sites for 
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proteins; thus, protein binding is primarily achieved through relatively weak, electrostatic 
interactions that may easily be displaced by stronger, competing interactions with other 
biomolecules. As a result, two common approaches to improve the growth factor 
retention capacity of collagens have been to covalently tether biomolecules of interest to 
its fibers or physically incorporate other ECM molecules with specific protein binding 
sequences, such as glycoproteins or GAGs, into its matrix. High retention of FGF-2, 
VEGF, and TGF-βs within collagen matrices has been previously achieved through 
covalent conjugation methods, such as EDC/NHS and riboflavin/UV light-mediated 
cross-linking [108, 109, 111]. Despite promising outcomes observed with the use of 
covalently tethered growth factors, chemical modification of many proteins can attenuate 
their overall bioactivity by disrupting active sites for signaling, heparin binding domains, 
charges contributing to electrostatic interactions, and the ability of cells to internalize the 
molecule [139, 140]. Alternatively, many studies have investigated covalent or non-
covalent addition of GAG chains to collagen matrices to enhance protein sequestration. 
‘‘Heparinized’’ collagen substrates can be created by covalently tethering heparin chains 
to collagen films using EDC/NHS cross-linking; when loaded with FGF-2, heparinized 
substrates exhibited improved HUVEC proliferation compared to unmodified collagen 
substrates [117]. Heparinized gelatin microparticles, also fabricated using EDC/NHS 
chemistry, demonstrated reduced BMP-4 and TPO release compared to gelatin 
microparticles and stimulated greater differentiation of ESCs down the mesoderm lineage 
and into hematopoietic progenitors than soluble morphogen delivery [112, 113]. Heparin 
has also been non-covalently incorporated into collagen matrices through physical 
entanglement of GAG chains and collagen fibers [116, 118], leading to stable 
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incorporation of heparin within the scaffold, as well as attenuated VEGF release and 
prolonged bioactivity [118].  
Aside from the presence of specific protein binding domains, other material 
properties can also influence the ability of ECM-based materials to deliver proteins in 
vitro and in vivo. For example, multiple studies have demonstrated that EDC/NHS cross-
linking of collagen fibers can result in denser collagen matrices that are more resistant to 
collagenase-mediated degradation, and that this is also often accompanied by increased 
retention of molecular cargo within the collagen scaffold [111, 141]. We have previously 
demonstrated a similar effect of gelatin microparticles loaded with BMP-4 and FGF-2, in 
which increased methacrylate cross-linking density resulted in decreased morphogen 
release and reduced susceptibility to collagenase degradation [114]. 
 
2.4.2 Glycosaminoglycan-based Materials  
	
The strong binding affinity of GAGs to a variety of proteins makes GAG-based 
materials a promising strategy for delivering morphogens with high spatial and temporal 
control. Numerous studies have investigated methods to fabricate biomaterials that 
immobilize GAG chains onto other materials or consist of modified GAG species that 
can be cross-linked to form pure GAG materials. The ability to maintain growth factor 
bioactivity and prolong growth factor half-life, while remaining biodegradable in vivo, 
provides GAGs with clear advantages as drug delivery systems. Heparin is most 
commonly used in GAG-based materials because of its high charge density, which 
confers its strong protein binding capacity, and well-studied interactions with potent 
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morphogens. Although chondroitin sulfate and heparan sulfate typically exhibit lower 
affinity for heparin binding proteins due to their decreased sulfation, biomaterials 
containing these GAG species have also been developed. Since chondroitin sulfate 
proteoglycans are abundant in cartilage ECM, chondroitin sulfate-containing materials 
have been frequently pursued for biomimetic cartilage tissue engineering applications 
[142, 143]. Moreover, given the natural anticoagulant ability of heparin, which stems 
from its strong affinity for antithrombin III, heparan sulfate presents an alternative GAG-
based protein delivery strategy for situations in which heparin’s anticoagulant activity 
may pose a risk [144].  
Similar to methods for heparinizing collagen matrices as described above, heparin 
and other GAGs can be non-covalently or covalently incorporated into a number of other 
bulk materials, including polyethylene glycol (PEG), poly-lactic-co-glycolic acid 
(PLGA), chitosan, and fibrin. For example, heparin incorporation into PEG-based 
hydrogels can be accomplished by cross-linking methacrylamide or methacrylate-
modified heparin with PEG dimethacrylate or diacrylate using free radical 
polymerization. Heparin incorporation into PEG hydrogels has been applied in bulk gels 
to enhance proliferation and osteogenic differentiation of MSCs either in the absence or 
presence of exogenous morphogens, such as FGF-2 and BMP-2 [123, 124, 128]. 
Importantly, methacrylamide and methacrylate-modified heparin species retain their 
ability to extend morphogen bioactivity and enhance morphogen presentation. Promising 
results have also been achieved with GAG incorporation into naturally derived materials 
such as chitosan and fibrin. Non-covalent incorporation of chondroitin sulfate into 
chitosan sponges has been used to modulate release of PDGF [119], while fibrin gels 
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containing covalently tethered heparin exhibit reduced BMP-2 release [122]. Finally, 
efforts have been made to fabricate pure GAG materials, such as methacrylated 
chondroitin sulfate nanoparticles and microparticles, in order to further maximize the 
growth factor holding capacity of biomaterials [145]. Low molecular weight heparin 
species (<8 kDa), such as fragmin, have been used in conjunction with the highly cationic 
peptide protamine to make GAG microparticles through stable ionic complexing, 
resulting in similar attenuation of FGF-2 release and enhancement of bioactivity [146]. 
The large number of GAG-modified materials that now exists to improve morphogen 
retention and enhance bioactivity highlights the broad utility of GAGs in biomaterial-
based strategies for protein sequestration. Several studies undertaken by Anseth and 
colleagues elucidated the stimulatory effects of morphogen-laden heparin-PEG hydrogels 
on MSC proliferation and differentiation, showcasing dramatic increases in alkaline 
phosphate (ALP) activity and osteogenic gene expression in the presence of heparin-
functionalized hydrogels compared to PEG hydrogels alone [124, 127]. PLGA 
microspheres coated with heparin-complexed FGF-2, BMP-7, IGF, and TGF-β3 have 
also been used as substrates for MSC culture, resulting in differential effects on MSC 
lineage commitment as evaluated by gene and protein expression, cell morphology, and 
biochemical assays [121]. Specifically, BMP-7 induced osteogenic differentiation, dual 
delivery of FGF-2 and IGF stimulated adipogenic differentiation, and TGF-β3 delivery 
resulted in chondrogenic differentiation, highlighting the versatility that heparin affords 
delivery systems by enhancing presentation of various morphogens contributing to tri-
lineage MSC differentiation. 
The sulfation patterns of GAG chains play a key role in the presentation of 
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morphogens, by modulating the electrostatic charges responsible for protein binding. 
Consequently, the ability to selectively desulfate GAG chains offers a means of 
manipulating morphogen binding and sequestration properties. Several studies have 
investigated chemical methods of desulfating GAG chains and its effects on protein 
binding. Fully sulfated heparin contains 2-O-sulfate, 6-O-sulfate, and N-sulfate groups, 
and common desulfation methods result in removal of one, two, or all of these sulfate 
groups [103, 115, 120]. Ratanavaraporn, et al. demonstrated that heparin chains 
desulfated at the 2-O-sulfate position retained more BMP-2 than native heparin and other 
desulfated species, and that MSCs cultured in gelatin hydrogels containing BMP-2 and 
non-covalently entangled 2-O desulfated heparin derivatives enhanced early osteogenic 
differentiation [115]. The sulfation patterns of heparin-containing microparticles can 
similarly modulate heparin-BMP-2 binding and subsequent BMP-2 bioactivity [120]. The 
importance of GAG sulfation patterns in ESC fate determination has also led to 
investigation into the effects of exogenous GAG addition in ESC cultures. For example, 
sulfating the 6-O positions of chitosan disaccharides can modulate their overall sulfate 
pattern and charge. When used as a substrate for ESC differentiation, sulfated chitosan 
can increase neural differentiation without the addition of exogenous morphogens [137]. 
	
2.4.3 Sequestration of Complex Cell-Secreted Mixtures of Proteins 
 
The success of numerous recombinant protein binding systems for in vitro stem 
cell fate regulation and in vivo growth factor delivery has recently led to the development 
of new strategies to sequester and present soluble factors that are endogenously produced 
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during in vitro cell culture. The sequestration of endogenously secreted growth factors 
has long been considered a possible mechanism by which GAG-based biomaterials 
enhance morphogen effects on cell populations beyond the potency of the morphogens 
themselves; however, it is only recently that studies have attempted to more 
systematically test this hypothesis. The ability to capture and concentrate numerous cell-
secreted and serum-borne morphogens using biomaterials may provide novel methods of 
more easily analyzing cell-secreted products and potentiating cell growth and 
differentiation through dynamic feedback between cells and biomolecules. Although this 
is an emerging concept in the field of stem cell engineering, several studies have begun to 
elucidate the effects of presenting complex mixtures of proteins on stem cell fate.  
Because many morphogens are considered heparin binding growth factors, GAG-
based biomaterials are prime candidates for sequestering cell-secreted proteins. Through 
the use of heparin-PEG hydrogels, Anseth and colleagues demonstrated the ability of 
GAG-based biomaterials to enhance the effects of exogenously added FGF-2 and BMP-2 
on MSC proliferation and differentiation [124, 127]. Further investigation within this 
system next aimed to modulate the presentation and availability of both serum-borne and 
cell-secreted morphogens. By depleting heparin binding proteins from serum-containing 
media and selectively adding back in fibronectin and BMP-2, the necessity of serum-
borne heparin binding proteins in inducing MSC osteogenesis as well as the role of 
exogenous heparin chains in concentrating fibronectin and BMP-2 was elucidated. A 
subsequent study investigated the role of heparin-PEG hydrogels in concentrating cell-
secreted morphogens, by incorporating fluvastatin, a small molecule known to increase 
cellular BMP-2 secretion, into the gels [123]. The additional presence of heparin in 
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fluvastatin-containing hydrogels increased osteogenic gene expression, likely due to the 
sequestration and concentration of cell-secreted BMP-2. 
Similar results have also been obtained using other strategies for GAG-mediated 
morphogen sequestration. Hudalla, et al. recently described the covalent tethering of a 
novel heparin binding peptide, derived from the heparin binding domain of FGF-2, at 
varying densities to oligoethylene glycol self-assembling monolayers using EDC/NHS 
chemistry; this peptide could sequester serum-borne heparin to subsequently modulate 
the presentation and availability of morphogens in culture [138, 147]. Sequestration of 
soluble heparin enhanced presentation of serum-borne FGF-2, resulting in increased 
HUVEC and MSC proliferation, and was hypothesized to similarly enhance presentation 
of endogenous, MSC-secreted FGFs [138, 147]. Investigation of this heparin binding 
peptide in osteogenic media also revealed a potential role of heparin sequestration in 
potentiating osteogenic differentiation mediated by MSC-secreted BMPs, corroborating 
results obtained by Anseth and colleagues. 
Some of the latest work by Healy and colleagues further illustrates the benefits of 
GAG-based morphogen sequestration [125, 126]. In a recent study, hyaluronic acid 
hydrogels were fabricated with covalently cross-linked heparin using acrylated 
hyaluronic acid and cleavable peptide cross-linkers via Michael type addition. Cardiac 
progenitor cells (CPCs) seeded onto hydrogels containing heparin-bound TGF-β1 
exhibited robust proliferation, differentiation, and formation of tubular structures. This 
was accompanied by dramatic increases in several matrix-bound morphogens, which 
contributed to endothelial cell mobilization (IGFBPs, VEGF, HGF) and vascular invasion 
(IL-10, endostatin), suggesting that heparin presentation both concentrated and amplified 
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cell-secreted signals to enhance CPC maturation. Moreover, heparin-mediated 
presentation of soluble signals also led to positive effects in vivo, where heparin-
containing hydrogels enhanced CPC survival and differentiation following hindlimb 
implantation. 
Heparin has also been used to concentrate cell-secreted morphogens in culture for 
delivery to primary myoblast and neural progenitor cells in vitro, as well as damaged 
tissues in vivo [8]. While whole ESC conditioned media induced proliferation and 
survival of both cell types, it was found that these mitogenic effects were mainly caused 
by the heparin binding fraction of the media. Heparin binding proteins were concentrated 
from conditioned media using heparin-agarose beads and eluted prior to in vitro delivery 
to primary myoblasts and in vivo delivery to sites of muscle injury. In both scenarios, 
heparin binding proteins enhanced proliferation, while conditioned media depleted of 




CHAPTER 3: DEVELOPMENT OF HEPARIN MICROPARTICLES FOR 




Recombinant growth factor delivery has shown utility in a number of tissue 
engineering applications. In particular, bone morphogenetic proteins (BMPs), which are 
potent osteoinductive growth factors, have been used extensively to treat bone defects in 
both research and clinical settings [148-150]. However, current treatment strategies 
require supraphysiological levels of recombinant proteins, such as BMPs, in order to 
stimulate endogenous mechanisms of repair. This inefficient use of growth factor is 
largely due to the inability of biomaterial delivery vehicles to provide adequate sustained 
presentation of growth factors necessary to stimulate repair over long periods of time. 
Current biomaterial delivery vehicles have major limitations, such as the rapid release of 
molecular cargo upon deployment, causing low retention of soluble factors at the site of 
interest [151-153], or alternatively, covalent tethering of growth factors to delivery 
materials that can reduce growth factor bioactivity [154, 155]. Thus, materials with the 
ability to strongly, but reversibly, interact with their molecular payload are necessary, and 
may decrease the amount of growth factor required for such therapies, while improving 
physiological response. 
 Recently, glycosaminoglycan-containing biomaterials have become an attractive 
delivery method for recombinant growth factors, due to their ability to strongly bind a 
																																																								
2 Modified from Hettiaratchi MH, Miller, T, Temenoff, JS, Guldberg RE, McDevitt TC. (2014). Heparin 
microparticle effects on presentation and bioactivity of bone morphogenetic protein-2. Biomaterials. 
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variety of growth factors in a reversible manner. Glycosaminoglycans (GAGs) are linear 
polysaccharide chains that bind positively charged growth factors primarily through their 
negatively charged sulfate groups and exist both as free chains and covalently-linked 
components of glycosylated proteins known as proteoglycans [91, 92]. GAGs such as 
heparin, heparan sulfate, and chondroitin sulfate are ubiquitous components of natural 
extracellular matrices (ECM) and are involved in sequestering and immobilizing growth 
factors within the cellular microenvironment [156-158]. Thus, GAG-based materials 
present the opportunity to harness the natural growth factor binding capacity of the ECM 
and deliver growth factors in a biomimetic manner with spatiotemporal control. Heparin, 
in particular, is highly negatively charged and has a strong affinity for a class of 
positively charged growth factors known as “heparin binding growth factors,” for which 
specific growth factor binding sequences on heparin chains have been identified [3, 159, 
160]. The non-covalent, reversible interactions between heparin and heparin-binding 
growth factors ensure that binding occurs with minimal impact on growth factor 
structure. Heparin-binding growth factors such as transforming growth factor β (TGF-β), 
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), insulin-like 
growth factors (IGFs), and bone morphogenetic proteins (BMPs), are especially 
influential in many developmental and regeneration processes, and it is thought that 
heparin itself may play a role in the preservation and presentation of such molecules 
through electrostatic interactions [161, 162].  
 The use of heparin and heparin-containing biomaterials for BMP-2 delivery, as 
well as the delivery of several other growth factors, including FGF-2, VEGF, and TGF-
β2, has been widely explored in both in vitro and in vivo test beds [163-168]. Although 
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several studies have investigated heparin-BMP-2 interactions, the effects of heparin-
BMP-2 binding on BMP-2 bioactivity have been inconsistent and depend largely on the 
amount of heparin and method of heparin immobilization. Previous studies have 
demonstrated that co-delivery of soluble heparin with BMP-2 can enhance BMP-2-
mediated osteogenesis or, contrastingly, interfere with BMP-2 and BMP receptor binding 
to inhibit osteogenesis, depending on the cell type and culture conditions [101, 104-106, 
169-171]. Nevertheless, the addition of heparin to biomaterials, including microparticles 
and bulk gels, has previously resulted in an improvement in growth factor retention and 
BMP-2-induced osteogenesis [122, 172-175]. Heparin-mediated delivery of BMP-2 has 
also resulted in a wide range of effects in vivo, with studies demonstrating variable 
amounts of mineralization in both ectopic and orthotopic sites [101, 115, 116, 144, 176], 
reflecting an inconsistent ability to form functional bone. Furthermore, the majority of 
these materials consist of relatively small amounts of heparin immobilized within a larger 
bulk material [167, 168, 177-180], which may attenuate heparin’s ability to effectively 
bind and present growth factors. As a result, previous reports on heparin-containing 
biomaterials may significantly underestimate the amount of BMP-2 that can be delivered 
via heparin binding. Thus, improving the growth factor binding ability of heparin-
containing biomaterials may enable consistent delivery of highly localized BMP-2 
concentrations necessary to stimulate effective bone formation. 
 Herein, we present a method of fabricating pure heparin microparticles from a 
modified heparin methacrylamide species that can be thermally cross-linked. Physical 
and chemical characterization of heparin microparticles was performed, and growth 
factor loading and release were quantified with different BMP-2 loading concentrations. 
	 36 
Additionally, growth factor bioactivity was confirmed by introducing BMP-2-laden 
heparin microparticles to cultures of C2C12 cells and evaluating BMP-2-induced alkaline 
phosphatase activity, as well as changes in DNA content. Overall, this study marks a 
crucial first step in developing heparin microparticles as a versatile delivery vehicle and 
therapeutic platform for growth factor-stimulated in vivo tissue engineering, by 
demonstrating their capacity to efficiently capture and present BMP-2 to induce a potent 
functional cell response. 
 
3.2 Materials and Methods 
	
3.2.1 Heparin Methacrylamide Modification 
	
Heparin ammonium salt from porcine intestinal mucosa (17-19 kDa; Sigma-
Aldrich, St. Louis, MO) was conjugated with N-(3-aminopropyl)methacrylamide 
(APMAm; Polysciences, Warrington, PA) using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC; Thermo Fisher Scientific, Waltham, MA) and N-
hydroxysulfosuccinimide (Sulfo-NHS; Thermo Fisher Scientific) as described in previous 
protocols [128, 181] (Figure 3.1A). EDC/Sulfo-NHS chemistry activates carboxyl groups 
on heparin for subsequent methacrylamide substitution via covalent bonds created with 
the primary amines on APMAm. Briefly, 325 mg of heparin ammonium salt was mixed 
with 10-fold molar excess of sulfo-NHS, EDC, and APMAm, in relation to heparin’s 
carboxyl groups, in a reaction volume of 200 mL at room temperature and pH 6.5. The 
total reaction time was 5 hours, with a second set of 10-fold molar excess of EDC and 
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APMAm being added after the first 2.5 hours, to replace reactants that had undergone 
hydrolysis. The reaction volume was then dialyzed against 2 L of water using dialysis 
tubing with a molecular weight cutoff of 3500 Da (Spectrum Laboratories, Rancho 
Dominguez, CA) for at least 48 hours to remove excess reactants; dialysis water was 
replaced every 12 hours. The remaining volume in the dialysis tubing (~200 mL) was 
lyophilized (Labconco, Kansas City, MO) for four days. 
5 mg of modified and unmodified heparin was dissolved in 750 µL deuterium 
oxide (Cambridge Isotope Laboratories, Tewksbury, MA) and analyzed using a Bruker 
Avance III 400 MHz spectrometer (Bruker Biospin Corp, Billerica, MA) for proton 
nuclear magnetic resonance (1H-NMR) spectra analysis. 1H-NMR spectra were phase 
corrected, baseline subtracted, and integrated using ACD/NMR processor 12.0 software. 
For the determination of methacrylamide modification degree, protons located at the C1 
position of heparin’s disaccharide units were integrated between the chemical shifts of 
δ=5.0 ppm and δ=5.75 ppm and assigned a reference value of 1. However, in modified 
heparin, the protons of the methacrylamide groups (δ=5.41 ppm and δ=5.66 ppm) have a 
similar chemical shift within the aforementioned heparin integration region. Therefore, an 
alternate region in the heparin spectra (δ=4.0 ppm and δ=4.33 ppm) that was not affected 
by the presence of methacrylamide signals was selected, set to an integral of 1, and 
compared to the integral of the methacrylamide protons at δ=5.41 ppm and δ=5.66 ppm. 
By taking the ratio of the integration regions of the methacrylamide protons (δ=5.41 ppm 
and δ=5.66 ppm) and heparin (δ=4.0 ppm and δ=4.33 ppm), the number of 
methacrylamide groups per heparin disaccharide unit was determined. 
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3.2.2 Heparin Microparticle Fabrication 
 
Heparin methacrylamide microparticles were fabricated using a water-in-oil 
emulsion followed by thermal cross-linking of the methacrylamide groups, similar to a 
previously developed protocol [145]. Briefly, 55.6 mg of heparin methacrylamide was 
dissolved in 440 µL of phosphate buffered saline (PBS; Corning Mediatech, Manassas, 
VA) and mixed with equimolar amounts (30 µL of a 0.3 M solution) of the free radical 
initiators ammonium persulfate (APS; Sigma Aldrich) and tetramethylethylenediamine 
(TEMED; Sigma Aldrich). Immediately after mixing, the solution was added dropwise to 
60 mL of corn oil and 1 mL of polysorbate 20 (Promega, Madison, WI), and the entire 
mixture was homogenized on ice at 3000 rpm for 5 minutes using a Polytron PT3100 
homogenizer (Kinematica, Switzerland) to create a water-in-oil emulsion. The emulsion 
was then submerged in a hot water bath (55ºC) and stirred to activate free radical 
polymerization and thermal cross-linking of the methacrylamide groups; the reaction 
proceeded for 30 minutes under nitrogen purging to prevent depletion of free radicals by 
the presence of oxygen. The solution was centrifuged at 3000 rpm for at least 10 minutes 
and the corn oil phase was removed. The resulting pellet of microparticles was washed 
once in acetone and centrifuged again (3000 rpm, 10 minutes), before undergoing several 
water washes to remove any excess oil or loosely cross-linked microparticles that did not 
settle with centrifugation. Prior to cell culture studies, microparticles were disinfected in 
a 70% ethanol solution for 30 minutes followed by three additional sterile water washes. 
The microparticles were then lyophilized for 24 hours and stored at 4ºC until use. 
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3.2.3 Heparin Microparticle Characterization 
 
To visualize the microparticles, samples were incubated with 0.0016% (w/v) 1,9-
dimethylmethylene blue (DMMB; Sigma Aldrich), which specifically stains sulfated 
GAGs, for 30 minutes at room temperature, and then washed several times with water 
before being imaged on a Nikon Eclipse TE2000-U inverted microscope (Nikon 
Instruments, Melville, NY). Microparticle size distribution was determined by using 
CellProfiler image analysis software [182] to evaluate images of microparticle samples. 
For size analysis, microparticles were stained with 0.1% (w/v) Safranin O for 30 minutes 
for enhanced contrast prior to imaging on a Nikon Eclipse TE2000-U inverted 
microscope. Images were then analyzed using a custom script on CellProfiler to quantify 
individual microparticle sizes. Briefly, images were loaded into CellProfiler and 
converted to grayscale. Microparticles were identified using the Otsu Adaptive 
thresholding method and the cross-sectional area of each microparticle was measured in 
order to estimate microparticle diameter. The number of microparticles per mg of 
polymer was determined using a Z2 Coulter Particle Counter with a 100 µm aperture 
(Beckman Coulter, Fullerton, CA). A known weight of lyophilized microparticles was 
resuspended in 5 mL of Isoton II diluent (Beckman Coulter) for counting. For scanning 
electron microscopy (SEM), 0.1 mg of lyophilized microparticles were resuspended in 
70% ethanol and placed on an SEM mounting stud covered in copper tape. The samples 
were left at room temperature overnight to allow the ethanol to evaporate. The studs were 
sputter coated with gold using a Hummer 5 Gold/Palladium Sputterer (Anatech, Union 
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City, CA) at 140-160 mTorr and 25-30 mA. Images were taken on a FEI Nova Nanolab 
200 Focused Ion Beam/Scanning Electron Microscope (FEI, Hillsboro, OR). 
	
3.2.4 Growth Factor Loading and Release 
 
The loading capacity of the microparticles for human VEGF (pI = 8.5), human 
FGF-2 (pI = 9.6), and human tumor necrosis factor alpha (TNF-α, pI = 5.3) [183-185] 
were investigated at a fixed growth factor concentration (10 ng/mL) and fixed 
microparticle amount (0.1 mg), while loading capacity for human BMP-2 (pI = 9.0) [42] 
was investigated over a broad range of growth factor concentrations (0.1–5000 µg/mg of 
microparticles) and microparticle amounts (0.02–200 µg). For comparison with gelatin 
methacrylate microparticles, 0.1 mg of both heparin microparticles and gelatin 
microparticles were incubated with a single fixed concentration of BMP-2 (10 ng/mL). 
All growth factors were purchased from R&D Systems. Microparticles were incubated 
with a single growth factor in 1 mL of 0.1% (w/v) bovine serum albumin (BSA; 
Millipore Corporation, Billerica, MA) in PBS, and rotated at 4ºC for 16 hours. The 
microparticles were then centrifuged, and the supernatant was removed and analyzed for 
growth factor content via ELISA (R&D Systems, Minneapolis, MN). Growth factor 
loading on the material was determined by subtracting the amount of growth factor 
remaining in solution for microparticle-containing samples from growth factor solutions 
rotated at 4ºC for 16 hours that lacked microparticles.  
Passive release of BMP-2 into 0.1% (w/v) BSA in PBS was monitored over a 
period of 28 days at both 4ºC and 37ºC. Heparin microparticles (0.1 mg) were incubated 
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with a range of BMP-2 concentrations to obtain growth factor loading between 25 and 
1000 ng BMP-2 per mg of microparticles. For comparison with gelatin methacrylate 
microparticles, heparin microparticles and gelatin microparticles (0.1 mg) were incubated 
with 25 and 50 ng/mL of BMP-2 respectively, to obtain an equal loading of 200 ng BMP-
2 per mg of microparticles. At various time points over 28 days, the microparticles were 
centrifuged at 3000 rpm for 5 minutes, and 300 µL samples of the supernatant were 
removed and replaced with an equivalent volume of fresh 0.1% (w/v) BSA in PBS. 
Release samples were then analyzed for growth factor content via ELISA. 
For investigating dual growth factor loading and release using BMP-2 and VEGF, 
0.1 mg of microparticles were either (1) incubated in 100 ng of BMP-2 for 16 hours first, 
followed for 16 hours of incubation in 100 ng of VEGF, (2) incubated in 100 ng of VEGF 
first, followed by incubation in 100 ng of BMP-2, or (3) incubated in 100 ng of BMP-2 
and 100 ng of VEGF simultaneously. BMP-2 and VEGF loading efficiencies, as well as 
displacement after loading with the second growth factor, were evaluated via ELISA of 
respective growth factor depleted solutions. Passive release of BMP-2 and VEGF into 
0.1% (w/v) BSA in PBS was monitored over a period of 7 days at 37ºC; samples were 
collected and analyzed similarly to BMP-2 release experiments. 
	
3.2.5 C2C12 Alkaline Phosphatase Activity Assay 
 
Skeletal myoblasts (C2C12; ATCC, Manassas, VA) were cultured in growth 
media consisting of DMEM (Corning Mediatech, Manassas, VA) supplemented with 
16% fetal bovine serum (FBS; Thermo Fisher Scientific – Hyclone, Logan, UT) and 
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maintained at 37ºC in a 5% CO2 humidified incubator. For the alkaline phosphatase 
(ALP) activity assay, C2C12 cells were seeded in 96-well plates at an initial density of 
20,000 cells per well and allowed to attach for 6 hours under growth conditions (16% 
FBS in DMEM). Cells were then switched to low serum media (1% FBS in DMEM), and 
the following treatments were added: soluble BMP-2 (5-1500 ng/mL), loaded and 
unloaded heparin microparticles (0.02-0.5 mg), and soluble unmodified heparin (0.1 mg). 
For transwell experiments, cells were cultured on the bottom compartment of a 96-well 
transwell plate (Corning), and microparticles were added above the polycarbonate 
membrane (0.2 µm pore diameter) placed on top. After 72 hours of treatment, cells were 
washed twice with PBS and lysed using 100 µL of CelLytic M (Sigma Aldrich). Cell 
lysate was stored at -80ºC prior to analysis.  
ALP activity of C2C12 cultures was measured by incubating 50 µL of cell lysate 
with 50 µL of CelLytic M and 100 µL of a substrate solution consisting of 3.33 mM 
MgCl2 (VWR, West Chester, PA), 500 mM 2-amino-2-methyl-1-propanol (Sigma 
Aldrich), and 6.67 mM p-nitrophenyl phosphate (pNPP; Sigma Aldrich). The reaction 
was terminated with 0.2 M NaOH after 5 minutes, and absorbance measured at 405 nm 
on a Synergy H4 microplate reader (Biotek, Winooski, VT). A standard curve for total 
ALP activity was generated using graded concentrations of the ALP product, 4-
nitrophenol (0-1 nmol/µL; Sigma Aldrich). 
	
3.2.6 C2C12 DNA Assay and Staining 
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DNA content of C2C12 cultures was measured using the QuantiFluor dsDNA kit 
(Promega, Madison, WI). Briefly, 20 µL of cell lysate were incubated with 80 µL of the 
assay buffer and 100 µL of the fluorescent DNA-binding dye for five minutes, protected 
from light. Fluorescence was measured on a Synergy H4 microplate reader (Bioteck, 
Winooski, VT), using an excitation wavelength of 504 nm and emission wavelength of 
519 nm. Total DNA content was correlated to fluorescence by comparison to a DNA 
standard curve (48.5 kb). DNA fold change was determined by dividing the final DNA 
content after 72 hours by DNA content after 6 hours of initial cell attachment (Day 0). 
C2C12 cultures were also fixed and stained with Hoechst for visualization of cell 
nuclei. Cells were washed twice with PBS and fixed with 4% paraformaldehyde in PBS 
(Alfa Aesar, Ward Hill, MA) for 15 minutes. Hoechst 33258 (50 mg/mL; Sigma Aldrich) 
was diluted 1:100 in 2% BSA and 0.1% polysorbate 20 in PBS and added to the cells for 
15 minutes, followed by two additional PBS washes. Fixed cultures were imaged with a 
laser scanning confocal microscope (Zeiss LSM 700-405; Carl Zeiss Inc., Oberkochen, 
Germany). 
	
3.2.7 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. Experiments were run 
with three or more replicates for each experimental group. Statistical significance was 
determined using one-way or two-way ANOVA as appropriate, followed by Tukey’s post 





3.3.1 Heparin Methacrylamide and Heparin Microparticle Characterization 
 
1H NMR indicated that approximately 50% of the carboxyl groups of heparin 
were conjugated with methacrylamide groups (Figure 3.1B). Heparin microparticle 
fabrication produced microparticles with an average diameter of 5.6 ± 4.0 µm (Figure 
3.2), and approximately 1.9 x 107 microparticles per mg of heparin methacrylamide 
polymer. SEM images of the microparticles depicted a smooth, spherical morphology 
(Figure 3.1C), while brightfield images revealed that the microparticles stained positively 
with DMMB, confirming the presence of sulfated GAGs (Figure 3.1D). 
 
Figure 3.1. Characterization of Heparin Microparticles. A) Heparin ammonium salt was 
combined with excess APMAm, sulfo-NHS, and EDC to produce heparin methacrylamide 
(HMAm). B) 1H-NMR results indicated that ~50% of carboxyl groups on heparin were 
substituted with methacrylamide groups. Degree of substitution was determined by comparing the 
integration regions of modified and unmodified heparin. C) Scanning electron microscopy image 
of heparin microparticles demonstrating the polydisperse and spherical nature of the 
microparticles. D) Image of heparin microparticles stained with 1,9-dimethylmethylene blue 




Figure 3.2. Heparin Microparticle Size Distribution. Microscope images of heparin 
microparticles were analyzed using a custom CellProfiler script. Microparticles exhibited a 
polydisperse, unimodal size distribution with an average diameter of 5.6 ± 4.0 µm. 
	
3.3.2 Growth Factor Loading on Microparticles 
 
Growth factors that had a net positive charge at pH = 7.5, such as FGF-2 (pI = 
9.6), VEGF (pI = 8.5), and BMP-2 (pI = 9.0), were depleted from solution, and exhibited 
high loading (~85%) on the negatively charged heparin microparticles (Figure 3.3A). In 
contrast, TNF-α (pI = 5.3), which is negatively charged at pH = 7.5, was not significantly 
depleted from solution, with only 1.9% ± 1.1% of the added growth factor loaded onto 
the microparticles (Figure 3.3A), revealing that growth factor loading on heparin 
microparticles was dependent on electrostatic charge interaction. Additionally, when 
compared to gelatin microparticles, heparin microparticles loaded ~44% more BMP-2 
than similarly cross-linked gelatin methacrylate microparticles (Figure 3.4A).  
 To further investigate the growth factor loading capacity of heparin 
microparticles, BMP-2 loading was measured with different amounts of microparticles 
(0.02-200 µg) and a fixed loading concentration of BMP-2 (20 ng/mL in 1 mL; Figure 
	 46 
3.3B). As expected, the percentage of BMP-2 loaded onto the microparticles increased in 
a dose-dependent manner with the addition of more microparticles, and nearly all of the 
BMP-2 was captured with >20 µg of microparticles, which loaded >95% of the added 
BMP-2. Conversely, the amount of BMP-2 loaded per milligram of microparticles 
decreased with increasing numbers of microparticles, indicating a reduced amount of 
BMP-2 bound per microparticle. 
 The relationship between microparticle loading capacity and BMP-2 solution 
concentration was evaluated using a fixed amount of microparticles (0.2 µg) and range of 
BMP-2 concentrations (0.1–5000 µg/mg of microparticles) (Figure 3.3C, D). Heparin 
microparticles depleted more BMP-2 from solution as the loading mass of BMP-2 was 
increased. At BMP-2 loading concentrations between 0.1-10 µg/mg of microparticles, the 
relationship between loading mass and BMP-2 bound was relatively linear, with 
approximately 80% of the added BMP-2 loaded onto the microparticles, regardless of 
loading concentration; however, as the BMP-2 loading mass increased beyond 10 µg/mg 
of microparticles, the percentage of BMP-2 loaded onto the microparticles decreased to 
<55% of the loading mass. Maximum BMP-2 loading was observed at approximately 300 
µg BMP-2/mg microparticles. 
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Figure 3.3. Growth Factor Loading Capacity of Heparin Microparticles. A) 0.1 mg of 
microparticles were incubated with 10 ng of FGF-2, VEGF, BMP-2, and TNF-α. Heparin 
microparticles depleted the majority of positively charged growth factors (FGF-2, VEGF, BMP-
2), while negatively charged TNF-α was not depleted. (* = p < 0.05 compared to all other 
conditions.) B) Heparin microparticles were incubated with 20 ng of BMP-2. Percentage of BMP-
2 depleted increased with the addition of more microparticles. Conversely, the amount of BMP-2 
depleted on a per mg of microparticles basis increased with decreasing microparticle amounts. C, 
D) 0.2 µg of microparticles were incubated with increasing amounts of BMP-2. Heparin 
microparticles deplete more BMP-2 from solution as the loading mass of BMP-2 is increased. 
Microparticles become saturated with BMP-2 at ~300 µg BMP-2/mg microparticles. 
	
	
Figure 3.4. Comparison of Growth Factor Loading and Release of Heparin and Gelatin 
Microparticles. A) 0.1 mg of heparin methacrylamide and gelatin methacrylate microparticles 
were incubated with 10 ng of BMP-2. Heparin microparticles depleted more BMP-2 than gelatin 
microparticles. (* = p < 0.05 as indicated.) B) Heparin and gelatin microparticles loaded with 200 
ng of BMP-2/mg of microparticles were allowed to passively release BMP-2 into at 37oC. 
Heparin microparticles retained more BMP-2 than gelatin microparticles over 28 days. (p < 0.05 
between gelatin and heparin microparticles at each time point.) 
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3.3.3 Growth Factor Release from Microparticles 
 
Release profiles of BMP-2 from heparin microparticles were investigated at 
different growth factor loading densities (25-1000 ng BMP-2/mg of microparticles) and 
temperatures (4ºC, 37ºC) (Figure 3.5). At both temperatures, microparticles exhibited low 
initial release within the first 6 hours (<10%), followed by additional sustained release 
over the next 4 weeks. Heparin microparticles loaded with higher concentrations of 
BMP-2 exhibited a greater initial release and overall cumulative release over the 28-day 
period than microparticles loaded at lower BMP-2 concentrations; the differences in final 
cumulative release were significant for release profiles at both temperatures, while the 
differences in initial release were significant at 37ºC. Despite drastically different BMP-2 
loading (ng BMP-2/mg microparticles), the cumulative percentage of BMP-2 released 
was independent of loading mass and similar for all growth factor loading concentrations 
at 4ºC (Figure 3.5D). Total release of BMP-2 after 28 days was <20% of the loaded 
growth factor at 37ºC, and <25% at 4ºC, indicating that the majority of growth factor was 
retained by the microparticles at both temperatures. Release profiles of BMP-2 from 
heparin microparticles were also compared to BMP-2 release from gelatin methacrylate 
microparticles. When both types of microparticles were loaded with the same amount of 
BMP-2 (200 ng BMP-2/mg microparticles), the BMP-2 release from the gelatin 
microparticles at 37ºC was greater at each time point, with ~30% of the growth factor 




Figure 3.5. BMP-2 Release from Heparin Microparticles. Heparin microparticles were 
incubated with different amounts of BMP-2 to obtain loading between 25-1000 ng BMP-2/mg of 
microparticles. Microparticles were allowed to passively release BMP-2 into a PBS solution over 
28 days. A) Release curves at 37oC presented as cumulative mass of BMP-2 released per mg of 
microparticles show that microparticles loaded with more BMP-2 exhibit greater release over 28 
days. B) Release curves at 37oC presented as cumulative percent of loaded BMP-2 show that 
percentage of BMP-2 released highest for the lowest loading amount investigated. C) Release 
curves at 4oC presented as cumulative mass of BMP-2 released per mg of microparticles also 
show that microparticles loaded with more BMP-2 exhibit greater release over 28 days. D) 
Release curves at 4oC presented as cumulative percent of loaded BMP-2 show that percentage of 
BMP-2 released was independent of loading mass and similar for all BMP-2 loading densities.  
	
3.3.4 Dual Growth Factor Loading and Release from Heparin Microparticles 
	
The ability of heparin microparticles to deplete multiple growth factors from 
solution was evaluated using stepwise and simultaneous loading with BMP-2 and VEGF. 
Microparticles depleted more BMP-2 from solution (~95% vs. ~55%), regardless of 
whether microparticles were incubated in BMP-2 first, VEGF-2 first, or both 
simultaneously (Figure 3.6A). Furthermore, when microparticles were first incubated in 
BMP-2, followed by VEGF, only 3.1% ± 0.3% of the BMP-2 was displaced; however, 
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when microparticles were incubated in VEGF, followed by BMP-2, 15.4% ± 0.8% of the 
VEGF was displaced (Figure 3.6B). Finally, release profiles of dual loaded microparticles 
demonstrated that VEGF release from the microparticles was greater than BMP-2 release. 
Although there were some differences in the cumulative amount of growth factor released 
when BMP-2 was loaded first (Figure 3.6C), VEGF was loaded first (Figure 3.6D), or 
both were loaded together (Figure 3.6E), VEGF release was consistently greater than 
BMP-2 release at all time points and in all conditions, at ~40% overall compared to 
~20% overall. This was likely due to the lower affinity of VEGF for heparin compared to 
BMP-2, as the dissociation constant of VEGF-heparin interactions (KD = 40-80 nM) [94] 
is higher than that of BMP-2-heparin interactions (KD = 20 nM) [3].  
	
Figure 3.6. BMP-2 and VEGF Loading and Release from Heparin Microparticles. A) Both 
stepwise and simultaneous loading of microparticles with BMP-2 and VEGF resulted in greater 
BMP-2 depletion than VEGF depletion. (* = p < 0.05 as indicated) B) Loading with VEGF 
followed by loading with BMP-2 resulted in higher VEGF displacement than the BMP-2 
displacement observed when BMP-2 was loaded prior to VEGF loading. (* = p < 0.05) 
Cumulative release of VEGF was higher than that of BMP-2 when A) BMP-2 was added first and 
VEGF was added second, B) VEGF was added first and BMP-2 was added second, and C) when 




3.3.5 Microparticle-mediated Effects on C2C12 Alkaline Phosphatase Activity 
 
The bioactivity of BMP-2 bound to heparin microparticles was examined using an 
ALP activity assay on skeletal myoblasts (C2C12). C2C12 cells were chosen as a 
platform to evaluate BMP-2 bioactivity, since the addition of BMP-2 to low serum 
culture conditions can robustly inhibit C2C12 myogenesis and enhance expression of 
osteogenic markers, such as ALP [186]. A fixed amount of microparticles (0.1 mg) was 
loaded with several BMP-2 amounts (10, 30, 100 ng) that stimulate ALP activity within 
the dynamic range of the cells (Figure 3.7). When normalized to DNA content, resulting 
ALP activity was comparable between soluble BMP-2 and loaded microparticle groups at 
10 and 30 ng, and lower for the loaded microparticle group at 100 ng (Figure 3.8A). 
Interestingly, unloaded heparin microparticles (without BMP-2) induced a 6-fold increase 
in ALP activity compared to no treatment, resulting in ALP activity that was comparable 
to that of 10 ng of soluble BMP-2 treatment (~1 nmol pNP/ng DNA). 
 The effect of microparticle dose on ALP activity was also determined by culturing 
C2C12 cells with different amounts of microparticles (0.02, 0.1, 0.5 mg) loaded with a 
fixed BMP-2 dose (30 ng total; Figure 3.8B). Representative images of Safranin O-
stained microparticles cultured with cells after 6 hours of attachment demonstrate 
differences in microparticle coverage area on a 96-well plate (Surface Area = 0.32 cm2) 
(Figure 3.8C). As expected, C2C12 cells cultured with 0.02 mg and 0.1 mg of BMP-2-
loaded microparticles stimulated higher ALP activity than no treatment and cells cultured 
with unloaded microparticles. However, 0.5 mg of loaded microparticles induced lower 
ALP activity that equivalent amounts of BMP-2 delivered solubly and with 0.02 and 0.1 
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mg of microparticles, with no difference in ALP expression between cultures containing 
0.5 mg of unloaded and loaded microparticles. Interestingly, increasing the amount of 
unloaded microparticles dose-dependently increased ALP, and 0.1 and 0.5 mg of 
unloaded microparticles induced higher ALP activity than no treatment.  
 In order to determine whether the stimulation of C2C12 ALP activity could 
simply be attributed to the presence of heparin in the cultures, C2C12 cells were treated 
with 0.1 mg of soluble modified heparin, with and without BMP-2 (Figure 3.8D). The 
presence of soluble heparin alone did not stimulate an increase in ALP activity compared 
to unloaded heparin microparticles. Additionally, when soluble heparin was incubated 
with 30 ng of BMP-2 beforehand and cultured with the cells, ALP activity was attenuated 
compared to soluble BMP-2 and an equivalent amount of loaded microparticles (1.07 ± 
0.08 nmol pNP/ng DNA compared to 1.45 ± 0.09 nmol pNP/ng DNA and 2.84 ± 0.09 
nmol pNP/ng DNA, respectively).  
	
Figure 3.7. Effect of Soluble BMP-2 on Alkaline Phosphatase Activity in C2C12 Cultures. 
C2C12 cells were cultured for 72 hours with 0-1500 ng/mL of soluble BMP-2. Cell lysate was 
incubated with p-nitrophenyl phosphate substrate to determine ALP activity. C2C12 cells 




Figure 3.8. Effect of Heparin Microparticles Loaded with BMP-2 on Alkaline Phosphatase 
Activity in C2C12 Cultures. C2C12 cells were cultured for 72 h with each treatment. Cell lysate 
was incubated with p-nitrophenyl phosphate substrate to determine ALP activity and normalized 
to DNA content. A) 0.1 mg of microparticles pre-loaded with BMP-2 induced ALP activity in a 
dose-dependent manner comparable to that of soluble BMP-2 at 10 and 30 ng, and lower than 
soluble BMP-2 at 100 ng. 0.1 mg of unloaded MPs also induced greater ALP activity than cells 
without treatment. (* = p < 0.05 as indicated; # = p < 0.05 for all conditions in group; $ = p < 
0.05 compared to unloaded MPs (0 ng)) B) C2C12 cells were cultured with different doses of 
microparticles (0.02 mg, 0.1 mg, 0.5 mg) that were either unloaded or loaded with 30 ng of BMP-
2. Loaded microparticles induced higher ALP activity than unloaded microparticles in all cases 
except for 0.5 mg of microparticles. (* = p < 0.05 as indicated; $ = p < 0.05 compared to no 
treatment and 0.02 mg of unloaded MPs (0 ng)) C) Representative images of C2C12 cells 
cultured without microparticles and with 0.02 mg, 0.1 mg, and 0.5 mg of microparticles in a 96-
well plate. Microparticles were stained with Safranin O for enhanced contrast. D) 0.1 mg of 
soluble heparin did not induce the same increase in ALP activity as 0.1 mg of unloaded 
microparticles. Soluble heparin in the presence of BMP-2 inhibited ALP activity compared to 
BMP-2 delivered solubly and via microparticles. (* = p < 0.05 as indicated; % = p < 0.05 
compared to no treatment; $ = p < 0.05 compared to unloaded MPs (0 ng); # = p < 0.05 compared 
to soluble heparin (0 ng)) 
 
3.3.6 Microparticle-mediated Effects on C2C12 DNA Content 
 
The DNA content of C2C12 cultures treated with a fixed number of BMP-2-
loaded microparticles (0.1 mg) increased 3-4 fold over the three day culture period, while 
	 54 
cultures treated with equivalent amounts of soluble BMP-2 did not display any 
appreciable change in DNA content (Figure 3.9A), suggesting that the presence of loaded 
microparticles increased cell number. At a fixed BMP-2 dose (30 ng), C2C12 cells 
cultured with fewer loaded microparticles (0.02 and 0.1 mg) at a higher BMP-2 loading 
density exhibited a ~3.5-fold increase in DNA content compared to unloaded 
microparticle controls, whereas cells cultured with 0.5 mg of microparticles exhibited no 
change in DNA content (Figure 3.9B). Comparable differences in cell number were 
observed with Hoechst staining of C2C12 cells cultured without microparticles and with 
various doses of microparticles in the presence of 30 ng of BMP-2 (Figure 3.9C). This 
result demonstrated that BMP-2 loading density of the microparticles may determine 
effects on DNA content, with higher loading densities stimulating larger DNA increases.  
 C2C12 cells cultured with 0.1 mg of soluble heparin and 0.1 mg of unloaded 
microparticles both exhibited similar decreases in DNA content over the culture period, 
indicating that the presence of heparin alone in the system reduced cell number (Figure 
3.9D). Although BMP-2-loaded microparticles induced an increase in DNA content 
compared to no treatment, cells cultured with soluble heparin in the presence of BMP-2 





Figure 3.9. Effect of Heparin Microparticles Loaded with BMP-2 on DNA Content in 
C2C12 Cultures. C2C12 cells were cultured for 72 h with each treatment. Cell lysate was 
incubated with a fluorescent dsDNA-binding dye to determine DNA content. Fold change in 
DNA is presented as final Day 3 DNA content compared to initial Day 0 DNA content. A) 
Microparticles loaded with BMP-2 increased DNA content compared to soluble BMP-2 controls. 
Unloaded microparticles did not increase DNA content. (* = p < 0.05 as indicated; $ = p < 0.05 
compared to unloaded MPs.) B) Cells cultured with 0.02 mg and 0.1 mg of microparticles in the 
presence of BMP-2 both exhibited an increase in DNA content compared to unloaded 
microparticle controls, while cells cultured with 0.5 mg of microparticles did not. (* = p < 0.05 as 
indicated; # = p < 0.05 compared to soluble BMP-2 (30 ng); % = p < 0.05 compared to 0.5 mg 
MP (30 ng)) C) Representative images of cells cultured without microparticles and with 0.02 mg, 
0.1 mg, and 0.5 mg of microparticles in the presence of 30 ng of BMP-2 for three days. Cell 
nuclei were stained with Hoechst. D) Cells cultured with soluble heparin without BMP-2 
displayed similar DNA content compared to cells cultured without treatment and with unloaded 
microparticles. Cells cultured with soluble heparin in the presence of BMP-2 did not exhibit an 
increase in DNA content. (* = p < 0.05 as indicated; $ = p < 0.05 compared to unloaded MPs; # = 






3.3.7 Contact-mediated Effects of Microparticles on C2C12 Cultures 
	
In order to determine whether the observed effects of heparin microparticles on 
C2C12 ALP activity and DNA content were contact-dependent, heparin microparticles 
were physically separated from the cells by a transwell membrane and added without 
BMP-2 or with 30 ng of BMP-2 (soluble or pre-loaded; Figure 3.10A). The presence of 
unloaded microparticles in direct contact with the cells increased normalized and total 
ALP activity compared to both no treatment and physically separated unloaded 
microparticles (Figure 3.10B, D). In BMP-2 treatment groups, ALP activity normalized 
to DNA content was similar between cells in direct contact with the microparticles and 
physically separated from the microparticles, regardless of whether the BMP-2 was added 
solubly or loaded onto the microparticles (Figure 3.10B). However, total ALP activity of 
C2C12 cultures physically separated from the microparticles was lower than that of direct 
contact cultures (Figure 3.10D). This was due to the fact that transwell separation of cells 
and microparticles in the presence of soluble or loaded BMP-2 did not affect DNA 
content over the culture period, while cultures in which the cells and microparticles were 
in direct contact exhibited significant DNA increases (3-4 fold; Figure 3.10C). This 
indicated that the changes in DNA content were contact-mediated. Similarly, while cells 
cultured in direct contact with unloaded microparticles exhibited a decrease in DNA 
content over three days, there was no change in DNA content when the cells and 





Figure 3.10. Contact-mediated Effect of Heparin Microparticles on Alkaline Phosphatase 
Activity and DNA Content in C2C12 Cultures. C2C12 cells were cultured for 72 h with each 
treatment. Cell lysate was incubated with p-nitrophenyl phosphate substrate to determine ALP 
activity and incubated with a fluorescent dsDNA-binding dye to determine DNA content. Fold 
change in DNA is presented as final Day 3 DNA content compared to initial Day 0 DNA content. 
A) Schematic indicating the conditions investigated with cells and microparticles in direct contact 
and physically separated. B) Normalized ALP activity of cells incubated with microparticles in 
direct contact and physically separated were comparable to each other and soluble BMP-2 
treatment, regardless of whether the BMP-2 in the culture was added solubly or pre-loaded onto 
the microparticles. Normalized ALP activity of cells in direct contact with unloaded 
microparticles was higher than that of cells separated from unloaded microparticles. C) Cells 
cultured in the presence of both BMP-2 and microparticles physically separated from the cells by 
a transwell demonstrated lower DNA content than cells cultured in direct contact with 
microparticles and in the presence of BMP-2. (* = p < 0.05 as indicated; $ = p < 0.05 compared 
to unloaded MPs) D) Total ALP activity of cells in direct contact with the microparticles was 
higher than that of cells that were separated from the microparticles via transwell insert and 
soluble BMP-2 treatment alone. Total ALP activity of cells in direct contact with unloaded 
microparticles was also higher than that of cells separated from unloaded microparticles. (* = p < 






3.3.8 Long-term Bioactivity of Microparticle-bound Growth Factors 
 
Since previous studies have demonstrated the ability of heparin to prolong the 
half-life of BMP-2 and maintain its bioactivity in culture [101, 172], we also evaluated 
whether complexing BMP-2 with heparin microparticles would result in a similar effect 
on BMP-2 bioactivity. We pre-incubated 30 ng of soluble BMP-2, 0.1 mg of unloaded 
microparticles, and 0.1 mg of microparticles loaded with 30 ng of BMP-2 in low serum 
media for 2 weeks at 37°C, and compared the ability of pre-incubated treatments to 
induce C2C12 ALP activity and cell proliferation with that of fresh soluble BMP-2, 
unloaded microparticles, and BMP-2-loaded microparticles. BMP-2-loaded heparin 
microparticles induced higher total ALP activity than unloaded heparin microparticles 
and soluble BMP-2 at both 0 and 2 weeks (Figure 3.11A). While the ALP activity 
induced by both BMP-2-loaded microparticles and soluble BMP-2 dropped significantly 
over the two week period of pre-incubation, there was no difference between the ALP 
activity induced by pre-incubated loaded microparticles and fresh soluble BMP-2; this 
result indicates that heparin microparticles were able to maintain BMP-2 bioactivity at a 
similar level as the fresh soluble protein even after a 2 week period of pre-incubation in 
the presence of low serum containing media. Moreover, BMP-2-loaded heparin 
microparticles retained their ability to increase cell proliferation in C2C12 cultures after 
both 0 and 2 weeks of pre-incubation (Figure 3.11B). 
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Figure 3.11 Effect of Heparin Microparticles on Long Term Bioactivity of BMP-2 in C2C12 
Cultures. C2C12 cells were cultured for 72 h with each treatment. Cell lysate was incubated with 
p-nitrophenyl phosphate substrate to determine ALP activity and incubated with a fluorescent 
dsDNA-binding dye to determine DNA content. A) BMP-2-loaded microparticles induced higher 
total ALP activity than unloaded microparticles and soluble BMP-2 at both time points. ALP 
activity induced by both BMP-2-loaded microparticles and soluble BMP-2 dropped over the 2-
week period of pre-incubation. (* = p < 0.05 as indicated; # = p < 0.05 compared to loaded MPs 
(0 weeks); $ = p < 0.05 compared to soluble BMP-2 (0 weeks)) B) Treatment with BMP-2-loaded 
microparticles resulted in higher DNA content after three days compared to unloaded 
microparticles and soluble BMP-2 treatment at both 0 and 2 weeks. (* = p < 0.05 as indicated) 
	
3.3.9 Reproducibility of Heparin Microparticle Fabrication Method 
 
In order to investigate the reproducibility of heparin microparticle fabrication, ten 
independent batches of microparticles made from six independent batches of heparin 
methacrylamide were evaluated for their ability to deplete BMP-2 (50 ng) and induce 
ALP activity and cell proliferation in C2C12 cultures. Phase images of microparticles 
cultured with C2C12 cells depict similar microparticle morphology between batches 
(Figure 3.12A), although microparticle clumping was more apparent in some batches 
than in others (MP #1, #2, #6, #9). Ultimately, microparticle clumping did not result in 
differences in BMP-2 loading ability, and each batch of microparticles depleted ~70-85% 
of the added BMP-2 (Figure 3.12B), as expected. BMP-2-loaded microparticles from 
each batch induced more ALP activity than unloaded microparticles (Figure 3.12C). 
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Although the degree of ALP activity induced was variable, all but one of the 
microparticle batches stimulated similar or greater ALP activity (Average ALP: 120.6 ± 
6.5 nmol pNPP) compared to soluble BMP-2 treatment (110.8 ± 10.6 nmol pNPP). 
Furthermore, ALP activity did not appear to be influenced by microparticle clumping. 
BMP-2-loaded microparticles also induced significant increases in C2C12 DNA content 
compared to soluble BMP-2 treatment (Figure 3.12D). Overall, these results demonstrate 
the reproducibility and robust functionality of the heparin microparticles. 
	
 
Figure 3.12. Reproducibility of Microparticle Loading and BMP-2 Bioactivity. Ten batches 
of microparticles made from six batches of heparin methacrylamide were evaluated for their 
ability to deplete BMP-2 and induce ALP activity and DNA increases in C2C12 cells. A) Phase 
images of 0.1 mg of microparticles cultured with 20,000 cells in 96-well plates. B) 0.1 mg of 
microparticles were loaded with 50 ng of BMP-2. All batches of microparticles depleted a similar 
amount of BMP-2 (~70-85%). C) C2C12 cells were cultured for 72 h with soluble BMP-2, 
unloaded microparticles, or BMP-2-loaded microparticles. Cell lysate was incubated with p-
nitrophenyl phosphate to determine ALP activity. Each batch of loaded microparticles induced 
higher ALP activity than unloaded microparticles. (* = p < 0.05 as indicated; # = p < 0.05 
compared to soluble BMP-2) D) Cell lysate was incubated with a fluorescent dsDNA-binding dye 
to determine DNA content. Treatment with loaded microparticles resulted in higher C2C12 DNA 
content after 72 h compared to soluble BMP-2. (* = p < 0.05 as indicated) 
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3.3.10 Effect of Lyophilization on BMP-2-Loaded Microparticles 
	
Another practical consideration in developing heparin microparticles as a BMP-2 
delivery system for clinical applications is the stability of both unloaded and loaded 
microparticles prior to use by a surgeon. Lyophilized heparin microparticles can be stored 
at 4°C for extended periods of time and maintain their ability to load functional BMP-2 
for at least two years (Figure 3.12, Batch #1). Furthermore, heparin microparticles can be 
loaded with BMP-2 and lyophilized for future use. 0.1 mg of microparticles were either 
loaded with 30 ng of BMP-2 overnight at 4°C and lyophilized for 24 hours or freshly 
loaded with 30 ng of BMP-2 overnight at 4°C. Lyophilized BMP-2-loaded microparticles 
demonstrated a similar cumulative BMP-2 release profile to freshly loaded microparticles 
(Figure 3.13A), releasing slightly more BMP-2 over 7 days (24.7% ± 1.0% vs. 21.3% ± 
0.3%). Moreover, lyophilized BMP-2-loaded microparticles induced robust ALP activity 
in C2C12 cells that was comparable to that of both soluble BMP-2 and freshly loaded 
BMP-2-loaded microparticles (Figure 3.13B). Lyophilized unloaded microparticles did 
not have an effect on ALP activity. Overall, these results demonstrate that lyophilization 
does not impact the bioactivity and release kinetics of microparticle-bound BMP-2, and 
thus BMP-2-loaded microparticles may be easily transported and stored in a lyophilized 




Figure 3.13. BMP-2 Release and Bioactivity from Lyophilized Loaded Heparin 
Microparticles. 0.1 mg of microparticles were either loaded with 30 ng of BMP-2 overnight and 
lyophilized for 24 hours or freshly loaded with 30 ng of BMP-2 overnight. A) Lyophilized loaded 
microparticles and freshly loaded microparticles demonstrated similar cumulative BMP-2 release 
profiles over 7 days with differences at 4 and 7 days. (* = p < 0.05 between groups at time point) 
B) Both lyophilized loaded microparticles and freshly loaded microparticles induced comparable 
normalized ALP activity to soluble BMP-2 treatment. Low serum media without BMP-2 or with 
unloaded microparticles did not induce ALP activity. (# = p < 0.05 compared to 0 ng of BMP-2, 




In this study, the ability of heparin methacrylamide microparticles to bind, retain, 
and present bioactive growth factors in vitro was investigated. Heparin microparticles 
depleted considerable amounts of several positively charged heparin-binding growth 
factors (BMP-2, VEGF, FGF-2) from solution, including a high quantity of BMP-2 that 
exceeded the maximum reported growth factor loading capacity of other heparin-
containing biomaterials by >1000-fold [115, 167, 168, 175, 187, 188] and surpassed the 
BMP-2 loading of gelatin methacrylate microparticles by nearly 50%. The majority of 
BMP-2 loaded onto heparin microparticles at various concentrations (25-1000 ng BMP-
2/mg microparticles) was retained within the hydrogel matrix, with <25% of the growth 
factor being released over 28 days. Heparin microparticles could also simultaneously 
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bind and release different amounts of multiple growth factors (BMP-2 and VEGF), in a 
manner related to their relative affinities for heparin.  
BMP-2-loaded microparticles stimulated ALP activity in C2C12 cells comparable 
to soluble BMP-2 treatment at multiple BMP-2 and microparticle doses, demonstrating 
that microparticle-bound BMP-2 maintained its bioactivity under conditions of low 
release. Moreover, in addition to inducing ALP activity, BMP-2-loaded microparticles 
also stimulated a striking contact-mediated increase in DNA content over the three day 
culture period, which was inhibited when cells and microparticles were physically 
separated and absent when cells were cultured with an equivalent amount of heparin 
instead. The ability of heparin microparticles to maintain BMP-2 bioactivity and elicit 
increases in C2C12 ALP activity and DNA content was also preserved after a 2-week 
period of pre-incubation at 37°C, as well as after lyophilization of BMP-2-loaded 
microparticles. Overall, this study illustrates that heparin microparticles can reproducibly 
retain and present high amounts of BMP-2 that elicit functional cell responses and can 
therefore serve as a potent vehicle for the sustained delivery of bioactive growth factors. 
Conventional heparin delivery strategies typically involve immobilization of 
soluble heparin onto other bulk biomaterials, such as collagen, PLGA, fibrin, or 
Sepharose [101, 115, 116, 122, 173, 174, 189]. However, the methacrylamide-mediated 
cross-linking reaction used here allows for the generation of hydrogel microparticles that 
consist purely of heparin, facilitating the delivery of highly concentrated molecular cargo. 
Heparin microparticles exhibit high BMP-2 retention (>75%), which may make them 
better suited for localized growth factor presentation than conventional delivery vehicles 
that exhibit much lower growth factor retention (<20%), such as polyethylene glycol 
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(PEG) and gelatin biomaterials [152, 190-192]. The gelatin methacrylate microparticles 
used in this study were thermally cross-linked with free radical polymerization in a 
manner similar to heparin methacrylamide [114]. Although gelatin also primarily 
interacts with positively charged growth factors electrostatically, heparin microparticles 
captured and retained more BMP-2 than gelatin microparticles, likely due to their higher 
charge density [91, 156].  
Furthermore, we have also demonstrated that heparin microparticles can be used 
to simultaneously deliver multiple growth factors (BMP-2 and VEGF), exhibiting a 
temporal offset in release profiles created by differences in heparin binding affinity. This 
ability of heparin microparticles to provide differential release profiles of co-delivered 
biomolecules may have utility in tissue regeneration strategies in which delivery of 
multiple growth factors is required; for example, bone defects in which revascularization 
is severely impeded may benefit from an initial fast release of VEGF followed by long 
term sustained presentation of BMP-2 [193-195]. However, since growth factor release 
from heparin microparticles is dependent upon a protein’s relative affinity for heparin, 
tuning the growth factor loading capacity and sequence/extent of growth factor release 
from a naturally derived biomaterial may pose a challenge, and some studies have 
demonstrated that the combinatorial delivery of growth factors may inhibit osteogenesis 
and bone regeneration if not suitably tuned [196, 197]. 
Previous studies investigating the co-delivery of heparin and BMP-2 have 
demonstrated both stimulatory and inhibitory effects on BMP-2-mediated osteogenesis 
[101, 104-106, 169-171]. In this study, ALP activity induced in C2C12 cells by soluble 
BMP-2 and microparticle-bound BMP-2 was comparable. Interestingly, since release 
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curves of BMP-2 from heparin microparticles at 37ºC indicated that the majority of 
BMP-2 was retained within the microparticles, ALP activity results suggested that the 
heparin-BMP-2 interaction formed by the microparticles effectively presented BMP-2 to 
cells and induced a functional cellular response without complete release of the growth 
factor. This finding agrees with several studies that have shown that co-delivery of 
heparin and BMP-2 promotes ALP secretion in several cell types, including C2C12 
skeletal myoblasts, MC3T3 pre-osteoblasts, and mesenchymal stem cells (MSCs) [101, 
106, 115]. Although the specific mechanism by which heparin enhances BMP-2 signaling 
remains unclear, co-delivery of BMP-2 and heparin may enhance BMP-2 cell signaling 
by facilitating formation of growth factor-receptor complexes on the cell surface [3, 198] 
or by prolonging the half life of BMP-2 in culture [101, 104, 144]. Furthermore, this 
mechanism could also explain the fact that unloaded heparin microparticles dose-
dependently elicited an increase in ALP activity without the addition of exogenous BMP-
2. Heparin microparticles could potentially sequester cell-secreted heparin-binding 
proteins, such as BMPs and other growth factors, thereby prolonging growth factor 
presentation and subsequently enhancing ALP activity [199].  
Unlike microparticle delivery of BMP-2, co-delivery of soluble heparin and 
BMP-2 resulted in ALP activity that was lower than that of soluble BMP-2 alone. This 
may suggest that soluble heparin binds to BMP-2 in solution, preventing its interaction 
with cell surface receptors and subsequently inhibiting further cell signaling [105, 106, 
171]. Since BMP-2-loaded heparin microparticles induced higher ALP activity than co-
delivery of soluble heparin and BMP-2, microparticle delivery of heparin may be a more 
efficient method of concentrating and presenting BMP-2 to cells. Heparin microparticles 
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may improve growth factor delivery by concentrating BMP-2 locally in the immediate 
proximity of the cells, where high densities of BMP-2 bound to the microparticles result 
in an effective increased local growth factor concentration. Similar effects have been 
observed in other systems containing surface-immobilized growth factors through direct 
growth factor tethering or indirect affinity-based growth factor-ECM interactions, in 
which the sustained presentation of immobilized growth factor stimulates enhanced cell 
signaling compared to similar concentrations of soluble growth factors [138, 200, 201]. 
Concentrated BMP-2 effects may be stronger when fewer microparticles are loaded with 
higher BMP-2 densities, as evidenced by the increased ALP activity observed with fewer 
microparticles loaded with the same total amount of BMP-2 (0.02 and 0.1 mg) while 
decreased ALP activity was observed with more microparticles (0.5 mg). Furthermore, 
total ALP activity decreased when cells and BMP-2-loaded microparticles were 
physically separated from each other, indicating that contact between cells and heparin 
materials are critical to efficient BMP-2 signaling. Ultimately, the ability to spatially 
concentrate growth factors using heparin microparticles may provide an advantage for 
numerous growth factor delivery applications, such as the regeneration of tissue defects, 
in which the local presentation of high concentrations of growth factor is often necessary 
to stimulate repair. This is similar to the native role played by cell membrane-bound 
GAG species during wound healing, in which signaling pathways involved in cell 
proliferation and migration, such as FGF signaling, are potentiated by direct GAG-
growth factor contact [202]. 
In addition to inducing ALP activity, BMP-2-loaded microparticles also 
stimulated a striking increase in DNA content in C2C12 cultures. Both heparin and 
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heparan sulfate have been shown to increase cell proliferation by binding to endogenous 
mitogens in the system, such as basic fibroblast growth factor (FGF-2), and facilitating 
their interactions with cell surface receptors [203, 204]. In studies with MSCs, delivering 
soluble BMP-2 with selectively desulfated heparin increased the number of MSCs in in 
vitro cultures, while native heparin did not [115]. This is similar to the effects observed 
herein, in which the combined presence of both heparin microparticles and BMP-2 
(soluble or pre-loaded) increased DNA content. Since changes in DNA content were not 
observed when soluble heparin was delivered or when C2C12 cells were physically 
separated from the microparticles, the effects of heparin microparticles on DNA content 
appear to be both contact-mediated and specific to the microparticle delivery platform. 
Taken together, these results indicate that BMP-2 laden heparin microparticles may 
simultaneously initiate cell signaling events related to both cell proliferation and ALP 
production, and that these effects may involve multiple pathways, such as Smad 1/5/8-
dependent and Smad 1/5/8-independent pathways, which have both previously been 
observed in BMP-2-stimulated C2C12 cells [101, 205, 206].   
The ability of heparin to prolong the bioactivity and functional cellular effects of 
co-delivered BMP-2 by protecting it from degradation and cell endocytosis has also been 
well documented in vitro [101, 104, 172]. Our results demonstrate that heparin 
microparticles can similarly extend BMP-2 bioactivity, as microparticle-bound BMP-2 
pre-incubated in cell culture media for 2 weeks at 37°C induced comparable C2C12 ALP 
activity to fresh soluble BMP-2 treatment. Conversely, the equivalent amount of soluble 
BMP-2 pre-incubated in cell culture media exhibited a significant loss of bioactivity, 
which we hypothesized was due to degradation of the protein. This protective aspect of 
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heparin-BMP-2 interactions has been further investigated by Seto, et al. in a recent paper 
that demonstrates the ability of soluble heparin to protect BMP-2 from heat denaturation 
[103]. Heat-treated BMP-2 maintained its ability to induce C2C12 ALP activity in the 
presence of native heparin, but not in the presence of selectively desulfated heparin 
species, suggesting that both the overall charge of the molecule and presence of 
individual sulfate groups may contribute to heparin-mediated BMP-2 preservation.  
Finally, because batch-to-batch variability and biomaterial stability are important 
considerations in the fabrication of any growth factor delivery vehicle, the reproducibility 
of the heparin microparticle fabrication method and effects of lyophilization on BMP-2-
loaded microparticles were also evaluated. Although individual batches of microparticles 
demonstrated slight differences in appearance (i.e. microparticle clumping), this did not 
affect the ability of the microparticles to load BMP-2 and induce ALP activity and cell 
proliferation in C2C12 cultures, with only one microparticle batch demonstrating lower 
ALP induction than soluble BMP-2 treatment. Furthermore, the method of 
methacrylamide functionalization used in this protocol consistently resulted in 50-60% 
methacrylamide substitution of heparin. Since the density of reactive groups on the 
heparin polymer is one factor that dictates the degree of cross-linking, it is expected that 
the cross-linking density and size distribution of each batch of microparticles fabricated 
using this protocol will be similar. Studies using gelatin methacrylate microparticles have 
demonstrated an effect of cross-linking density on microparticle size, elastic modulus, 
and growth factor loading and release [114]; thus, controlling the methacrylamide 
functionalization and cross-linking density of heparin microparticles will aid in 
maintaining reproducible biomaterial properties.  
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In terms of biomaterial stability, our results demonstrate that lyophilized 
microparticles maintain their BMP-2 loading and presentation capacity for at least two 
years, suggesting a long shelf life that will be amendable to clinical use. Furthermore, the 
ability to lyophilize BMP-2-loaded microparticles without disrupting BMP-2-heparin 
interactions and changing the release profile and bioactivity of the growth factor may 
mean that heparin microparticles can be stored in loaded form until use, making both 




The results of this study demonstrate that heparin microparticles can be used to 
reproducibly sequester and retain large amounts of bioactive BMP-2, and that enhanced 
presentation of BMP-2 via heparin microparticles can elicit a comparable cellular 
response to soluble BMP-2 treatment. Heparin microparticles offer a versatile platform 
for growth factor delivery, as loaded microparticles can be directly injected and retained 
in a tissue defect site, providing a much higher surface area for efficient growth factor 
presentation and contact with infiltrating cells. Consequently, heparin microparticles may 
be an effective method of delivering and spatially retaining growth factors for a variety of 
applications, including both in vitro growth factor-mediated induction of cell fates and in 





CHAPTER 4: HEPARIN MICROPARTICLES FACILITATE HEALING OF A 




Large tissue defects of the extremities resulting in significant bone loss are a 
particularly challenging problem for orthopedic surgeons; these injuries often lead to 
inadequate healing and subsequent non-union due to the complexity of the injury 
environment and lack of robust biological cues that can initiate and resolve the bone 
healing cascade [2, 21, 30]. The discovery and pharmaceutical production of bone 
morphogenetic proteins (BMPs), particularly BMP-2 and BMP-7, have resulted in 
effective strategies to overcome the injury environment and stimulate bone growth 
following injury [4, 32, 33]. However, limitations in the ability of current BMP delivery 
vehicles, such as the clinically used collagen sponge, to provide adequate growth factor 
retention within bone defects hinder these therapies from widespread use [40-42, 153]. 
Consequently, biomaterials that can provide more sustained presentation of BMPs within 
bone defects are necessary to improve bone regeneration strategies in the clinic. 
Animal models of bone repair provide valuable test beds for evaluating novel 
biomaterial strategies for the delivery of BMPs, and include a variety of fracture models, 
segmental defects, and non-unions [207]. Segmental defect models of the femur, tibia, 
mandible, and calvaria are most commonly used to explore methods of BMP-induced 
bone regeneration across large gaps in the tissue and are typically investigated as 
critically sized defects, which are characterized by their inability to achieve bony 
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bridging without intervention [208-210]. Furthermore, segmental defects created in load-
bearing bones such as the femur and tibia present additional challenges for repair, since 
the bone that regenerates must be able to withstand the normal mechanical loading 
environment in order to be functional, and are thus more representative of 
musculoskeletal injuries of the extremities.  
Since segmental bone defects are inherently difficult to heal, models of ectopic 
bone formation can serve as valuable intermediate platforms to more easily screen the 
osteoinductive abilities of therapeutics. Biomaterials implanted in muscle and the kidney 
capsule can induce ectopic mineralization due to the presence of skeletal progenitor cells 
and a highly vascular environment, respectively [211]. Subcutaneous implantation of 
materials enables the evaluation of large tissue engineering scaffolds [212] and allows for 
longitudinal tracking of exogenous cells and biomolecules within materials via in vivo 
imaging of luminescence or fluorescence that cannot easily be visualized in deeper 
tissues [212]. However, subcutaneous implantation of osteoinductive materials typically 
results in lower ectopic bone formation than materials implanted in the muscle and 
kidney capsule [213, 214], due to the lack of appropriate progenitor cells and reduced 
vascularity. 
Many BMP delivery vehicles that have demonstrated promise in vivo thus far 
have been tested in ectopic mineralization models [215]. Calcium phosphate ceramics, 
which mimic the inorganic mineral component of bone, can readily adsorb BMPs and 
possess attractive mechanical properties as bone graft substitutes [216-220]. Conversely, 
a number of soft hydrogels have also been developed for BMP delivery due to their 
tunable protein release profiles, biodegradability, and injectability. Ectopic bone 
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formation has been previously demonstrated using BMP-2-loaded hydrogels fabricated 
from hyaluronic acid [172, 221], fibrin [222, 223], alginate [224], polyethylene glycol 
(PEG) [225, 226], poly(lactic-co-glycolic acid) (PLGA) [227, 228], and numerous 
composite materials. Fewer materials have demonstrated promise in critically sized 
defect models; however, several studies have documented robust bone healing in defects 
treated with BMP-2 delivered from many of the aforementioned material strategies, 
including ceramics and both natural and synthetic hydrogels [229-232].  
In our laboratory, we have developed a novel BMP-2 delivery system consisting 
of a degradable RGD-functionalized alginate gel injected into the lumen of a perforated 
polycaprolactone (PCL) nanofiber mesh tube [233, 234]. This BMP-2 delivery vehicle 
can induce robust bone healing in a rat model of a critically sized femoral defect and 
restore the mechanical properties of the regenerated femurs to ~75% of intact bone [234]. 
Furthermore, when compared to BMP-2 delivery using the clinical collagen sponge, our 
alginate/PCL mesh delivery system prolonged BMP-2 retention and increased 
remineralization of the defect space [233]. 
Despite these promising results, the half-life of BMP-2 delivered to the bone 
defect using the alginate/PCL mesh system is still relatively short, with >40% of the 
growth factor leaving the thigh within the first three days after delivery [233]. Since 
regeneration of the damaged bone tissue is a dynamic process involving several weeks of 
coordinated cellular responses and biomolecule presentation, the ability to maintain a 
substantial depot of bioactive BMP-2 within the bone defect over longer periods of time 
may help to improve the healing response.  
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One strategy to prolong BMP-2 retention in vivo involves the presentation of 
affinity molecules to specifically bind BMP-2 through electrostatic interactions. Since 
heparin has been shown to strongly and reversibly bind growth factors, biomaterials are 
often “heparinized” to increase their growth factor loading capacity [235]. Several studies 
have demonstrated that incorporating heparin chains into biomaterial scaffolds, such as 
collagen, calcium phosphate, and various hydrogels, can improve BMP-2 retention both 
in vitro and in vivo [116, 223, 227, 236-238]. Chapter 3 described the development of 
pure heparin microparticles that retain large amounts of bioactive BMP-2 in vitro [107]. 
These microparticles can be easily mixed into the hydrogel component of the 
alginate/PCL mesh delivery system for in vivo delivery, providing a simple method of 
adding heparin into the tissue engineering construct and subsequently increasing the 
growth factor loading capacity of the system in a dose dependent manner.  
Herein, we investigated the incorporation of heparin microparticles into the 
alginate/PCL mesh delivery vehicle and its effect on BMP-2 retention both in vitro and in 
vivo, as well as its eventual impact on bone formation in ectopic and orthotopic sites in a 
rat model. This study served as the initial in vivo evaluation of heparin microparticles as a 
BMP-2 delivery vehicle using a low dose of BMP-2 (10 µg BMP-2/kg body weight) 
compared to clinical standards; it revealed that the delivery of heparin microparticles to a 
segmental bone injury contributes to significant changes in BMP-2 retention and 





4.2 Materials and Methods 
	
4.2.1 Fabrication of Alginate/Polycaprolactone Constructs 
	
Hybrid alginate/polycaprolactone tissue engineering constructs for in vivo 
delivery were fabricated as previously described [234]. Briefly, irradiated, RGD-
functionalized alginate (FMC Biopolymer, Philadelphia, PA) was first slowly dissolved 
in α-MEM (Corning Mediatech, Manassas, VA) at room temperature to achieve a 3% 
(w/v) alginate solution. Equal volumes of α-MEM and 0.1% rat serum albumin (RSA; 
Sigma, Aldrich) in 4 mM HCl were then added to dilute the alginate to 2% (w/v) prior to 
cross-linking. At this stage, the requisite amounts of BMP-2 (0-5 µg) and/or heparin 
microparticles (0-5 mg) per 150 µL of alginate hydrogel were added into the solution in 
0.1% RSA in HCl. Heparin microparticles were fabricated as previously described [107]. 
The 2% alginate solution was then cross-linked with excess calcium sulfate (8.4 mg/mL; 
Sigma Aldrich) by rapid mixing between two 1 mL syringes (Becton-Dickinson, Franklin 
Lakes, NJ) connected through a Luer-Lok style connector (Cole-Parmer, Vernon Hills, 
IL). After several minutes of mixing, the alginate was allowed to solidify at room 
temperature for 30 minutes before being transferred to 4°C for storage overnight. 
Polycaprolactone (PCL) nanofiber mesh tubes were also fabricated as previously 
described [234]. Briefly, PCL (Sigma Aldrich) was dissolved overnight with gentle 
stirring in a 90:10 solution of hexafluoro-2-propanol (HFP; Sigma Aldrich) and 
dimethylformamide (DMF; Sigma Aldrich) to obtain a 12% (w/v) PCL solution. 5 mL of 
solution was loaded into a 5 mL syringe (Becton Dickinson) with a 20-gauge blunt-tip 
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needle (Howard Electronic Instruments, El Dorado, KS), bubbles were removed, and the 
syringe was mounted onto a PHD2000 Infusion syringe pump (Harvard Apparatus, 
Holliston, MA). For the electrospinning setup, the syringe pump was placed so that the 
needle tip was ~20 cm away from a rectangular copper collection plate covered with 
aluminum foil for PCL nanofiber deposition. The syringe pump was set to a constant 
infuse rate of 0.75 mL/hr and infuse diameter of 12.060 mm, and a high voltage supply 
(HV Power Supply, Gamma High Voltage Research, Ormond Beach, FL) was connected 
to the syringe needle and collection plate to provide a voltage difference of ~15-20 kV. 
The voltage was periodically adjusted to maintain a Taylor cone at the needle tip during 
electrospinning. 4.5 mL of PCL solution were infused through the syringe pump for each 
mesh, creating circular meshes with an area of ~100 cm2 and thickness of ~500 µm.  
12 mm by 19 mm rectangles with twenty-three, evenly spaced 0.9 mm diameter 
perforations were laser-cut into the meshes to prepare nanofiber mesh tubes for tissue 
engineering constructs. Each rectangular sheet was rolled into a tube with an inner 
diameter of 5 mm and length of 12 mm and glued using UV cure adhesive (1187-M MD 
Medical Device Adhesives & Coatings, DYMAX, Torrington, CT; BlueWave LED 
Prime UVA Spot Curing System, DYMAX, Torrington, CT). Mesh tubes were sterilized 
by 100% ethanol evaporation overnight, followed by immersion in 70% ethanol for 4 
hours, immersion in PBS for 30 minutes, and finally immersion in α-MEM up until use. 
For all assays, 150 µL of alginate gel were injected through a 22-gauge, blunt-tip 
needle (Howard Electrical Instruments) into the center of each nanofiber mesh tube 
immediately prior to use. For in vitro assays, alginate was allowed to set in the mesh tube 
for at least 10 minutes prior to immersion in any solution. For in vivo assays, alginate was 
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injected into the mesh tube after it had been placed in the femoral defect. 
	
4.2.2 BMP-2 Release from Alginate/Polycaprolactone Constructs 
 
Passive release of BMP-2 from alginate/PCL constructs into 0.1% (w/v) BSA in 
PBS was monitored over a period of 21 days at 37°C. Alginate/PCL constructs were 
fabricated with or without 1 mg of heparin microparticles and 0.5-2.5 µg of BMP-2. 
Microparticles were loaded with BMP-2 in a small volume of 0.1% BSA in 4 mM HCl 
(25 µL/mg MPs) for 16 hours at 4°C the day before construct assembly. BMP-2 was 
added into the construct one of three ways: (1) solubly into the alginate solution, (2) 
solubly into the alginate solution with 1 mg of heparin microparticles added separately, or 
(3) loaded onto the microparticles and then added into the alginate solution; in all cases, 
BMP-2 and microparticles were added prior to alginate cross-linking. After alginate/PCL 
constructs were assembled and allowed to set for at least 10 minutes, the constructs were 
transferred to individual wells in an ultra-low attachment 24-well plate (Corning) and 1 
mL of 0.1% BSA in PBS was added. At various time points over 21 days, the solution 
was completely removed and centrifuged at 3000 rpm for 5 minutes to separate the 
supernatant from any alginate or microparticle debris. The supernatant was removed and 
replaced with 1 mL of fresh 0.1% BSA in PBS before the solution was added back to the 
wells. This step was included to ensure minimal loss of alginate and microparticles from 




4.2.3 Fluorescent Labeling of BMP-2 and Heparin Microparticles 
	
BMP-2 was fluorescently labeled using Vivotag-S 750 Flurochrome (VS750; 
Perkin Elmer, Waltham, MA; Ex: 750 nm, Em: 780 nm), which contains an NHS ester 
reactive group for coupling to primary amines on proteins. BMP-2 was reconstituted at 
250 µg/mL in 100 mM NaPO4 (pH = 7.4), and VS750 was reconstituted at 50 µg/mL in 
100 mM NaPO4 (pH = 7.4). 40 µL of BMP-2 was mixed with 60 µL of VS750 to achieve 
a final BMP-2 concentration of 100 µg/mL in a solution containing 10 times molar excess 
of label. The reaction was allowed to proceed at room temperature in the dark for 4 hours. 
Following this, the solution was transferred to a Slide-A-Lyzer MINI dialysis device 
(MWCO = 3.5 kDa; Thermo Fisher Scientific) to dialyze out hydrolyzed NHS and 
unreacted label. Dialysis into 100 mM NaPO4 (pH = 7.4) proceeded for 24 hours, with 
complete buffer changes after 1 and 4 hours. BMP-2 labeling and removal of excess dye 
was confirmed by taking samples of the solution for gel electrophoresis, followed by near 
infrared imaging on an Odyssey gel scanner (Li-cor Biotechnology, Lincoln, NE), as well 
as fractionation through a PD-10 desalting column (GE Healthcare Bio-Sciences, 
Pittsburgh, PA), followed by quantification of fluorescence of each molecular weight 
fraction of the BMP-2 solution using a Synergy H4 microplate reader (Biotek). 
Fluorescently labeled BMP-2 was stored at -20°C until use. 
Fluorescently labeled heparin microparticles were fabricated by conjugation of 
Alexa Fluor 647 hydrazide (AF647; Thermo Fisher Scientific; Ex: 650 nm, Em: 670 nm) 
to heparin methacrylamide prior to microparticle formation. A hydrazide-functionalized 
label was used to allow conjugation of the label to the remaining unmodified carboxyl 
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groups on the heparin methacrylamide chains. Heparin methacrylamide was reconstituted 
at 10 mg/mL in 100 mM NaPO4 (pH = 7.4) and combined with 0.1 M EDC and 1 mM 
AF647 hydrazide; the reaction was allowed to proceed at room temperature in the dark 
for 2 hours. The reaction volume was then dialyzed against water (MWCO = 3.5 kDa; 
Spectrum Laboratories) for 24 hours to remove excess reactants; dialysis buffer was 
replaced after 1 and 4 hours. The remaining volume in the dialysis tubing (~50 mL) was 
lyophilized for two days and then stored in the fridge, protected by light, until heparin 
microparticle fabrication using the aforementioned protocol. Heparin microparticle 
labeling was confirmed through confocal microscopy and macroscopic imaging on an 
IVIS® Spectrum platform (Ex: 640, Em: 720; Perkin Elmer). 
 
4.2.4 Subcutaneous Implant Surgical Procedure 
 
Subcutaneous implant studies were undertaken to (1) determine the persistence of 
heparin microparticles within the alginate/PCL constructs, (2) evaluate the ability of 
constructs with or without BMP-2 and heparin microparticles to form ectopic mineral, 
and (3) track retention of BMP-2 in constructs with or without heparin microparticles. All 
subcutaneous implant surgical procedures were conducted according to the Georgia 
Institute of Technology Institutional Animal Care and Use Committee (IACUC) protocol 
A16043. 13-week-old female Sprague Dawley rats (Charles River Labs, Wilmington, 
MA) were anesthetized using isoflurane prior to surgery. Two lateral incisions were made 
on the back of each animal and a tunneling device was used to create four individual 
subcutaneous pockets for construct insertion, as previously described [212]. A metal rod 
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and cannula were used to insert two constructs near the forelimbs and two near the 
hindlimbs. Constructs from each group were randomly distributed according to location.  
For microparticle retention and ectopic mineralization studies, constructs 
consisted of PCL meshes containing (1) 150 µL alginate only (n=6), (2) 1 mg of labeled 
microparticles in 150 µL alginate (n=6), (3) 5 µg of BMP-2 in 150 µL alginate (n=6), and 
(4) 5 µg of BMP-2 loaded onto 1 mg of labeled microparticles in 150 µL alginate (n=6). 
Animals for these studies were euthanized using carbon dioxide asphyxiation after 6 
weeks post-surgery. For BMP-2 tracking studies, constructs consisted of PCL meshes 
containing (1) 2.5 µg of labeled BMP-2 in alginate (n=8) and (2) 2.5 µg of labeled BMP-
2 loaded onto 1 mg of microparticles in alginate (n=8). These animals were euthanized 
after 3 weeks. 
	
4.2.5 In Vivo/Ex Vivo Fluorescence Imaging 
	
In vivo and ex vivo fluorescent imaging was performed using an IVIS® Spectrum 
platform (Perkin Elmer). For evaluation of AF647-labeled microparticle retention, 
alginate/PCL constructs were imaged ex vivo (Ex: 640, Em: 720) prior to subcutaneous 
implantation and immediately after explanting at 6 weeks. For VS750-labeled BMP-2 
tracking, longitudinal in vivo imaging (Ex: 745, Em: 800) was performed immediately 
following subcutaneous implantation on Day 0, as well as on Day 1, 4, 7, 10, 14, and 21, 
as previous studies have demonstrated loss of detectable fluorescent signal after 21 days 
[233]. Alginate gels contained either (1) 2.5 µg of labeled BMP-2 (n=8) or (2) 2.5 µg of 
labeled BMP-2 loaded onto 1 mg of microparticles (n=8). Animals were placed on their 
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sides for imaging of two constructs at once. Total fluorescent counts and radiant 
efficiency were evaluated for each construct at each time point, both in vivo and ex vivo, 
using a ~7 cm2 elliptical region of interest (ROI) in the Living Image Software (Perkin 
Elmer). Background fluorescence from the animal’s skin was subtracted from each 
measurement, and fluorescent signal at each time point was normalized to the initial 
fluorescent signal measured at Day 0. BMP-2 retention data was fit to a one-phase 
exponential decay equation (y=aexp(-λx)) in MATLAB to obtain the decay constant, λ. 
IVIS® imaging was also used for in vitro experiments to confirm fluorescent labeling of 
BMP-2 and heparin microparticles and to determine the distribution of labeled 
microparticles in alginate, before and after syringe injection. 
	
4.2.6 Femoral Defect Surgical Procedure 
	
Femoral defect studies were undertaken to determine the ability of constructs with 
and without heparin microparticles and BMP-2 to promote bone healing in a critically 
sized defect. All surgical procedures were conducted according to the Georgia Institute of 
Technology IACUC protocol A14037. 13-week-old female Sprague Dawley rats (Charles 
River Labs) were anesthetized using isoflurane prior to surgery, and bilateral surgeries 
were performed as previously described [233, 239]. Briefly, after opening up the leg 
using an anterior approach, a radiolucent fixation plate (polysulfone) and two stainless 
steel risers were screwed directly onto the femur of the rat for limb stabilization, and an 
oscillating saw was used to create an 8-mm wide, full thickness diaphyseal defect. A PCL 
nanofiber mesh tube was inserted into the defect to cover the bone ends, and 150 µL of 
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alginate were injected through the perforations into the center of the tube. Each alginate 
gel contained one of the following: (1) 1 mg of unloaded microparticles (n =4), (2) 2.5 µg 
of BMP-2 (n=5), or (3) 2.5 µg of BMP-2 loaded onto 1 mg of microparticles (n=5). 
Animals were euthanized after 2 or 12 weeks post-surgery. 
	
4.2.7 Faxitron and Micro-computed Tomography 
	
Construct mineralization was evaluated 6 weeks post-surgery, after constructs 
were harvested and fixed in 10% neutral buffered formalin for 48 hours. Ex vivo micro-
computed tomography (CT) was performed using a microCT42 scanner (Scanco, 
Switzerland) as previously described [213, 214], with a voxel size of 16 µm, voltage of 
55 kVp, and current of 145 µA. A threshold of 80 was set for new mineral formation, and 
a Gaussian filter (sigma = 1.2, support = 1) was applied to suppress noise. 
Longitudinal in vivo radiographs of femurs were obtained at 2, 4, 8, and 12 weeks 
post-surgery, using a Faxitron MX-20 Digital machine at a voltage of 23 kV and 
exposure time of 15 seconds; radiographs were used to qualitatively access bony bridging 
across the defect space. In vivo micro-CT of femurs was performed at 4, 8, and 12 weeks 
post-surgery to quantify total bone volume and overall mineral density. Animals were 
anesthetized and scanned at a medium resolution using a VivaCT40 live animal scanner 
(Scanco) with a voxel size of 38.5 µm, voltage of 55 kVp, and current of 109 µA [234]. 
Mineral was quantified within the central 6 mm (160 scan slices) of each 8 mm defect. A 
global threshold for new mineral was set at 50% of the average mineral density of native 
cortical bone, and a Gaussian filter (sigma = 1.2, support = 1) was used to suppress noise.  
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4.2.8 Biomechanical Testing 
	
Femurs removed from rats at 12 weeks underwent torsion testing using a uniaxial 
torsion testing system (Bose EnduraTEC ELF200; Bose Electroforce Systems Group, 
Eden Prairie, MN), in order to compare the strength of the regenerated bone in the defect 
to that of native bone (age-matched historical data). Briefly, fixation plates and soft tissue 
were removed from isolated femora, before the bone ends were placed in hot Wood’s 
metal (Alfa Aesar, Haverhill, MA), allowed to solidify, and mounted into the machine. 
Torsion was applied at a rate of 3º per second until failure, allowing for the determination 
of maximum torque and calculation of torsional stiffness, using the slope of the linear 
segment of the torque-rotation curve. 
	
4.2.9 Histological Sectioning and Staining 
	
To determine the distribution of heparin microparticles within alginate gels, 
alginate/PCL constructs with or without 1-5 mg of microparticles (n=3) were fabricated 
and processed for cryosectioning. Constructs were incubated in successively more 
concentrated solutions of sucrose and optimal cutting temperature (OCT) compound 
(Sakura Finetek USA Inc., Torrance, CA) at room temperature under vacuum in order to 
promote complete infiltration of OCT compound into the hydrogel matrix. Constructs 
were then transferred to 100% OCT compound and frozen in a bath of 100% ethanol and 
dry ice. 5 µm sections were obtained and stained with Safranin O to visualize alginate 
and heparin microparticles. 
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For in vivo subcutaneous implant studies, all constructs were collected for 
histology after 6 weeks post-surgery. For in vivo femoral defect studies, femurs from 
each treatment group demonstrating representative bone formation (as evaluated by 
radiography) were isolated for histology at 2 and 12 weeks post-surgery. After 
harvesting, the constructs and femurs were fixed in 10% neutral buffered formalin at 4°C 
for 24 and 48 hours, respectively, followed by decalcification at room temperature using 
a formic acid decalcifier (Cal Ex-II, Thermo Fisher Scientific) with gentle agitation and 
complete replacement of the solution every 2-3 days for up to two weeks. Complete 
decalcification of constructs and femurs was verified using vivaCT scoutview. Samples 
were then dehydrated through submersion in a series of alcohol and xylene solutions and 
vacuum-embedded in paraffin wax (Paraplast, Sigma Aldrich) at 60°C. 5 µm midsagittal 
sections of the defects were obtained for histological analysis using Safranin O/Fast 
Green staining in order to characterize microparticle and alginate persistence, mineral 
formation, and gross tissue morphology.  
Immunohistochemistry for Ki67 antigens was performed using a rat/mouse MIB-
5 antibody (1:50, Dako, Carpinteria, CA), followed by a horseradish peroxidase 
secondary antibody (Vector Labs, Burlingame, CA), to evaluate cell proliferation within 
the defect space. Gill’s hematoxylin served as a counterstain to visualize cell nuclei, and 
Safranin O was used to visualize heparin microparticles. Histological sections of rat small 
intestine were also processed for immunohistochemistry and treated with mouse serum, 
followed by the horseradish peroxidase secondary antibody, as a control for nonspecific 
antibody binding, and MIB-5 antibody followed by the horseradish peroxidase secondary 
antibody as a Ki67 positive control. 
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4.2.10 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. In vitro experiments 
were run with a minimum of three replicates for each experimental group. For in vivo 
subcutaneous implant experiments, 6-8 constructs per group were implanted. For in vivo 
bone defect experiments, longitudinal micro-CT was conducted on 4-5 femurs per group, 
and biomechanical testing was conducted on 3-4 femurs per group. Statistical 
significance was determined using one-way or two-way ANOVA as appropriate, 
followed by Bonferroni’s post hoc analysis (Graphpad Prism, Version 5.0, La Jolla, CA). 
For data that did not satisfy the assumptions of equal variances and Gaussian 





4.3.1 Distribution of Heparin Microparticles in Alginate Gel 
 
Two different methods were used to establish whether heparin microparticles 
could be evenly distributed throughout the alginate hydrogels without disrupting calcium-
mediated cross-linking. First, alginate hydrogels were fabricated with Alexa Fluor 647-
labeled heparin microparticles at a density of 1 mg of microparticles per 150 µL of 
alginate and imaged on an IVIS® platform to evaluate the distribution of fluorescence. 
Addition of heparin microparticles prior to alginate cross-linking using the dual syringe 
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method resulted in even distribution of fluorescent signal throughout the alginate 
hydrogel in the syringe (Figure 4.1A(i)). Furthermore, when the alginate gel was injected 
through a blunt-tip needle in 150 µL aliquots, similar to injection during surgery, the 
fluorescence in each of the three aliquots was similar (Figure 4.1B). This was the case for 
alginate gels injected into PCL mesh tubes (Figure 4.1A(ii), B; 3.87x107 ± 0.04x107) or 
directly onto a glass slide (Figure 4.1A(iii), B; 5.64x107 ± 0.09x107). The presence of the 
PCL mesh tube around the alginate hydrogel attenuated the fluorescent signal detected by 
the IVIS® platform, but did not affect the variability of the signal between similarly 
treated hydrogels. 
Alginate hydrogels were also fabricated for histological processing using 0, 1, and 
5 mg of heparin microparticles per 150 µL alginate construct. In Safranin O stained 
cryosections from hydrogel constructs, microparticles appeared as dark red, punctate 
circles, while alginate stained lighter orange-red (Figure 4.1C). Heparin microparticles 
(indicated by black arrows) were well distributed in constructs containing either 1 mg or 
5 mg of microparticles; however, the higher concentration of microparticles appeared to 
interfere with alginate cross-linking and resulted in a poorly formed gel. Consequently, 






Figure 4.1. Quantitative and Qualitative Evaluation of Heparin Microparticle Distribution 
in Alginate/PCL Constructs. A) AF647-labeled heparin microparticles were mixed into 2% 
RGD-alginate at a density of 1 mg of MPs per 150 µL of alginate and imaged on an IVIS® 
imaging platform (Ex: 640, Em: 720) before and after syringe injection. IVIS® images depict (i) 
homogeneous fluorescence throughout the syringe prior to injection, (ii) alginate/PCL constructs 
(1 mg of MPs in 150 µL of alginate) that exhibit comparable fluorescence, and (iii) alginate 
hydrogels without PCL meshes (1 mg of MPs in 150 µL of alginate) that exhibit comparable 
fluorescence. B) Quantification of radiant efficiency detected in images (ii) and (iii) revealed 
differences in fluorescent signal due to the presence of the PCL mesh, but low variability between 
individual constructs or hydrogels. (* = p < 0.001 as indicated) C) Representative images of 
Safranin O-stained sections of constructs containing 0, 1, or 5 mg of microparticles per 150 µL of 
2% alginate. Black arrows indicate microparticles. 
	
4.3.2 BMP-2 Release from Alginate/Polycaprolactone Constructs 
 
In order to determine whether heparin microparticles could improve BMP-2 
retention in alginate/PCL constructs, 150 µL alginate constructs fabricated with or 
without 1 mg of heparin microparticles were loaded with 0.5 or 2.5 µg of BMP-2 and 
allowed to passively release BMP-2 into a 0.1% (w/v) BSA in PBS solution over 21 days. 
At the lower BMP-2 dose (Figure 4.2A), constructs containing BMP-2 solubly entrapped 
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within the alginate (“BMP-2”) exhibited higher BMP-2 release at each time point 
compared to constructs containing BMP-2 loaded onto heparin microparticles within the 
alginate (“Loaded MPs”). At the higher BMP-2 dose (Figure 4.2B), differences in 
cumulative BMP-2 release between solubly entrapped BMP-2 and BMP-2 loaded onto 
the microparticles were only observed after 14 days. Interestingly, alginate/PCL 
constructs containing 1 mg of unloaded microparticles and 2.5 µg of solubly entrapped 
BMP-2 (“Unloaded MPs + BMP-2”) demonstrated cumulative BMP-2 release that fell 
between that of the other two groups. Finally, when constructs loaded with 2.5 µg of 
BMP-2 were washed with BSA/PBS at the end of the 21-day period, the amount of BMP-
2 retrieved from the constructs was higher in constructs lacking microparticles (Figure 
4.2C), likely due to the inability to detect BMP-2 that remained bound to the 
microparticles via ELISA. Overall, only a small fraction of the BMP-2 initially 
incorporated into the constructs could be retrieved through BSA/PBS washes after 21 
days (3-7%); this could be due to a number of reasons, including protein degradation and 








Figure 4.2. BMP-2 Release from Alginate/PCL Constructs with or without Heparin 
Microparticles. BMP-2 was mixed directly into the alginate solution (BMP-2), loaded onto 1 mg 
of microparticles prior to being mixed into the alginate solution (Loaded MPs), or mixed into the 
alginate solution along with 1 mg of empty microparticles (Unloaded MPs). Assembled 
alginate/PCL constructs were immersed in 1 mL of 0.1% BSA in PBS, which was sampled over 
21 days. A) When 0.5 µg of BMP-2 was used, constructs containing BMP-2-loaded 
microparticles retained more BMP-2 overall. ($ = p < 0.05 at each time point) B) When 2.5 µg of 
BMP-2 was used, BMP-2 release from constructs without microparticles was greater than BMP-2 
release from loaded microparticle-containing constructs after 2 weeks. ($ = p < 0.05 between 
BMP-2 and Loaded MPs) C) After 21 days, all constructs originally loaded with 2.5 µg of BMP-2 
were thoroughly rinsed in PBS to remove remaining BMP-2. Constructs containing 
microparticles yielded less detectable BMP-2. (* = p < 0.05 compared to BMP-2) 
	
4.3.3 Microparticle Retention in Subcutaneous Implants 
 
Alginate/PCL constructs containing 1 mg of Alexa Fluor 647-labeled heparin 
microparticles with or without 5 µg of BMP-2 were implanted subcutaneously in the 
backs of rats for 6 weeks in order to determine whether heparin microparticles could be 
retained in the constructs following in vivo implantation. Fluorescence imaging of 
constructs was performed using an IVIS® platform prior to implantation and immediately 
following explanting; constructs were placed on glass slides for imaging as depicted and 
oriented such that the same number of perforations were visible in each PCL mesh 
(Figure 4.3A). IVIS® imaging revealed retention of ~55% of the initial fluorescent signal 
from heparin microparticles after 6 weeks in vivo (Figure 4.3B); there were no 
differences in fluorescence retention between unloaded (“MP”) and BMP-2-loaded 
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microparticles (“MP + BMP-2”). After constructs were explanted and imaged, they were 
fixed and processed for histological analysis. Safranin O/Fast Green staining of 
constructs revealed the presence of intact heparin microparticles (yellow arrows) in all 
microparticle-containing constructs after 6 weeks in vivo (Figure 4.3C, D). Constructs 
containing BMP-2-loaded microparticles also contained areas of mineralized bone 
formation (dark green staining) (Figure 4.3C), while constructs containing unloaded 




Figure 4.3. Retention of Heparin Microparticles in Subcutaneously Implanted 
Alginate/PCL Constructs. AF647-labeled microparticles (unloaded or loaded with 5 µg of 
BMP-2) were mixed into 2% RGD-alginate at a density of 1 mg of MPs per 150 µL of alginate; 
alginate/PCL constructs were implanted subcutaneously in the backs of rats for 6 weeks (n=6). A) 
Representative IVIS® image (Ex: 640, Em: 720) depicting explanted alginate/PCL constructs with 
and without labeled microparticles after 6 weeks. B) Quantification of radiant efficiency detected 
in IVIS® images of constructs immediately prior to implantation (Week 0) and following 
explanting (Week 6). Radiant efficiency was normalized to Week 0 values. AF647 signal 
decreased over 6 weeks in both unloaded and loaded microparticle-containing constructs. (* = p < 
0.05 as indicated) Safranin O/Fast Green staining of alginate/PCL constructs containing C) BMP-
2-loaded microparticles and D) unloaded microparticles demonstrates the persistence of intact 
microparticles after 6 weeks in vivo, as indicated by yellow arrows.  
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4.3.4 BMP-2 Retention in Subcutaneous Implants 
 
Alginate/PCL constructs containing fluorescently labeled BMP-2 were also 
implanted subcutaneously to track in vivo retention of BMP-2 over time. Constructs 
containing either 2.5 µg of BMP-2 or 2.5 µg of BMP-2 loaded onto 1 mg of heparin 
microparticles were implanted and imaged periodically for three weeks using an IVIS® 
platform. Representative fluorescence images demonstrate a decrease in fluorescent 
signal from subcutaneously implanted constructs over time (Figure 4.4A-D). 
Quantification of fluorescent signal using a 7 cm2 region of interest and normalized to 
Day 0 values confirmed this decrease in signal (Figure 4.4E). Although no differences in 
BMP-2 retention were observed between constructs with and without heparin 
microparticles at individual time points, constructs containing microparticles exhibited a 
lower average decay constant when this data was fit to an exponential decay curve, 
indicating prolonged BMP-2 retention (Figure 4.4F). When constructs were explanted 
after 21 days and imaged, the remaining radiant efficiency and number of fluorescent 
counts were higher in constructs containing heparin microparticles, indicating a greater 




Figure 4.4. Longitudinal BMP-2 Tracking of Subcutaneously Implanted Alginate/PCL 
Constructs. 2.5 µg of VS750-labeled BMP-2 (alone or loaded onto 1 mg of heparin 
microparticles) were mixed into 150 µL of 2% RGD-alginate. Alginate/PCL constructs were 
implanted subcutaneously in the backs of rats for 3 weeks (n=8) and imaged on an IVIS® 
platform at Day 0, 1, 4, 7, 10, 14, and 21 after surgery. A-D) Representative fluorescence IVIS® 
images of subcutaneous implants at indicated time points. E) Quantification of in vivo VS750 
fluorescence over time (normalized to Day 0 fluorescence) revealed somewhat faster loss of 
BMP-2 signal from constructs lacking microparticles; however, these data were not significantly 
different. F) Decay constants from BMP-2 retention data fit to a one-phase exponential decay 
curve revealed differences in average decay constants of constructs treated with No MPs and 1 
mg MPs. (* = p < 0.05 as indicated) G) Quantification of ex vivo VS750 fluorescence from 
explanted constructs 21 days post-surgery. (* = p < 0.01 as indicated) 
	
4.3.5 Ectopic Mineralization in Subcutaneous Implants 
	
To evaluate their ability to induce ectopic mineralization, subcutaneously 
implanted alginate/PCL constructs that had been loaded with heparin microparticles and 
BMP-2 were also scanned using micro-CT after 6 weeks in vivo. Constructs containing 
alginate only, 1 mg of unloaded microparticles, 5 µg of BMP-2, and 5 µg of BMP-2 
loaded onto 1 mg of microparticles were evaluated. Quantification of micro-CT scans 
demonstrated low mineral volume in constructs containing alginate only and unloaded 
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microparticles; on the other hand, constructs containing BMP-2 only and BMP-2 loaded 
onto heparin microparticles demonstrated variable amounts of ectopic mineral formation 
(Figure 4.5A). Due to the variability in mineral formation, there were no significant 
differences in average mineral volumes. Safranin O/Fast Green staining of constructs 
revealed ectopic mineral in both BMP-2 and BMP-2-loaded microparticle-containing 
constructs (white arrows; Figure 4.5B, C). This ectopic mineralization study confirmed 
that both BMP-2 alone and BMP-2-loaded microparticles within alginate/PCL constructs 
could induce mineralization in vivo; however, due to the variability exhibited in this 




Figure 4.5. BMP-2-Mediated Ectopic Mineralization of Subcutaneously Implanted 
Alginate/PCL Constructs. Alginate/PCL constructs were assembled and implanted 
subcutaneously in the backs of rats for 6 weeks (n=6).  One of each of the following groups was 
implanted into each rat: 150 µL of 2% RGD-alginate, 1 mg unloaded microparticles in 150 µL of 
alginate, 5 µg of BMP-2 in 150 µL of alginate, or 5 µg of BMP-2 loaded onto 1 mg of 
microparticles in 150 µL of alginate. A) Quantification of mineral volume in alginate 
PCL/constructs. Safranin O/Fast Green staining of constructs containing B) BMP-2 only and C) 
BMP-2-loaded microparticles demonstrates the formation of ectopic mineral after 6 weeks in 
vivo, as indicated by white arrows.  
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4.3.6 Orthotopic Mineralization in Femoral Defects 
	
After alginate/PCL constructs containing BMP-2-loaded heparin microparticles 
were confirmed to induce mineralization in an ectopic site, the ability of loaded 
microparticles to stimulate bone healing in a femoral defect model was investigated. 
Femoral defects were treated with 2.5 µg of BMP-2, 2.5 µg of BMP-2 loaded onto 1 mg 
of heparin microparticles, or 1 mg of unloaded heparin microparticles. After twelve 
weeks, bony bridging was observed in all defects treated with BMP-2 alone (“BMP-2”) 
(5/5), 60% of defects treated with BMP-2-loaded microparticles (“MP + BMP-2”) (3/5), 
and none of the defects treated with unloaded microparticles (“MP”) (0/4). 
Representative radiographs at 2, 4, 8, and 12 weeks demonstrate the progression of bone 
formation in defects treated with BMP-2 and BMP-2-loaded microparticles (Figure 
4.6A). Of defects treated with loaded microparticles, three bridged completely (top row), 
while two exhibited bone formation throughout the bone defect but did not bridge 
(bottom row). 
Longitudinal in vivo micro-CT scans at 4, 8, and 12 weeks provided bone volume 
(Figure 4.6B) and bone mineral density (Figure 4.6C) quantification of the regenerated 
femurs. As expected, minimal bone regeneration was observed in the defect following 
treatment with unloaded microparticles, although the mineral that did form had a similar 
density to that of BMP-2-regenerated femurs at 8 and 12 weeks. Both BMP-2-containing 
groups induced higher mineral formation than unloaded microparticles. Overall, BMP-2-
loaded microparticles induced less mineral volume than BMP-2 treatment; however, 
these differences were not significant at each individual time point. Mineral density of the 
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regenerated bone increased after 4 weeks in both BMP-2 and BMP-2-loaded 
microparticle treated femurs; there were no differences between the mineral densities of 





Figure 4.6. Qualitative and Quantitative Assessment of Orthotopic Mineralization in 
Femoral Defects. Bilateral femoral defects were treated with alginate/PCL constructs containing 
1 mg of unloaded heparin microparticles, 1 mg of microparticles loaded with 2.5 µg of BMP-2, or 
2.5 µg of BMP-2 (n=4-5). A) Representative radiographs of femurs at 2, 4, 8, and 12 weeks post-
surgery. All defects (5/5) containing BMP-2 bridged, while only 3/5 defects containing BMP-2-
loaded microparticles bridged. Radiographs of femurs treated with BMP-2-loaded microparticles 
are representative images of both bridging and non-bridging cases. No defects containing 
unloaded microparticles bridged. B) Quantification of mineral volume in bone defects using 
micro-CT at 4, 8, and 12 weeks post-surgery. Both BMP-2 and BMP-2-loaded microparticle 
treated femurs demonstrated higher bone formation than unloaded microparticles at each time 
point (* = p < 0.05 compared to unloaded microparticles). BMP-2 treatment induced higher bone 
formation than loaded microparticles overall (p < 0.001), although these differences were not 
significant at individual time points. C) Mineral density of regenerated bone in defects containing 
unloaded microparticles was higher than that of the other treatments at 4 weeks ($ = p < 0.05 as 
indicated). Mineral densities of loaded microparticles and BMP-2 treated defects increased over 
12 weeks. (# = p < 0.05 compared to 4 weeks.) 
	
4.3.7 Biomechanical Properties of Regenerated Femurs  
	
After 12 weeks, all animals were euthanized, and femurs were removed for 
torsion testing to evaluate the mechanical properties of the regenerated bone. Both 
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bridged and non-bridged samples were tested. Femurs regenerated by BMP-2 and BMP-
2-loaded microparticles exhibited maximum torque and torsional stiffness that were not 




Figure 4.7. Biomechanical Testing of Regenerated Femurs. Femurs were isolated and 
mechanically tested via torsion to failure (n=3-4). Mechanical properties were compared against 
that of intact femurs of age-matched rats (historical data [234]). A) Maximum torque withstood 
by femurs treated with BMP-2 and BMP-2-loaded microparticles. B) Stiffness demonstrated by 
femurs treated with BMP-2 and BMP-2-loaded microparticles. No differences were observed 
between groups or compared to intact bone. 
 
4.3.8 Histological Analysis of Femoral Defects  
 
Sections from representative femurs 12 weeks post surgery were stained with 
Safranin O/Fast Green to visualize tissue morphology within the bone defect site. 
Sections of femurs treated with BMP-2 alone revealed areas of residual alginate (shown 
in red) surrounded by areas of new mineral formation (white arrows; Figure 4.8A). On 
the other hand, sections of femurs treated with unloaded heparin microparticles did not 
show any bone formation, and only fibrous tissue could be observed, interspersed 
between alginate and remaining microparticles (yellow arrows; Figure 4.8B). Femurs 
treated with BMP-2-loaded microparticles demonstrated similar areas of mineral 
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formation to femurs treated with BMP-2 alone, in close proximity to both residual 
alginate and intact microparticles (Figure 4.8C). Immunohistochemistry for the cell 
proliferation marker Ki67 on femurs explanted after 2 weeks post-surgery revealed 
minimal positive staining in femurs treated with BMP-2 alone (Figure 4.8D). However, 
both femurs treated with unloaded microparticles and BMP-2-loaded microparticles 
exhibited Ki67+ cell nuclei throughout the defect, with some cells in close proximity to 
regions of microparticles (Figure 4.8E, F), suggesting that cells infiltrating the defect site 
were proliferating in response to heparin microparticles but not in response to BMP-2 
alone. As an additional control, sections of rat small intestine were incubated with Ki67 
antibody or mouse serum, followed by the horseradish peroxidase secondary antibody; 
horseradish peroxidase staining was only observed in the presence of Ki67 (Figure 4.9). 
	
 
Figure 4.8. Histological Analysis of Regenerated Femurs. Representative femurs were fixed, 
decalcified, and embedded in paraffin for sectioning and staining. Safranin O/Fast Green staining 
of femurs treated for 12 weeks with A) 2.5 µg of BMP-2, B) 1 mg of unloaded heparin 
microparticles, and C) 2.5 µg of BMP-2 loaded onto 1 mg of heparin microparticles. Ki67 
antibody staining of femurs treated for 2 weeks with D) 2.5 µg of BMP-2, E) 1 mg of unloaded 
heparin microparticles, and F) 2.5 µg of BMP-2 loaded onto 1 mg of heparin microparticles. 





Figure 4.9. Negative and Positive Controls for Ki67 Staining. A) Sections of rat small intestine 
incubated in mouse serum, followed by secondary horseradish peroxidase antibody, did not 
display positive staining. B) Small intestine incubated with Ki67 antibody, followed by secondary 




Heparin, with its known affinity for a number of potent growth factors, has been 
frequently added to biomaterial delivery vehicles to slow the release of biomolecules 
from a site of interest. In this study, we investigated the incorporation of heparin 
microparticles into an alginate/PCL tissue engineering construct that has been previously 
used in our laboratory for in vivo delivery of BMP-2. We demonstrated that heparin 
microparticles could be evenly dispersed throughout the alginate hydrogel network, to 
reduce the total amount of BMP-2 released in vitro and attenuate the overall rate of BMP-
2 loss from subcutaneous implants. Furthermore, BMP-2-loaded heparin microparticles 
could be retained in vivo within alginate/PCL constructs implanted both subcutaneously 
and in the femoral bone defect, inducing mineral formation in both ectopic and orthopic 
sites and leading to bony bridging of 60% of the defects treated. Despite lower mineral 
volumes observed in defects treated with BMP-2-loaded microparticles compared to 
BMP-2 alone, both treatments lead to comparable restoration of biomechanical 
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properties. Histological analysis of defects after 2 and 12 weeks revealed persistence of 
intact microparticles throughout the entire period of bone healing, as well as an early 
increase in the number of proliferating Ki-67+ cells within the defect site in the presence 
of both unloaded and BMP-2-loaded heparin microparticles.  
 Of the heparinized materials that have been developed for BMP-2 delivery, a 
number have demonstrated improved BMP-2 retention and sustained release profiles in 
vitro compared to non-heparinized controls. For example, the covalent addition of 
heparin into PLGA scaffolds extended the time required for total BMP-2 release from 
under four hours to three weeks [173], while the incorporation of 1-10% heparin into 
hyaluronan microgels dose-dependently increased BMP-2 loading and decreased BMP-2 
release [167]. We observed similar results in our experiments, in which the addition of 1 
mg of heparin microparticles into alginate/PCL constructs reduced in vitro BMP-2 
release by 50% compared to constructs containing BMP-2 alone, at two different doses of 
BMP-2 (0.5 and 2.5 µg). Interestingly, when BMP-2 was mixed into alginate hydrogels 
in the presence of 1 mg of empty microparticles, we also observed a slight attenuation in 
BMP-2 release in vitro, suggesting that free BMP-2 within the hydrogel may associate 
with microparticles over time. Similar results have been observed in other composite 
hydrogels, including methylcellulose and hyaluronan-methylcellulose hydrogels 
containing empty PLGA nanoparticles and soluble SDF-1, NT-3, and BDNF [240]. 
We next evaluated BMP-2 retention in alginate/PCL constructs in vivo with 
longitudinal fluorescence imaging techniques. Few studies have attempted to assess 
differences in the in vivo release profiles of growth factors from implanted biomaterials 
due to the difficulty of consistently and accurately imaging through deeper tissue; 
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however, the evaluation of in vivo release profiles may provide more accurate 
information for developing in vivo applications. For example, Shah, et al. performed in 
vivo imaging of fluorescently tagged PDGF-BB and BMP-2 in a calvarial defect for 14 
and 21 days, respectively [241], and in our previous studies, we demonstrated the ability 
to detect fluorescently tagged BMP-2 within a femoral defect for 21 days [233]. In our 
current study, in order to enhance the signal of the delivered BMP-2 while minimizing 
background fluorescence, we chose to implant alginate/PCL constructs in superficial 
locations along the backs of the rats. Fluorescent signal was detected for 21 days in this 
location, with constructs containing BMP-2-loaded microparticles displaying a lower 
decay constant (λ = 0.12) indicative of slower overall release compared to constructs 
containing BMP-2 alone (λ = 0.80). The differences observed between in vitro and in 
vivo BMP-2 release may be due to several causes, including fluorophore degradation, 
discrepancies due to different measurement methods (BMP-2 release in vitro vs. BMP-2 
retention in vivo), altered interactions of BMP-2 with alginate and heparin microparticles 
following fluorophore addition, and the presence of numerous proteases and cells in the 
subcutaneous environment that could accelerate BMP-2 release and degradation. While 
the ideal environment to investigate BMP-2 release would be the bone defect itself, in 
which many different cell types and biomolecules reside, there are significant technical 
challenges in imaging fluorescent molecules implanted deeper within tissues; 
additionally, previous studies have reported consistent BMP-2 release profiles from 
subcutaneous and bone defect sites [194].  
Given that the molecular cargo of this tissue engineering construct was loaded 
directly onto the heparin microparticles, microparticle retention in vivo likely dictated 
	 100 
BMP-2 retention and distribution throughout the subcutaneous space and bone defect. Ex 
vivo IVIS® imaging and Safranin O/Fast Green staining of ectopically implanted 
constructs revealed the persistence of microparticles throughout the 6-week period of 
implantation, with retention of ~55% of the original fluorescent signal from AF647-
labeled microparticles. Furthermore, when constructs containing microparticles were 
implanted into the bone defect, Safranin O/Fast Green staining after 12 weeks similarly 
depicted the remaining microparticles throughout areas of residual alginate and 
regenerated bone. Unlike alginate, heparin microparticles were not hydrolytically 
degradable; thus, the loss of fluorescent signal observed following ectopic construct 
implantation may be due to several other reasons, including cell-mediated microparticle 
degradation and clearance via the bloodstream following alginate degradation [242, 243]. 
Ultimately, while subcutaneous implantation of alginate/PCL constructs provided 
valuable information regarding BMP-2 and microparticle retention, ectopic 
mineralization induced by BMP-2-loaded microparticles demonstrated promising but 
highly variable results. Consequently, further investigation was conducted in an 
orthotopic bone defect model, in which BMP-2-loaded heparin microparticles induced 
robust mineralization within the defect space, resulting in bridging of 60% of the treated 
defects and restoration of mechanical properties similar to that of intact femurs. Despite 
these encouraging results, defects treated with alginate/PCL constructs containing BMP-2 
alone out-performed BMP-2-loaded microparticles, with increased mineral volumes and 
complete bridging in all defects.  
The reduction in overall bone healing displayed in defects treated with BMP-2-
loaded microparticles may be attributed to the differences in BMP-2 retention and 
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presentation caused by the presence of microparticles in the constructs. Both in vitro and 
in vivo results suggested that heparin microparticles increased BMP-2 retention within 
the constructs. Although we have demonstrated that heparin microparticles provide the 
sustained BMP-2 presentation necessary to induce cellular differentiation in vitro upon 
contact [107], an initial burst release of BMP-2 from the construct may also be required 
to promote chemotaxis and initial cell infiltration into the alginate hydrogel [153, 244]. 
Furthermore, in our previous publication, we also highlighted the importance of BMP-2 
presentation, demonstrating that barriers to cell-microparticle contact, such as transwell 
separation and inadequate numbers of BMP molecules per microparticle, decreased the 
efficiency of C2C12 alkaline phosphatase induction and, potentially, BMP signaling. The 
dosing of BMP-2 and microparticles in this study resulted in a theoretical concentration 
of ~5 million BMP-2 molecules per microparticle. Since heparin microparticles are on a 
similar size scale as cells (5 µm compared to 10 µm) and are expected to retain the 
majority of loaded BMP-2 based on in vitro results, this high density of spatially confined 
BMP-2 molecules may have reduced the probability of infiltrating cells contacting BMP-
2 molecules and increased steric hindrance of BMP-receptor interactions on cell surfaces.  
Interestingly, both unloaded and BMP-2-loaded microparticles also induced 
proliferation of infiltrating cells after 2 weeks in vivo as evidenced by Ki67+ staining in 
proximity to microparticles. We have previously addressed this phenomenon in regards to 
in vitro C2C12 proliferation in the presence of BMP-2-loaded microparticles, speculating 
that other mitogenic proteins may have bound to heparin microparticles and interacted 
with cells. We expect that similar events may be occurring in vivo in the bone defect, and 
that the concentration of serum borne proteins with high affinity for heparin, such as 
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fibronectin, apolipoproteins, and thrombospondins, may modulate cell proliferation [245-
247]. Binding and adsorption of serum components to heparin microparticles and their 
subsequent effects on growth factor loading and release is an important consideration in 




In summary, delivery of BMP-2 using heparin microparticles incorporated into an 
alginate/PCL tissue engineering construct resulted in increased BMP-2 retention in vivo 
and robust mineralization within an orthotopic bone defect site, but did not perform as 
well as alginate/PCL constructs containing BMP-2 alone. Since the results observed in 
this study may be due to microparticle-mediated differences in BMP-2 retention and 
presentation, future BMP-2 delivery strategies using heparin microparticles will aim to 
mitigate this by further tuning the kinetics of BMP-2 release. This may be accomplished 
using a number of approaches, including changing the number of microparticles to alter 
BMP-2 distribution in the defect, introducing a combination of alginate-bound and 
microparticle-bound BMP-2 to provide a burst release of growth factor followed by 
sustained presentation, or incorporating more recently developed degradable heparin 
microparticles to prolong the timeframe of BMP-2 release into the surrounding tissue 
[120]. Ultimately, this study demonstrated the utility of heparin microparticles for BMP-2 
delivery in a segmental bone defect model and provided valuable information about in 
vivo BMP-2 retention and presentation that informed additional experiments using this 
hybrid biomaterial system.   
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CHAPTER 5: DEVELOPMENT OF A MATHEMATICAL MODEL FOR BMP-2 




In Chapter 4, we demonstrated that the addition of BMP-2-loaded heparin 
microparticles into alginate/PCL tissue engineering constructs resulted in attenuated 
mineralization within a rat femoral bone defect. It was hypothesized that this was partly 
due to the increased retention of BMP-2 by the microparticles (and, by extension, within 
the alginate construct), resulting in a low chemotactic effect and reduced cell infiltration 
from surrounding tissues. The ability to easily “dose in” specific amounts of heparin 
microparticles into this system provides us with the unique opportunity to further 
investigate the effect of BMP-2-microparticle interactions on BMP-2 release kinetics and 
retention in a tissue engineering construct. Given the vast number of combinations 
available in choosing both BMP-2 and microparticle doses, a computational model was 
created to explore the factors that influence BMP-2 release kinetics in the alginate/PCL 
construct in silico prior to conducting further in vivo experiments. Moreover, since the 
diffusion of BMP-2 through alginate hydrogel was expected to play an important role in 
BMP-2 release from the construct, a robust method to experimentally determine BMP-2 
diffusion through hydrogels was also developed. 
Both natural and synthetically engineered affinity-based growth factor delivery 
systems rely on specific protein-material interactions that can be defined by a 
characteristic association/binding rate constant (kon) and dissociation/unbinding rate 
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constant (koff). In the case of synthetic materials, these interactions can often be tuned by 
varying the density and strength of protein binding partners presented on a material [10, 
134, 135, 248], as well as the relative amounts of free and bound protein [249, 250]. 
Natural affinity-based interactions, such as antibody-protein interactions and heparin-
protein interactions, have provided the basis for designing many engineered protein 
delivery systems. Heparin’s reversible interactions with a number of potent growth 
factors (BMPs, FGFs, VEGF, NT-3) have been well-documented and exploited for 
biomaterial development [235, 251, 252]; however, heparin itself lacks the tunability of 
growth factor binding affinities that many synthetic materials offer. Thus, biomaterials 
that allow incorporation of graded amounts of heparin, such as hybrid hydrogels 
containing heparin chains [120, 168] and the heparin microparticle-containing 
alginate/PCL construct described herein, present the opportunity to more specifically 
select the degree of protein affinity that a material exhibits. 
Computational modeling can aid in designing and characterizing biomaterials for 
affinity-based growth factor delivery. Models have been previously developed to describe 
protein release from a number of affinity-based biomaterials [139, 253-256], including, 
most notably, FGF-2 and NGF release from a heparin-containing fibrin hydrogel [248, 
257, 258], proteolysis-mediated VEGF release from a fibrin network [259], and the 
release of therapeutic fusion proteins (FGF-2 and chondroitinase ABC) from affinity 
peptide-modified hydrogels [260]. However, the majority of models developed thus far 
have focused primarily on specific interactions between proteins and affinity ligands, 
with minimal investigation into the additional role of protein diffusion through ligand-
containing hydrogels. Moreover, even fewer models have attempted to combine diffusion 
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through a biomaterial with diffusion into surrounding tissue to gain a better 
understanding of how a released protein will penetrate an in vivo tissue defect over time, 
since the biological complexity of tissue injury environments renders such scenarios 
difficult to model over long time periods. 
Consequently, we aimed to both create a computational model of in vivo BMP-2 
delivery to a bone defect site and develop a facile method to experimentally determine 
the diffusion of therapeutic proteins, such as BMP-2, through commonly used biomaterial 
delivery vehicles. The model we developed employed both theoretical and 
experimentally determined values for BMP-2-microparticle affinities, BMP-2 diffusion 
through the alginate hydrogel, and BMP-2 diffusion through tissue surrounding the bone 
defect site. BMP-2 release was modeled over period of 14 days, because this time frame 
encompasses the majority of BMP-2 release in vivo, while minimizing the amount of 
biomaterial degradation and tissue remodeling that can occur, and simplifying the 
parameters required for the model. 
Since the development of this model required an accurate measure of BMP-2 
diffusion through the alginate hydrogel that makes up the bulk of the biomaterial delivery 
vehicle, we also developed a method to easily determine protein diffusion through 
hydrogels. By tracking the one-dimensional diffusion of a fluorescently labeled protein 
through a capillary tube over time, we were able to measure protein diffusion as 
accurately as standard well plate release assays, which can be subject to variability and 
require larger amounts of proteins and materials. This method was tested using several 
model proteins of various molecular weights, as well as BMP-2. Diffusion was 
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investigated in three commonly used hydrogels for BMP-2 delivery, including alginate 
[233], collagen [41, 153, 261], and poly-ethylene glycol (PEG) [262, 263].   
Overall, these studies aimed to broaden the current understanding of affinity-
based protein delivery systems, by providing a more comprehensive mathematical model 
of in vivo BMP-2 delivery and demonstrating the tunability of the alginate/PCL construct 
when affinity ligands, such as heparin microparticles, are included. Since heparin 
microparticles can be easily and dose-dependently added into the alginate/PCL delivery 
system, this tissue engineering construct provides the opportunity to investigate tunable 
BMP-2 release kinetics. Finally, by developing a robust method to measure protein 
diffusion through hydrogels, we also aimed to improve evaluation of protein release from 
biomaterial delivery vehicles, by providing tailored diffusion coefficients that are more 
accurate than those determined from theoretical calculations and easier to obtain than 
using other methods.  
 
5.2 Materials and Methods 
	
5.2.1 Fluorescent Labeling of Proteins 
	
Proteins were fluorescently labeled for microscopy using NHS-fluorescein (5/6-
carboxyfluorescein succinimidyl ester; Thermo Fisher Scientific; Ex: 494 nm, Em: 518 
nm). Human immunoglobin G (IgG, MW = 150 kDa; Sigma Aldrich), bovine serum 
albumin (BSA, MW = 63 kDa; Sigma Aldrich), and bovine α-chymotrypsin (αCT, MW = 
25 kDa; Sigma Aldrich) were reconstituted at 50 nM in 100 mM NaPO4 (pH = 8.5), 
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while human recombinant BMP-2 (MW = 25 kDa; R&D Systems) was reconstituted in 
the same buffer at 10 nM due to its reduced solubility at basic pH. NHS-fluorescein was 
reconstituted in DMSO at 2 mM and diluted in sodium phosphate buffer to 750 nM for 
labeling IgG, BSA, and αCT, and 150 nM for labeling BMP-2 in order to achieve 15 
times molar excess of label to protein. The reaction was allowed to proceed at room 
temperature in the dark for 4 hours in a total reaction volume of 100 µL. Following this, 
excess label was removed via gel filtration through Zeba Spin Desalting Columns with a 
7 kDa molecular weight cut-off (Thermo Fisher Scientific). Protein labeling and removal 
of excess dye was confirmed by fractionation through a PD-10 desalting column (GE 
Healthcare Bio-Sciences), followed by quantification of fluorescence of each molecular 
weight fraction of the protein solution using a Synergy H4 microplate reader (Biotek). 
Proteins were stored at 4°C until use. 
	
	
5.2.2 Preparation of Hydrogels 
 
RGD-functionalized alginate (FMC Biopolymer, Philadephia, PA), which has 
previously been used for BMP-2 delivery in a rat femoral bone defect [233, 234], was 
reconstituted at 2% (w/v) in a 5:1 solution of Minimal Essential Media – Alpha 
Modification (αMEM; Thermo Fisher Scientific) and 4 mM hydrochloric acid (Sigma 
Aldrich). For alginate cross-linking via calcium sulfate, 2% alginate solution was mixed 
with excess CaSO4 (61.7 mM final concentration) using the dual syringe method 
described previously [234] and in Chapter 4. Following gelation, alginate was injected in 
microcentrifuge tubes through a 22-gauge, blunt-tip needle to mimic injection in the bone 
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defect during surgery. Hollow borosilicate tubes (L: 100 mm, ID: 600 µm; VitroCom, 
Mountain Lakes, NJ) were immersed in a microcentrifuge tube containing ~100 µL of 
alginate hydrogel and tapped against the bottom of the microcentrifuge tube to fill ~3-4 
cm of each capillary tube.  
For alginate cross-linking via calcium chloride, hollow borosilicate tubes (L: 100 
mm, ID: 600 µm; VitroCom, Mountain Lakes, NJ) were directly immersed in ~100 µL of 
uncross-linked 2% alginate solution such that liquid was drawn up via capillary action to 
fill ~3-4 cm of each tube. An insulin syringe with a 15-mm, 27-gauge needle (BD, 
Franklin Lakes, NJ) was used to inject a solution of 100 mM calcium chloride into the 
tubes in direct contact with the alginate solution. Calcium chloride was allowed to diffuse 
into the alginate solution overnight at 4°C to promote calcium-mediated cross-linking. 
Collagen Type I from rat tail (Corning) in 0.02 N acetic acid at 8-11% (w/v) was 
mixed with 1 N sodium hydroxide and ethylenediaminetetraacetic acid (EDTA) on ice to 
obtain a final collagen solution of 6% (w/v) at a neutral pH (~7.4), as previously 
described [264]. Hollow borosilicate tubes (L: 100 mm, ID: 600 µm) were immersed in 
~100 µL of collagen solution such that liquid was drawn up via capillary action to fill ~3-
4 cm of each tube. Tubes were incubated in a humidified incubator at 37°C with 5% CO2 
overnight to promote collagen gelation.  
Four-arm polyethylene glycol maleimide (PEG-MAL, 20 kDa; Laysan Bio, Arab, 
AL) was reconstituted in 20 mM HEPES (pH = 7.4) at 8% (w/v) and mixed with an equal 
volume of VPM cross-linker peptide (GCRDVPMSMRGGDRCG; AAPTEC, Louisville, 
KY) in 20 mM HEPES (pH = 7.4) at 1.2% (w/v) to get a final PEG-MAL solution of 4% 
(w/v), which has been previously used for BMP-2 and VEGF delivery in a mouse radial 
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bone defect model [262, 263]. Hollow borosilicate tubes (L: 100 mm, ID: 600 µm) were 
immersed in ~100 µL of PEG-MAL solution such that liquid was drawn up via capillary 
action to fill ~3-4 cm of each tube. The cysteine groups on the VPM peptide were 
allowed to react with the maleimide groups on the PEG macromer at room temperature at 
an acidic pH for at least 15 minutes until gelation had occurred. 
	
5.2.3 Protein Diffusion through Hydrogels in Capillary Tubes 
	
Fluorescently labeled proteins were diluted to 50 µg/mL for capillary tube 
diffusion experiments. After tubes were filled with collagen, alginate, or PEG hydrogels, 
an insulin syringe with a 15-mm, 27-gauge needle was used to inject the protein solutions 
into the tubes in direct contact with the hydrogels. Tubes were tapped gently to remove 
air bubbles from the interface. Three tubes were then placed on a glass microscope slide 
approximately 0.5 mm apart and with the protein-hydrogel interfaces aligned. The ends 
of the tubes were affixed to the glass slide and sealed using Silly PuttyTM (Crayola, 
Easton, PA) to avoid evaporation of the protein solution or water loss from the hydrogels. 
This set-up is depicted in Figure 5.1. 
Slides were imaged using a Zeiss AxioObserver XLmulti S1 inverted microscope 
(Carl Zeiss, Jena, Germany) with Zeiss MTB2004 64 bit software and an incubated stage. 
Images were taken at 37°C using a 2.5x objective lens, 0.5x camera, and GFP channel 
(Ex: 488 nm). A fluorescence image was taken every 4 minutes over a period of 2 hours 
to yield a total of 31 images. Hydrogels were visually inspected under the 2.5x objective 
lens at the end of the experiment to ensure no macroscopic structural changes had 
	 110 
occurred during imaging [262, 263]. Experiments with each protein and hydrogel were 
conducted in triplicate. Diffusion of free fluorescein dye (MW = 0.33 kDa; Thermo 
Fisher Scientific) was also evaluated as a small molecule control. 
 
 
Figure 5.1. Capillary Tube Diffusion Set Up. For microscope imaging, three capillary tubes 
filled with hydrogel and protein solution were affixed to a glass slide (approximately 0.5 mm 
apart) using Silly PuttyTM. 
	
5.2.4 Calculation of Effective Diffusion Coefficients in Capillary Tubes 
 
Images from the capillary tube diffusion experiments were analyzed using ImageJ 
Software (NIH, Bethesda, MD). Images were opened as a stack and converted to gray 
scale; next, a line was drawn through the long axis of each tube to define a region of 
interest for fluorescence intensity measurements. The fluorescence intensity across each 
tube was measured within the microscope field of view (3.6 mm) and recorded for all 31 
images, yielding a matrix of fluorescence intensity values at each time and distance. 
Fluorescence intensity throughout the hydrogel was normalized to the average 
fluorescence intensity displayed in the protein reservoir. 
Diffusion of proteins through hydrogels in capillary tubes was approximated as 
one-dimensional diffusion from an infinite protein reservoir, since the length of the 
hydrogels (~3-4 cm) was much greater than their diameter (~600 µm), and the 
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fluorescence intensity of the protein reservoirs did not change significantly over the 
course of the experiments. Thus, diffusion through capillary tubes could be described 
using the following equation [264, 265]: 
 
𝐹 𝑥, 𝑡 ∝ 𝑒𝑟𝑓𝑐 !
! !!""!
            (1) 
 
in which erfc is the complementary error function, F = fluorescence normalized to the 
initial time point (dimensionless), x = distance from the protein reservoir (cm), t = time 
since protein-hydrogel contact (s), and Deff = effective diffusion coefficient (cm2/s). 
Normalized fluorescence intensity values were inputted into a custom MATLAB code 
(Appendix A), in which the fmincon function was used to perform non-linear curve 
fitting, evaluate the complementary error function, and determine Deff. 
 
5.2.5 Protein Release from Hydrogels in Well Plates 
 
In order to compare typical protein release methods to the capillary tube diffusion 
method, 2% (w/v) alginate hydrogels containing 2.5 µg of BMP-2 were cross-linked 
using calcium sulfate and the dual syringe method mentioned above, and injected through 
a blunt-tip needle to form discs with a diameter of ~10 mm and thickness of ~2 mm 
(Total Volume = ~150 µL). The discs were then transferred to a 6-well plate (CoStar® 
Ultra-low Attachment Plate; Corning) and immersed in 10 mL of 0.1% (w/v) BSA in 
PBS for protein release in a 37°C humidified incubator with 5% CO2. Small volume 
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samples (500 µL) were collected after 0.5, 1, 2, 4, 6, 9.5, and 24 hours and analyzed for 
BMP-2 content via ELISA; 500 µL of fresh solution was added after sample collection. 
	
5.2.6 Calculation of Effective Diffusion Coefficients in Well Plates 
 
The alginate discs made for well plate diffusion experiments satisfied both the 
infinite slab condition (disc diameter at least 4 times larger than thickness) and near-zero 
concentration boundary condition (fluid volume at least 20 times greater than hydrogel 
volume); thus, diffusion from the protein-filled hydrogel could be described using the 






            (2) 
 
in which t = time (s), δ = half of the disc thickness (cm), Mt = mass of BMP-2 in the 
release volume at time t (ng), M∞ = final mass of BMP-2 in the release volume after 
equilibrium is reached at time infinity (ng), and Deff = effective diffusion coefficient 
(cm2/s). Using BMP-2 masses obtained via ELISA, Mt/M∞ was plotted against t1/2 and 
linear regression was used to determine the effective diffusion coefficient. 
 
5.2.7 COMSOL Model Development 
 
COMSOL Multiphysics software (Version 5.1.0.180; Burlington, MA) was used 
to develop a mathematical model to describe diffusion of BMP-2 from alginate and 
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heparin microparticle-containing alginate constructs within a femoral bone defect in vivo. 
The three-dimensional geometry of the construct (cylinder, D = 4.5 mm, L = 10 mm) and 
thigh (cylinder, D = 15 mm, L = 18 mm) (Figure 5.2A) was reduced to a two-dimensional 
modeling domain consisting of two nested rectangles with axial symmetry (Figure 5.2B).  
 
Figure 5.2. 3D and Reduced 2D Geometry of Alginate Construct in Rat Thigh. A) Three-
dimensional geometry of alginate construct in bone defect in which construct is modeled as inner 
cylinder and surrounding thigh tissue is modeled as outer cylinder. B) Reduced two-dimensional 
geometry of alginate construct in bone defect consisting of two nested rectangles with axial 
symmetry, such that rotation around r=0 (red line) results in an inner and outer cylinder. 
 
The reaction engineering interface was used to describe BMP-2 release from 
heparin microparticles (reaction), BMP-2 diffusion through alginate hydrogel (transport 
of dilute species), and BMP-2 diffusion through tissue (transport of dilute species). These 
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) as a function of DBMP,Alg = diffusion coefficient of BMP-2 through alginate 
(m2/s), CBMP,Alg = BMP-2 concentration in alginate (mol/m3), and RBMP,Alg = rate of BMP-
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which describes the change in BMP-2 concentration in the thigh tissue over time 
(!!!"#,!"##
!"
) as a function of DBMP,Tiss = diffusion coefficient of BMP-2 through thigh 
tissue (m2/s) and CBMP,Tiss = BMP-2 concentration in thigh tissue (mol/m3); 
 
𝑅!"#,!"# = 𝑘!""𝐶!"#!!" − 𝑘!"𝐶!"#𝐶!"            (5) 
 
which describes the rate of BMP-2 appearance/disappearance in the alginate (RBMP,Alg) 
based on binding with free sites on heparin microparticles to form the microparticle-
BMP-2 complex (CBMP+MP) at the association rate constant, kon, and dissociation from 
occupied sites on heparin microparticles to form free BMP-2 (CBMP) and free 
microparticle binding sites (CMP) at the dissociation rate constant, koff.  
Several assumptions were made in order to model this complex biological system. 
First, it was assumed that the alginate hydrogel did not appreciably degrade in the time 
frame investigated (21 days); thus DBMP,Alg was not time-dependent, and heparin 
microparticles did not diffuse from their locations in the alginate construct or leave the 
construct boundary (DMP,Alg = 0). Heparin microparticles were also assumed to be evenly 
distributed throughout the hydrogel, since this was demonstrated via histology and 
fluorescence imaging in Chapter 4. Furthermore, since the alginate hydrogel and thigh 
were semi-solid materials that allowed transport of BMP-2, which was somewhat 
spatially constrained, both materials were modeled as liquids in a batch reactor that was 
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not well mixed. At the boundary between the alginate hydrogel and the thigh, it was 
assumed that the BMP-2 concentrations were equal (CBMP,Alg = CBMP,Tiss). Finally, 
interstitial fluid flow and advection in the bone defect were considered negligible.  
The parameters necessary for the equations above were defined and inputted into 
the COMSOL reaction engineering interface to compute solutions for alginate constructs 
(1) with and without heparin microparticles and (2) with BMP-2 either initially loaded 
into the alginate or loaded onto the microparticles; a time-dependent, direct solver 
(PARDISO) and an extra fine, user-defined mesh were used. All parameters are defined 
in Table 5.1 below for a low dose of BMP-2 (2.5 µg) delivered using 1 mg of heparin 
microparticles. The effective diffusion coefficient of BMP-2 through alginate (DBMP,Alg) 
was calculated based on experimental data collected in capillary tube and well plate 
diffusion experiments, while the effective diffusion coefficient of BMP-2 through the 
surrounding nanofiber mesh and thigh tissue (DBMP,Tiss) was approximated using previous 
BMP-2 retention data obtained through fluorescent BMP-2 tracking in the segmental 
bone defect [233]. The total number of BMP-2 binding sites on heparin microparticles 
was calculated on a per molecule basis using previous data that revealed the maximum 
binding capacity of heparin microparticles to be ~300 µg BMP-2/mg microparticles 
[107]. Previous data on the release of BMP-2 from heparin microparticles in PBS was 
also used to verify that the association and dissociation rate constants chosen accurately 
described the system. Rate constants were initially chosen based on literature values for 
BMP-2 binding to linear heparin (KD = 20 nM, kon = 5.1e-04 1/nMs, koff = 0.01 1/s) [3] 
and subsequently adjusted for heparin microparticles using a COMSOL model of in vitro 
BMP-2 and heparin microparticle interactions, which revealed that a slightly higher 
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dissociation constant than that of linear heparin was necessary to accurately model the 
experimental results (KD = 50 nM, kon = 5.1e-04 1/nMs, koff = 0.025 1/s).  
 
Table 5.1. Parameters Used in COMSOL Model of BMP-2 Diffusion in Bone Defect 









Length of Alginate Cylinder 10 mm  
Diameter of Thigh Cylinder 15 mm  




BMP-2 Diffusion Through Alginate 
 







BMP-2 Diffusion Through Thigh 
 
Effective Diffusion  
Coefficient (DBMP,Tiss) 
 
2.0E-08 cm2/s [233] 
 
BMP-2 Interactions with Heparin 
Microparticles 
 
(2.5 µg BMP-2 with 1 mg of 
microparticles) 
 






Number of Binding Sites 7.0E15  
Number of BMP-2 Molecules 5.8E13  
Dissociation Constant (KD) 50 nM Adapted from [3] 
Dissociation Rate Constant (kon) 
 
5.1E-04 1/nMs Adapted from [3] 
 Association Rate Constant (koff) 0.025 1/s 
 
Adapted from [3] 
	
5.2.8 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. Diffusion experiments 
were run with a minimum of three replicates for each experimental group. Statistical 
significance was determined using one-way or two-way ANOVA as appropriate, 
followed by Bonferroni’s post hoc analysis (Graphpad Prism, Version 5.0, La Jolla, CA). 







5.3.1 Determination of Diffusion Coefficients Using Capillary Tube Method 
 
In order to test the capillary tube method of evaluating hydrogel diffusivities, 
effective diffusion coefficients of proteins through 2% alginate (CaCl2 cross-linked) and 
6% collagen hydrogels were calculated for free fluorescein, BMP-2, and several model 
proteins of various molecular weights (α-chymotrypsin, bovine serum albumin, 
immunoglobin) by fitting the time- and space-dependent changes in fluorescence 
intensity throughout the hydrogel to a one-dimensional model of diffusion (Equation 1) 
[264, 265]. Samples images of BSA diffusion through 2% alginate hydrogels at 0 and 3 
hours, can be seen in Figure 5.3 below. As expected, free fluorescein, which is a small 
molecule with a molecular weight of 0.3 kDa, displayed a higher effective diffusion 
coefficient than all model proteins diffusing through either alginate or collagen hydrogels 
(Figure 5.4A). There was no effect of the hydrogel used on the diffusivity of model 
proteins overall.  
When the diffusion coefficients of model proteins were compared, it was found 
that α-chymotrypsin exhibited higher diffusion in collagen hydrogels compared to higher 
molecular weight proteins (bovine serum albumin, immunoglobin), while the diffusion 
coefficients of all of these proteins were similar in alginate (Figure 5.4B). This was likely 
due to the increased weight percent of collagen hydrogels compared to alginate 
hydrogels, which could further hinder diffusion. Despite the fact that few differences 
were observed, a linear correlation was identified when effective diffusion coefficients 
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were plotted against the molecular weights of model proteins (Figure 5.5), suggesting that 
the effective diffusion coefficient was, as expected and previously demonstrated [268-
270], negatively correlated with protein molecular weight (R2 = 0.96 for alginate, R2 = 
0.84 for collagen).  
 
 
Figure 5.3. Images of Capillary Tube Diffusion Experiment. A) Bright field image of capillary 
tubes filled with 2% (w/v) alginate (CaSO4 cross-linked) hydrogels. Fluorescence (GFP) images 
of fluorescein-labeled BSA diffusing through alginate hydrogels at B) 0 hours and C) 3 hours. 
Protein reservoirs are on the left side of the images. 
	
 
Figure 5.4. Effective Diffusion Coefficients of Free Fluorescein and Model Proteins in 
Hydrogels. A) Effective diffusion coefficients of fluorescein and model proteins (bovine α-
chymotrypsin, bovine serum albumin, and human immunoglobin) in 2% (w/v) alginate (CaCl2 
cross-linked) and 6% (w/v) collagen hydrogels. Diffusion coefficients were determined using 
image analysis of fluorescently labeled biomolecules diffusing through capillary tubes filled with 
hydrogels. (# = p < 0.05 compared to all other proteins) B) Effective diffusion coefficients of 
only model proteins in 2% (w/v) alginate (CaCl2 cross-linked) and 6% (w/v) collagen hydrogels. 





Figure 5.5. Effective Diffusion Coefficients of Model Proteins in Hydrogels. Effective 
diffusion coefficients of model proteins (bovine α-chymotrypsin, bovine serum albumin, and 
human immunoglobin) in 2% (w/v) alginate (CaCl2 cross-linked) and 6% (w/v) collagen 
hydrogels plotted as a function of molecular weight. Trend lines represent linear fit of data for 
each hydrogel. 
	
Effective diffusion coefficients of the therapeutic protein of interest, BMP-2, were 
determined for diffusion through 2% alginate (CaCl2 cross-linked), 2% alginate (CaSO4 
cross-linked), 6% collagen, and 4% PEG hydrogels in capillary tubes. BMP-2 diffusion 
coefficients through 2% alginate (CaCl2) and 6% collagen were comparable to diffusion 
coefficients of bovine α-chymotrypsin, which has a similar molecular weight and 
isoelectric point to BMP-2 (α-chymotrypsin: MW=25 kDa, pI=8.75; BMP-2: MW=26 
kDa, pI=9.15). Interestingly, diffusion of BMP-2 through 2% alginate gels that were 
CaSO4 cross-linked prior to filling capillary tubes and 4% PEG hydrogels was 
significantly slower (Figure 5.6). For CaSO4 cross-linked alginate gels, slower BMP-2 
diffusion may have been caused by entrapped air bubbles created during syringe cross-
linking (as opposed to cross-linking after capillary tube loading). For PEG gels, slower 
BMP-2 diffusion may be attributed a smaller mesh size and structural differences caused 
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by the branched nature of the smaller PEG chains (~5 kDa) compared to the larger, more 
fibrillar collagen and alginate monomers (130-200 kDa). 
 
Figure 5.6. Effective Diffusion Coefficients of BMP-2 Through Various Hydrogels. Effective 
diffusion coefficients of BMP-2 diffusing through 2% (w/v) alginate (CaCl2 cross-linked), 6% 
(w/v) collagen, 2% (w/v) alginate (CaSO4 cross-linked), and 4% (w/v) PEG hydrogels. Diffusion 
coefficients were determined using image analysis of fluorescently labeled BMP-2 diffusing 
through capillary tubes filled with hydrogel. (* = p < 0.05 as indicated) 
 
5.3.2 Determination of Diffusion Coefficients Using Well Plate Method 
 
In order to verify the accuracy of the capillary tube method for determining 
diffusion coefficients through hydrogels, BMP-2 diffusion from a CaSO4 cross-linked 2% 
alginate hydrogel in a 6-well plate was also monitored and used to calculate an effective 
diffusion coefficient with Equation 2. BMP-2 release from the alginate discs was 
monitored over 24 hours and reached a plateau after 9.5 hours (M∞) (Figure 5.7B); the 
linear portion of the release curve was plotted as Mt/M∞ vs. t1/2 (Figure 5.7C), and the 
slope was evaluated to determine the effective diffusion coefficient. Of the 2.5 µg of 
BMP-2 loaded into the hydrogel disc, only ~200 ng total (8%) were released, despite 
considerable hydrogel degradation after only 6 hours in 0.1% BSA in PBS (Figure 5.7A); 
this may have been due to a number of reasons, including protein adsorption on plastic 
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surfaces and difficulty detecting BMP-2 via ELISA due to presence of alginate chains. 
Nevertheless, the portion of BMP-2 released and detected revealed an approximate 
effective diffusion coefficient of 1.2E-06 cm2/s, which was similar to the diffusion 
coefficient of 1.7E-06 cm2/s determined using the capillary tube method. The differences 
in the diffusion coefficients obtained may have been due to the aforementioned sources 
of protein loss or structural differences in hydrogels formed in glass capillary tubes 
versus plastic well plates.  
 
 
Figure 5.7. Effective Diffusion Coefficient of BMP-2 Through Alginate Hydrogel Disc. 2% 
(w/v) alginate containing 2.5 µg BMP-2 was CaSO4 cross-linked in syringes and injected into 
~150 µL discs. Discs were placed in 10 mL of 0.1% BSA in PBS, and 500 µL samples of release 
media were taken periodically over 24 hours. A) Alginate discs began breaking apart and 
degrading after 6 hours in 0.1% BSA in PBS. B) BMP-2 release from alginate discs was 
measured via ELISA over 24 hours. C) Using the linear portion of the BMP-2 release curve, 
Mt/M∞ was plotted against the square root of time, and the slope was used to determine the 






5.3.3 COMSOL Simulations with Low Dose BMP-2 
 
COMSOL simulations were run to model BMP-2 release from alginate/PCL 
constructs under the conditions investigated in vivo in Chapter 4, as well as a number of 
additional conditions. Simulations were run with and without microparticles, with 
partially loaded and unloaded microparticles (0% and 50% of total BMP-2), and with 
varying amounts of microparticles (0.001, 0.01, 0.1, 1 mg of microparticles). Table 5.2 
below lists the simulations run using a low dose of BMP-2 (2.5 µg). 
 
































2.5 µg of BMP-2 loaded in 0.001 mg of Microparticles in Alginate  
 
COMSOL simulations of the conditions investigated in vivo in Chapter 4 (2.5 µg 
of BMP-2 in alginate and 2.5 µg of BMP-2 loaded onto 1 mg of heparin microparticles) 
revealed drastically different BMP-2 release profiles. Figure 5.8 displays heat maps of 
BMP-2 spatial distribution in the alginate construct and thigh after 1 and 14 days, as well 
as plots of the percentage of BMP-2 in the alginate and thigh over time. When BMP-2 
was delivered in the alginate hydrogel (Figure 5.8A), 86% of the BMP-2 delivered was 
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released from the alginate construct into the surrounding tissue. Conversely, when the 
same amount of BMP-2 was delivered via 1 mg of heparin microparticles (Figure 5.8B), 
the model predicted that only 0.2% of the BMP-2 delivered was released into the 
surrounding tissue and 0.1% remained soluble within the alginate, while >99% of the 
BMP-2 delivered remained entrapped within the microparticles. This low release of 
BMP-2 was likely due to the large excess of BMP-2 binding sites (~6.9E15) available 
within constructs containing this number of microparticles, which could have resulted in 
re-association of BMP-2 that had previously dissociated from microparticles. 
 
Figure 5.8. COMSOL Simulations of Low Dose BMP-2 Delivered in Alginate and on 1 mg 
of Heparin Microparticles. COMSOL simulations were run with A) 2.5 µg of BMP-2 in 
alginate and B) 2.5 µg of BMP-2 loaded onto 1 mg of microparticles in alginate. Heat maps 
display spatial distribution of BMP-2 concentration at 1 and 14 days. Graphs depict percentage of 
BMP-2 distributed between alginate hydrogel and thigh tissue between 0 and 14 days. In 
simulations of the microparticle-containing constructs, >99% of the delivered BMP-2 remains 
bound to the microparticles over the entire 14-day period. 
 
Based on the above COMSOL simulations, it was hypothesized that the initial 
microparticle-containing alginate constructs investigated in vivo led to inadequate BMP-2 
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release and limited chemotactic stimulus for infiltrating cells, eventually resulting in a 
reduction in bone volume formed. Thus, further simulations were run to determine which 
parameters could be modified to increase BMP-2 release into the surrounding thigh 
tissue, while ensuring that a sufficient amount of BMP-2 remained within the construct to 
provide an osteogenic stimulus for infiltrating cells. Simulations were run to determine 
whether delivering a split dose of BMP-2 within the alginate and microparticles or 
delivering unloaded microparticles in a construct with alginate-bound BMP-2 would 
increase the amount of BMP-2 leaving the construct. Figure 5.9 depicts results from 
simulations run for (A) unloaded microparticles (all BMP-2 in alginate), (B) 50% loaded 
microparticles (split BMP-2 dose), and (C) 100% loaded microparticles (no BMP-2 in 
alginate); the total amount of BMP-2 delivered in all of these simulations was 2.5 µg. The 
model predicted that changing the loading regime of the microparticles would not 
drastically change the amount of BMP-2 leaving the alginate construct and entering the 
tissue, with the total amount of BMP-2 released into the tissue ranging from 0.2-0.4% 
after 14 days. Introducing unloaded heparin microparticles into an alginate construct 
loaded with BMP-2 was predicted to result in almost all of the BMP-2 in the construct 
associating with the empty microparticles in the delivery syringe before being injected 
into the bone defect for surgery; again, this model prediction may be attributed to the 




Figure 5.9. COMSOL Simulations of Low Dose BMP-2 Split Between Alginate and 1 mg of 
Heparin Microparticles. COMSOL simulations were run with A) 2.5 µg of BMP-2 in alginate 
with 1 mg of unloaded heparin microparticles (0% loaded), B) 2.5 µg of BMP-2 with 50% loaded 
onto 1 mg of microparticles and 50% alginate-bound (50% loaded), and C) 2.5 µg of BMP-2 
loaded entirely on 1 mg of microparticles (100% loaded). Heat maps display spatial distribution 
of BMP-2 concentration at 1 and 14 days. Graphs depict percentage of BMP-2 distributed 
between alginate hydrogel and thigh tissue between 0 and 14 days. Regardless of loading regime, 
the majority of BMP-2 delivered re-associates with the microparticles, and >99% of the BMP-2 
remains microparticle-bound over 14 days; only 0.2-0.4% of the BMP-2 enters the thigh tissue. 
 
Thus, we next took advantage of the ability to dose-dependently alter the number 
of BMP-2 binding sites in the alginate construct by varying the number of microparticles 
delivered from 0.001-1 mg, with the goal of reducing the probability of BMP-2 
molecules re-associating with microparticles after dissociation. Reducing the number of 
microparticles by 10-fold (0.1 mg or 2.0E06 microparticles) resulted in a 10-fold increase 
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in the amount of BMP-2 leaving the alginate construct (2.7% compared to 0.2%); the 
number of binding sites on 0.1 mg of microparticles was still in an excess of the number 
of BMP-2 molecules by an order of magnitude, promoting re-association of >95% of 
BMP-2 to microparticles (Figure 5.10B). However, when the number of microparticles 
was reduced by 100-fold (0.01 mg or 2.0E05 microparticles), and the total number of 
binding sites was of a similar magnitude to the number of BMP-2 molecules (7.0E13 
sites and 5.8E13 BMP-2 molecules), BMP-2 dissociation from the microparticles and 
release into the surrounding tissue increased drastically, with predicted values of ~30% of 
the delivered BMP-2 entering the tissue, ~60% remaining bound to the microparticles, 
and ~10% free in the alginate hydrogel after 14 days (Figure 5.10C). Reducing the 
number of microparticles further, by 1000-fold (0.001 mg or 2.0E04 microparticles), 
resulted in far fewer binding sites than BMP-2 molecules (7.0E12 sites and 5.8E13 BMP-
2 molecules), and a similar release profile to constructs without microparticles, with the 
majority of BMP-2 leaving the alginate hydrogel (79%) and only 8% of the BMP-2 
remaining on the microparticles (Figure 5.10D). Thus, using a similar number of 
microparticle binding sites (0.01 mg microparticles) and BMP-2 molecules resulted in the 
most evenly distributed combination of both BMP-2 release and retention and better 




Figure 5.10. COMSOL Simulations of Low Dose BMP-2 Delivered Using Varying Amounts 
of Microparticles. COMSOL simulations were run with A) 2.5 µg of BMP-2 loaded onto 1 mg 
of heparin microparticles, B) 2.5 µg of BMP-2 loaded onto 0.1 mg of microparticles (10-fold 
reduction), C) 2.5 µg of BMP-2 loaded onto 0.01 mg of microparticles (100-fold reduction), D) 
2.5 µg of BMP-2 loaded onto 0.001 mg of microparticles (1000-fold reduction), and E) 2.5 µg of 
BMP-2 loaded into alginate without microparticles. Heat maps display spatial distribution of 
BMP-2 concentration at 14 days. Graphs depict percentage of BMP-2 distributed between 
alginate hydrogel and thigh tissue between 0 and 14 days. Decreasing the number of 
microparticles in the system resulted in an increased amount of BMP-2 leaving the tissue 
engineering construct and entering the surrounding tissue. 
 
5.3.4 COMSOL Simulations with High Dose BMP-2 
 
Given the high affinity of heparin microparticles for BMP-2, resulting in low 
release of bound BMP-2 overall, it was hypothesized that heparin microparticles could 
also improve the spatial distribution of bone formation following treatment with high 
doses of BMP-2 (30 µg). Such BMP-2 doses typically result in the formation of 
heterotopic bone outside of the bone defect site when delivered in alginate hydrogel 
(Chapter 6) or collagen sponge (Chapter 7; Krishnan and Priddy, et al. In review.). Thus, 
heparin microparticles could be used to better localize BMP-2 release and subsequent 
bone formation within the bone defect. Since varying the number of microparticles 
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delivered was predicted to be the best way to alter the release kinetics of BMP-2 from the 
system, COMSOL simulations were run using a 30 µg BMP-2 dose in alginate or loaded 
onto 0.01-1 mg of heparin microparticles. 
When 30 µg of BMP-2 were delivered using 1 mg of microparticles, >99% of the 
BMP-2 remained bound to the microparticles and only 0.2% of the BMP-2 entered the 
surrounding tissue after 14 days (Figure 5.11A); this was comparable to what was 
predicted for delivery of low dose BMP-2 with heparin microparticles, and was similarly 
due to the large excess of microparticle binding sites compared to BMP-2 molecules 
(7.0E15 sites and 3.5E14 BMP-2 molecules). When the number of microparticles in the 
system was reduced 10-fold to 0.1 mg (2.0E06 microparticles), the predicted amount of 
BMP-2 leaving the construct increased to 13%, with 83% of the BMP-2 bound to the 
microparticles and the residual 4% remaining free in the alginate hydrogel after 14 days 
(Figure 5.11B). However, a further reduction in the amount of microparticles (100-fold, 
0.01 mg or 2.0E5 microparticles) resulted in fewer microparticle binding sites than BMP-
2 molecules (7.0E13 sites and 3.5E14 BMP-2 molecules), and subsequently, the majority 
of the BMP-2 delivered was predicted to exit the construct (78%), with only 9% 
remaining bound to the microparticles (Figure 5.11C). This release profile was similar to 
that of alginate constructs lacking microparticles (Figure 5.11D), which has previously 
resulted in poor BMP-2 localization and heterotopic bone formation (Krishnan and 
Priddy, et al. In review.). Thus, delivering 30 µg of BMP-2 using 0.1-1 mg of heparin 
microparticles was expected to improve BMP-2 localization within the bone defect site. 
Furthermore, delivery of 30 µg of BMP-2 using 0.1 mg of microparticles was predicted to 
result in similar BMP-2 release into the surrounding tissue compared to delivery of 5 µg 
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of BMP-2 in alginate after 14 days (~4 µg; Figure 5.12); delivery of 5 µg of BMP-2 in 
alginate has previously exhibited robust bone formation in this animal model [233, 234], 
suggesting that its BMP-2 release profile promotes mineralization. 
 
 
Figure 5.11. COMSOL Simulations of High Dose BMP-2 Delivered Using Varying Amounts 
of Microparticles. COMSOL simulations were run with A) 30 µg of BMP-2 loaded onto 1 mg of 
heparin microparticles, B) 30 µg of BMP-2 loaded onto 0.1 mg of microparticles (10-fold 
reduction), C) 30 µg of BMP-2 loaded onto 0.01 mg of microparticles (100-fold reduction), and 
D) 30 µg of BMP-2 loaded into alginate without microparticles. Heat maps display spatial 
distribution of BMP-2 concentration at 14 days. Graphs depict percentage of BMP-2 distributed 
between alginate hydrogel and thigh tissue between 0 and 14 days. Decreasing the number of 
microparticles in the system resulted in an increased amount of BMP-2 leaving the tissue 





Figure 5.12. Comparison of COMSOL Simulations Using 5 µg of BMP-2 and 30 µg of BMP-
2 Loaded onto 0.1 mg of Microparticles. COMSOL simulations were run with A) 5 µg of BMP-
2 in alginate and B) 30 µg of BMP-2 loaded onto 0.1 mg of microparticles. Heat maps display 
spatial distribution of BMP-2 concentration at 14 days. Graphs depict amount of BMP-2 
distributed between alginate hydrogel and thigh tissue between 0 and 14 days. Both conditions 
result in similar release of BMP-2 into tissue over 14 days. 
 
5.3.5 COMSOL Model Sensitivity Analysis  
	
Finally, a sensitivity analysis was run on several key parameters used in the 
COMSOL model to determine which parameters had the greatest effects on BMP-2 
release kinetics and could potentially result in changes to the overall BMP-2 distribution 
if they deviated from the expected values. The sensitivity analysis was run using 0.1 mg 
of heparin microparticles and 2.5 µg of BMP-2, since the large excess of binding sites 
present on 1 mg of microparticles made it difficult to detect differences caused by 
changes in BMP-2-microparticle interactions.  
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Under the standard parameters used, 97% of the BMP-2 delivered was predicted 
to remain on the microparticles after 14 days, while 0.3% and 2.7% were released into the 
alginate and surrounding tissue, respectively. When the dissociation kinetics of BMP-2 
from microparticles were increased 10-fold (koff = 0.25 1/s), the amount of BMP-2 
released from the microparticles increased substantially, with 18% of the delivered BMP-
2 being released into the tissue and 76% remaining on the microparticles. Conversely, 
when the dissociation constant was decreased 10-fold (koff = 0.0025 1/s), the majority of 
BMP-2 remained bound to the microparticles (>99%). Interestingly, increasing and 
decreasing the effective diffusion coefficient of BMP-2 through alginate did not have a 
effect on BMP-2 release from the construct. On the other hand, when the diffusion 
coefficient of BMP-2 through the surrounding tissue was increased 10-fold (DBMP,Tiss = 
2.0E-07 cm2/s), BMP-2 release into the tissue increased to 9%, and the amount remaining 
of the microparticles dropped to 90%. When DBMP,Tiss was decreased 10-fold (2.0E-09 
cm2/s), BMP-2 retention of the microparticles was increased to 99%. 
Overall, the sensitivity analysis suggested that the results of the COMSOL model 
are governed primarily by the dissociation kinetics of BMP-2 from heparin microparticles 
(i.e. the affinity of heparin microparticles for BMP-2) and the diffusion coefficient of 
BMP-2 through the surrounding tissue, whereas the diffusion coefficient of BMP-2 
through alginate does not play an important role. Deviations from the expected values for 
koff and DBMP,Tiss are more likely to result in changes to the overall BMP-2 distribution, 
and thus, the heparin-BMP-2 dissociation constant and BMP-2 diffusion through 






Figure 5.13. Sensitivity Analysis of Key Parameters in COMSOL Model. COMSOL 
simulations were run with 2.5 µg of BMP-2 loaded onto 0.1 mg of microparticles, and several key 
parameters were increased and decreased by 10-fold to determine the model’s sensitivity to 
deviations in these values. A) Graph of BMP-2 distribution in microparticles, alginate, and tissue 
based on the standard modeling parameters. Graphs of BMP-2 distribution if dissociation 
constant of BMP-2 from heparin microparticles was B) increased 10-fold (koff = 0.25 1/s) or C) 
decreased 10-fold (koff = 0.0025 1/s). Graphs of BMP-2 distribution if BMP-2 diffusion through 
alginate was D) increased 10-fold (DBMP,Alg = 1.7E-05 cm2/s) or E) decreased 10-fold (DBMP,Alg = 
1.7E-07 cm2/s). Graphs of BMP-2 distribution if BMP-2 diffusion through tissue was F) 




In order to improve heparin microparticle-based BMP-2 delivery in vivo, an in 
silico investigation of BMP-2 delivery strategies was conducted following the initial in 
vivo segmental defect study using heparin microparticles described in Chapter 4. A 
COMSOL model was created to determine how the relative amounts of BMP-2 and 
microparticles in the system, as well as different microparticle loading regimes, could 
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impact overall BMP-2 release from alginate/PCL constructs implanted in the femoral 
defect site. Interestingly, constructs containing the dose of heparin microparticles used in 
the initial in vivo study (1 mg) were predicted to exhibit low BMP-2 release (<0.4%), 
regardless of the proportion of the BMP-2 loaded onto the microparticles vs. entrapped 
within the alginate. These results were supported by in vitro BMP-2 release profiles, 
which, despite demonstrating a higher magnitude of BMP-2 release overall, revealed that 
alginate/PCL constructs containing loaded microparticles exhibited BMP-2 release that 
was not statistically different from that of constructs containing unloaded microparticles 
co-delivered with the same amount of BMP-2 (Figure 4.2B). The high quantity of 
theoretical unoccupied BMP-2 binding sites on 1 mg of heparin microparticles compared 
to the number of BMP-2 molecules delivered may be the most significant factor 
contributing to the low BMP-2 release predicted in this scenario, since the likelihood of 
BMP-2 molecules rebinding to heparin microparticles and impeding release from the 
construct is increased.  
Attenuated BMP-2 release demonstrated in the presence of heparin microparticles 
in the alginate/PCL construct may explain the lower bone volumes observed following 
heparin microparticle-mediated BMP-2 delivery in vivo; however, considering that 60% 
of the defects treated with heparin microparticles exhibited mineralized bridging (Figure 
4.6), it is unlikely that only 0.2% of delivered BMP-2 entered the surrounding tissue. This 
possible discrepancy between in vivo experimental data and in silico model simulations 
may be due to a variety of biological factors that could not be accurately recapitulated in 
this model, including early alginate degradation, microparticle movement, and changes in 
the diffusivity of the construct following cell infiltration and material degradation. 
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Although we chose to ignore the effects of interstitial fluid flow on advective transport in 
order to simplify the parameters of the model, literature values for typical interstitial flow 
velocities observed within tissues suggest that advection may indeed play a role in BMP-
2 transport in the bone defect. The Peclet number of the system, which is a indication of 
the relative contributions of advection and convection to transport of a biomolecule, 
could be calculated based on our approximated BMP-2 diffusion coefficient through 
tissue (2.00E-8 cm2/s) and theoretical interstitial fluid velocity (6.00E-7 cm/s) [271]; the 
Peclet number was found to be on the order of ~1600, indicating a potentially significant 
contribution of advection; this parameter could be incorporated into future models. 
Furthermore, numerous cytokines, ECM proteins, and growth factors present in 
the tissue injury site with affinity for heparin may displace BMP-2 from heparin 
microparticles upon contact and accelerate its release [1]. The role of serum proteins in 
BMP-2-heparin microparticle interactions is an important consideration, which will be 
explored further in Chapter 7. Although the current model does not take into account 
competitive protein binding as a factor affecting BMP-2 dissociation from microparticles, 
future iterations could include this aspect to increase model accuracy. Additionally, a 
COMSOL model of in vitro BMP-2 release from alginate/PCL constructs in well plates 
could also be developed to validate the some of the parameters chosen for the in vivo 
COMSOL model. 
Despite these shortcomings, the computational model developed provides 
valuable information that informed the design of the in vivo experiments described in 
Chapter 6 and will contribute to future experiments that employ a heparin microparticle-
based protein delivery vehicle. The drastic changes in BMP-2 release caused by changing 
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the number of microparticles delivered revealed that microparticle dosing could provide 
the alginate/PCL construct with a substantial degree of BMP-2 affinity tunability. The 
sensitivity analysis of key model parameters, such as the kinetics of BMP-2-microparticle 
association/dissociation and BMP-2 diffusion through alginate and surrounding tissue, 
further confirmed that the interactions between BMP-2 and heparin microparticles played 
the most significant role in determining BMP-2 release from the construct, and thus 
changing the number of available BMP-2 binding sites (i.e. microparticles) could present 
a simple strategy for altering these interactions. Other researchers have created delivery 
systems that tailor affinity interactions by selectively desulfating heparin to change its 
affinity for growth factors [103, 115, 120] and isolating ECM and protein fragments to 
serve as more specific affinity ligands [134, 272, 273]. The computational model 
developed in this work can also be applied to these systems in the future by simply 
changing the kinetics of protein association/dissociation (kon, koff) to suit these specific 
affinity ligands.  
In addition to the mathematical model developed, a simple and robust method for 
determining protein diffusion through hydrogels was also established to fulfill the need 
for an accurate effective diffusion coefficient for BMP-2 through 2% (w/v) alginate. 
Since alginate is a naturally derived material that exhibits high natural and post-
processing variability [274-276], the ability to experimentally determine a diffusion 
coefficient for the specific alginate used in our studies was imperative. The equation 
describing one-dimensional diffusion that was chosen for our analysis has typically been 
applied to diffusion of proteins through in vivo capillary beds and has been widely used 
to investigate interstitial transport in normal and neoplastic tissues [265]. Previously, 
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diffusion of gelatin nanoparticles through collagen hydrogels in capillary tubes has been 
investigated as an in vitro model of nanoparticle penetration through collagen-rich tumor 
tissues. We sought to adapt this in vitro model of tumor transport so that it could be more 
broadly applied as a method of determining diffusion through various hydrogels. 
The capillary tube diffusion method was successfully used to evaluate the 
effective diffusion coefficients of several model proteins in addition to our protein of 
interest (BMP-2) in alginate, collagen, and PEG hydrogels, since all of these hydrogels 
have previously shown utility as BMP-2 delivery vehicles [42, 234, 263]. Diffusion of 
model proteins through hydrogels decreased with increasing molecular weight, as 
previously observed [268-270], and no differences were detected between diffusion in 
2% (w/v) alginate (CaCl2 cross-linked) and 6% (w/v) collagen hydrogels. In fact, the 
effective diffusion coefficients for BMP-2 through these hydrogels were similar to that of 
BMP-2 diffusion through water, as calculated using the Stokes-Einstein equation (1.3E-
06 cm2/s) [269], suggesting that the low weight percentages of the gels and density of 
crosslinks were not high enough to cause hindered diffusion.  
Interestingly, BMP-2 diffusion was decreased through 2% (w/v) alginate 
hydrogels that were cross-linked with CaSO4 prior to filling capillary tubes and also 4% 
(w/v) PEG hydrogels. Cross-linking alginate hydrogels using CaSO4 and the dual syringe 
method introduced numerous air bubbles into the gel, similar to air bubbles introduced 
into gels using during surgical injection; these air bubbles may have impeded protein 
diffusion. Since the dual syringe method has typically been used for alginate preparation 
for the segmental defect model [234], we were able to use our diffusion characterization 
method to obtain an effective diffusion coefficient unique to our system, while 
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demonstrating that distinct differences in diffusion through alginate hydrogels can occur 
simply due to cross-linking method. As mentioned previously, for PEG hydrogels, slower 
BMP-2 diffusion may be attributed to a smaller hydrogel mesh size due to the branched 
nature of the PEG chains. The four-arm PEG-MAL used within this study contained 
uniformly spaced cross-linking sites at the end of each ~5 kDa branch. On the other hand, 
individual collagen fibers (~130 kDa) and alginate chains (150-200 kDa) are more 
fibrillar in nature; larger, non-uniform meshes are typically formed by these natural 
materials that rely heavily on physical entanglement as well as electrostatic interactions 
for cross-linking, and the spacing between cross-links can vary. Overall, the capillary 
tube method of determining diffusion coefficients provides comparable results to 
standard protein release assays, but over a shorter period of time and without variability 
introduced by hydrogel and protein degradation. While other fluorescence-based 
diffusion analyses often require microfluidic platforms [277] or confocal microscopes to 
perform fluorescence recovery after photo-bleaching (FRAP) [278], this method can be 
easily performed with a standard laboratory microscope with a low power objective and 




Herein, we described the development of a mathematical model to predict BMP-2 
release from an alginate/PCL tissue engineering construct within a segmental bone 
defect, as well as a novel method for evaluating protein diffusion in hydrogels commonly 
used for BMP-2 delivery. Together, these new developments provide insight into in vitro 
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protein diffusion through hydrogel biomaterials and may help to design better biomaterial 
delivery vehicles that can effectively modulate protein release in vivo. The ability to 
model varying numbers of heparin microparticles in the alginate/PCL construct helped to 
both reveal the tunable nature of this system and inform future in vivo experiments using 
heparin microparticles. Furthermore, these versatile platforms can be more broadly 
applied to other tissue engineering constructs in the future, providing valuable 







CHAPTER 6: HEPARIN MICROPARTICLES REDUCE HETEROTOPIC BONE 




In Chapter 5, we developed a mathematical model, which predicted that the 
presence of heparin microparticles in alginate/PCL constructs would attenuate BMP-2 
release in vivo; furthermore, the in vivo bone healing results in a femoral bone defect 
model that were presented in Chapter 4 demonstrated that the delivery of a low dose of 
BMP-2 using heparin microparticles resulted in decreased mineral formation. Together, 
these data led to the hypothesis that heparin microparticles reduced BMP-2 release from 
the alginate/PCL construct, resulting in decreased BMP-2 availability and suboptimal 
bone healing. Since heparin microparticles have exhibited a strong affinity for BMP-2 
both in vitro and in vivo thus far, they may be better suited for use in bone healing 
applications in which highly localized delivery of BMP-2 is required.  
BMP-2 use in the clinic is typified by supraphysiological growth factor doses 
ranging from 0.1-0.5 mg BMP-2/kg body weight, although off-label use of doses as high 
as 1 mg BMP-2/kg body weight have also been reported [6, 9, 36, 279, 280]; high BMP-2 
doses are required in order to ensure stimulation of endogenous repair mechanisms 
despite rapid growth factor release from the site of interest. In comparison, the rat 
femoral defect model described herein exhibits consistent bony bridging using BMP-2 
doses of 0.01-0.02 mg BMP-2/kg body weight [233, 234]. The significantly higher doses 
of BMP-2 required for bone healing in humans compared to pre-clinical rodent models 
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may be attributed to a lower capacity for bone regrowth following traumatic injury [281], 
and thus biomaterial strategies developed with lower doses of BMP-2 in rats may be 
required to effectively deliver higher BMP-2 doses when ultimately used in humans. 
The absorbable collagen sponge, most commonly used in the clinic as a BMP-2 
delivery scaffold, has also contributed to the use of supraphysiological BMP-2 doses in 
humans. Collagen sponges entrap BMP-2 through weak electrostatic interactions, 
resulting in a burst release of molecular cargo upon implantation in the tissue defect; 
thus, low retention of BMP-2 at the site of interest has necessitated the use of high BMP-
2 doses in order to ensure adequate stimulation of bone healing. The lack of definitive 
dose response data for BMP-2 treatment in humans due to differences in surgical 
approaches used between studies has also made lowering standard doses while 
maintaining similar efficacy difficult [9, 279, 280]. 
Due to the collagen sponge’s limited ability to control BMP-2 diffusion following 
implantation in vivo, a number of side effects associated with rapid growth factor loss 
have been documented in patients. Excessive soft tissue inflammation or seroma [9, 44, 
282], hematoma [9, 283], and heterotopic ossification [43, 45, 283] adjacent to the bone 
defect site have been observed following delivery of higher doses of BMP-2 using the 
clinical collagen sponge. In patients undergoing off-label BMP-2 treatment for spinal 
fusion, adverse events have been documented to occur in as many as 23-28% of patients 
[9, 44]. Heterotopic ossification in particular has been reported in both on- and off-label 
use of BMP-2-loaded collagen sponges in the clinic, as well as a number of pre-clinical 
animal studies in which relatively high doses of BMP-2 have been delivered in canine 
and rat segmental defect models [284, 285]. Overall, these studies highlight the 
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limitations of current BMP-2 delivery strategies and motivate further investigation into 
methods of spatially limiting BMP-2 diffusion in vivo when high dose BMP-2 is used. 
Our laboratory has recently investigated high, clinically relevant doses of BMP-2 
(0.12 mg BMP-2/kg body weight) in a rat femoral defect model, and recapitulated the 
incidence of heterotopic bone observed using a collagen sponge delivery vehicle 
(Krishnan and Priddy, et al. In review.). In comparison, the use of our alginate/PCL tissue 
engineering construct reduced heterotopic ossification from >50% to <30% of the total 
bone volume, but could not completely eliminate bone formation outside of the defect 
space, suggesting that an appreciable amount of BMP-2 was still released into the 
surrounding tissue. Alternatively, the high growth factor loading capacity of heparin 
microparticles (~300 µg BMP-2/mg microparticles) and low in vitro release of loaded 
BMP-2 (<20%) [107] make heparin-based materials a prime candidate for improving 
high dose BMP-2 delivery and reducing the incidence of heterotopic ossification. The in 
vivo results presented in Chapter 4, which use heparin microparticles in an alginate/PCL 
construct as a carrier of low dose BMP-2, suggested that increased BMP-2 retention 
within the tissue engineering constructs (Figure 4.4) may have been responsible for the 
decreased mineral volumes observed within the defect (Figure 4.6).  
Thus, in this study, we chose to deliver 30 µg of BMP-2 (0.12 mg BMP-2/kg 
body weight) in a rat femoral defect model using alginate/PCL constructs with and 
without 0.1-1 mg of heparin microparticles. The ability to cross-link alginate hydrogels 
with varying amounts of BMP-2-laden microparticles gave us the opportunity to tune the 
density of BMP-2 presentation and effective BMP-2 release profiles of the alginate/PCL 
constructs used. Since the results of our computational model predicted that loading 30 
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µg of BMP-2 onto 0.1 or 1 mg of heparin microparticles would result in release of ~13% 
(4 µg) or ~0.2% (0.06 µg) of the total BMP-2 dose, respectively, we could compare these 
release profiles with that of a construct containing no heparin microparticles, which has 
been shown to induce some heterotopic bone formation with a predicted release of ~86% 
(25.8 µg) of the delivered BMP-2 over 14 days. Herein, we present both in vitro and in 
vivo BMP-2 release profiles from alginate/PCL constructs with or without heparin 
microparticles, followed by the results of the in vivo study investigating bone healing in 
an orthotopic model in response to BMP-2 delivery vehicles of varying effective BMP-2 
affinities. 
 
6.2 Materials and Methods 
	
6.2.1 Fabrication of Alginate/Polycaprolactone Constructs 
	
Alginate/PCL constructs for in vitro testing and in vivo delivery were fabricated 
as described previously [233, 234] and in Chapter 4. Heparin microparticles were 
fabricated as previously described [107]. Briefly, irradiated, RGD-functionalized alginate 
(FMC Biopolymer) was first slowly dissolved in α-MEM (Corning Mediatech) for 4 
hours at room temperature to achieve a 3% (w/v) alginate solution. Equal volumes of α-
MEM and 0.1% rat serum albumin (RSA; Sigma, Aldrich) in 4 mM HCl were then added 
to dilute the alginate to 2% (w/v) prior to cross-linking. At this stage, the requisite 
amounts of BMP-2 (2.5-30 µg) and/or heparin microparticles (0-1 mg) per 150 µL of 
alginate hydrogel were added into the solution in 0.1% RSA in HCl. The 2% alginate 
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solution was then cross-linked with excess calcium sulfate (8.4 mg/mL; Sigma Aldrich) 
by rapid mixing between two 1 mL syringes (Becton-Dickinson) connected through a 
Luer-Lok style connector (Cole-Parmer, Vernon Hills, IL). After several minutes of 
mixing, the alginate was allowed to solidify at room temperature for approximately 30 
minutes before being transferred to 4°C for storage overnight. 
Polycaprolactone (PCL) nanofiber mesh tubes were also fabricated as previously 
described [234]. Briefly, PCL (Sigma Aldrich) was dissolved overnight with gentle 
stirring in a 90:10 solution of hexafluoro-2-propanol (HFP; Sigma Aldrich) and 
dimethylformamide (DMF; Sigma Aldrich) to obtain a 12% (w/v) PCL solution. 5 mL of 
solution was loaded into a 5 mL syringe (Becton Dickinson) with a 20-gauge blunt-tip 
needle (Howard Electronic Instruments), bubbles were removed, and the syringe was 
mounted onto a PHD2000 Infusion syringe pump (Harvard Apparatus). For the 
electrospinning setup, the syringe pump was placed so that the needle tip was ~20 cm 
away from a rectangular copper collection plate covered with aluminum foil for PCL 
nanofiber deposition. The syringe pump was set to a constant infuse rate of 0.75 mL/hr 
and infuse diameter of 12.060 mm, and a high voltage supply (HV Power Supply, 
Gamma High Voltage Research, Ormond Beach, FL) was connected to the syringe needle 
and copper collection plate to provide a voltage difference of ~15-20 kV. The voltage 
was periodically adjusted to maintain a Taylor cone at the needle tip during 
electrospinning [286]. A total of 4.5 mL of PCL solution was infused for each mesh, 
creating a circular mesh with an area of ~100 cm2 and thickness of ~500 µm.  
12 mm by 19 mm rectangles with twenty-three, evenly spaced 0.9 mm diameter 
perforations were laser-cut into the meshes to prepare nanofiber mesh tubes for tissue 
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engineering constructs. Each rectangular sheet was rolled into a tube with an inner 
diameter of 5 mm and length of 12 mm and glued using UV cure adhesive (1187-M MD 
Medical Device Adhesives & Coatings, DYMAX, Torrington, CT; BlueWave LED 
Prime UVA Spot Curing System, DYMAX, Torrington, CT). Mesh tubes were sterilized 
by 100% ethanol evaporation overnight, followed by immersion in 70% ethanol for 4 
hours, immersion in PBS for 30 minutes, and finally immersion in α-MEM up until use. 
For both in vitro and in vivo assays, 150 µL of alginate gel was injected through a 
22-gauge, blunt-tip needle (Howard Electrical Instruments) into the center of each 
nanofiber mesh tube immediately prior to use. For in vitro assays, alginate was allowed to 
set in the mesh tube for at least 10 minutes prior to immersion in any solution. For in vivo 
assays, alginate was injected into the mesh tube after it was placed in the bone defect. 
	
6.2.2 BMP-2 Release from Alginate/Polycaprolactone Constructs 
 
Passive release of BMP-2 from alginate/PCL constructs into 0.1% (w/v) BSA in 
PBS was monitored over a period of 7 days at 37°C. Alginate/PCL constructs were 
fabricated with 2.5 µg of BMP-2 mixed into alginate alone or loaded onto 0.1 or 1 mg of 
heparin microparticles prior to mixing into alginate. Microparticles were loaded with 
BMP-2 in a small volume of 0.1% BSA in 4 mM HCl (25 µL/mg MPs) for 16 hours at 
4°C the day before construct assembly. After alginate/PCL constructs were assembled 
and allowed to set for at least 10 minutes, the constructs were transferred to individual 
wells in an ultra-low attachment 24-well plate (Corning) and 1 mL of 0.1% BSA in PBS 
was added. At various time points, the solution was removed and centrifuged at 3000 rpm 
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for 5 minutes to separate the supernatant from any alginate or microparticle debris. The 
supernatant was removed and replaced with 1 mL of fresh 0.1% BSA in PBS before the 
entire solution was added back to the wells. This step was included to ensure minimal 
loss of alginate and microparticles from the system at each time point. Release samples 
were then analyzed for BMP-2 content via ELISA. 
 
6.2.3 Subcutaneous Implant Surgical Procedure 
 
Subcutaneous implant studies were undertaken to track in vivo retention of BMP-
2 in constructs with or without heparin microparticles. BMP-2 was fluorescently labeled 
for tracking using the near-infrared dye Vivotag-750 (Perkin Elmer), according to the 
protocol reported in Chapter 4. All subcutaneous implant surgical procedures were 
conducted according to the Georgia Institute of Technology Institutional Animal Care 
and Use Committee (IACUC) protocol A16043. Briefly, 13-week-old female Sprague 
Dawley rats (Charles River Labs, Wilmington, MA) were anesthetized using isoflurane 
prior to surgery. Two lateral incisions were made on the back of each animal and a 
tunneling device was used to create four individual subcutaneous pockets for construct 
insertion, as previously described [212]. A metal rod and cannula were used to insert two 
constructs near the forelimbs and two near the hindlimbs. Constructs from each group 
were randomly distributed according to location (proximity to left forelimb, right 
forelimb, left hindlimb, and right hindlimb).  
Constructs consisted of PCL meshes surrounding 150 µL alginate hydrogels 
containing (1) 2.5 µg of labeled BMP-2 in alginate (n=8), (2) 2.5 µg of labeled BMP-2 
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loaded onto 0.1 mg of microparticles in alginate (n=8), and (3) 2.5 µg of labeled BMP-2 
loaded onto 1 mg of microparticles in alginate (n=8). Animals for these studies were 
euthanized using carbon dioxide asphyxiation after three weeks post-surgery. 
	
6.2.4 In Vivo and Ex Vivo Fluorescence Imaging 
	
In vivo and ex vivo fluorescent imaging was performed using an IVIS® Spectrum 
platform (Perkin Elmer). For VS750-labeled BMP-2 tracking, longitudinal in vivo 
imaging (Ex: 745, Em: 800, 5 second exposure) was performed immediately following 
subcutaneous implantation on Day 0, as well as on Day 1, 4, 7, 10, 14, and 21, as 
previous studies have demonstrated loss of detectable fluorescent signal after 21 days 
[233]. Alginate gels contained (1) 2.5 µg of labeled BMP-2 (n=8), (2) 2.5 µg of labeled 
BMP-2 loaded onto 0.1 mg of microparticles (n=8), or (3) 2.5 µg of labeled BMP-2 
loaded onto 1 mg of microparticles (n=8). Animals were placed on their sides for imaging 
of two constructs at once. Total fluorescent counts and radiant efficiency were evaluated 
for each construct at each time point, both in vivo and ex vivo, using a ~7 cm2 elliptical 
region of interest (ROI) in the Living Image Software (Perkin Elmer). Background 
fluorescence from the animal’s skin was subtracted from each measurement, and 
fluorescent signal at each time point was normalized to the initial fluorescent signal 
measured at Day 0. BMP-2 retention data was fit to a one-phase exponential decay 
equation (y=aexp(-λx)) in MATLAB to obtain the decay constant, λ. Constructs were 
explanted after 21 days and also imaged ex vivo using the IVIS® Spectrum platform to 
examine residual BMP-2 fluorescence. 
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6.2.5 Femoral Defect Surgical Procedure 
	
Femoral defect studies were undertaken to determine the ability of constructs with 
and without heparin microparticles and BMP-2 to promote bone healing and reduce 
heterotopic ossification in a critically sized defect. All surgical procedures were 
conducted according to the Georgia Institute of Technology IACUC protocol A14037. 
13-week-old female Sprague Dawley rats (Charles River Labs) were anesthetized using 
isoflurane prior to surgery, and unilateral surgeries were performed as previously 
described [233, 239]. Briefly, after opening up the leg using an anterior approach, a 
radiolucent fixation plate (polysulfone) and two stainless steel risers were screwed 
directly onto the femur of the rat for limb stabilization, and an oscillating saw was used to 
create an 8-mm wide, full thickness diaphyseal defect. A PCL nanofiber mesh tube was 
inserted into the defect to cover the bone ends, and 150 µL of alginate was injected 
through the perforations into the center of the tube. Each alginate gel contained one of the 
following: (1) 30 µg of BMP-2 (n=14), (2) 30 µg of BMP-2 loaded onto 0.1 mg of 
microparticles (n=13), or (3) 30 µg of BMP-2 loaded onto 1 mg of microparticles (n=14). 




6.2.6 Faxitron and Micro-computed Tomography 
 
Longitudinal in vivo radiographs of femurs were obtained at 2, 4, 8, and 12 weeks 
post-surgery, using a Faxitron MX-20 Digital machine at a voltage of 23 kV and 
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exposure time of 15 seconds; radiographs were used to qualitatively assess bony bridging 
across the defect space. In vivo micro-computed tomography (CT) of femurs was 
performed at 4, 8, and 12 weeks post-surgery to quantify total bone volume and overall 
mineral density, as well as the spatial distribution of bone formation and mineral density 
inside and outside of the defect space. Animals were anesthetized and scanned at a 
medium resolution using a VivaCT40 live animal scanner (Scanco, Switzerland) with a 
voxel size of 38.5 µm, voltage of 55 kVp, and current of 109 µA. Mineral was quantified 
within the central 5.85 mm (152 scan slices) of each 8 mm defect, and three different 
volumes of interest (VOIs) were identified: (1) total mineral volume of the thigh within 
the central region of interest, (2) mineral volume within the defect space, as defined by 6 
mm diameter circular contours corresponding to the diameter of the nanofiber mesh, and 
(3) heterotopic mineral volume, which fell outside of the 6 mm diameter circular 
contours. A global threshold for new bone formation was set at 50% of the average 
mineral density of native cortical bone, and a Gaussian filter (sigma = 1.2, support = 1) 
was applied to suppress noise.  
	
6.2.7 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. In vitro experiments 
were run with a minimum of three replicates for each experimental group. For in vivo 
BMP-2 retention experiments, 8 constructs from each group were implanted. For in vivo 
bone defect experiments, longitudinal micro-CT was conducted on 13-14 femurs per 
group. Statistical significance was determined using one-way or two-way ANOVA as 
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appropriate, followed by Bonferroni’s post hoc analysis (Graphpad Prism, Version 5.0, 
La Jolla, CA). For data that did not satisfy the assumptions of equal variances and 
Gaussian distributions, the nonparametric Kruskal-Wallis test was used. P < 0.05 was 




6.3.1 In Vitro BMP-2 Release from Alginate/Polycaprolactone Constructs 
	
	
BMP-2 release from alginate/PCL constructs containing 0.1 mg of BMP-2-loaded 
heparin microparticles was evaluated similarly to BMP-2 release from constructs 
containing 1 mg of heparin microparticles presented in Chapter 4. 150 µL alginate 
constructs fabricated with 0, 0.1, or 1 mg of heparin microparticles were loaded with 2.5 
µg of BMP-2 and allowed to passively release BMP-2 into a 0.1% (w/v) BSA in PBS 
solution over 7 days (Figure 6.1). Constructs containing 1 mg of BMP-2-loaded heparin 
microparticles released less BMP-2 than constructs containing 0.1 mg of microparticles 
or constructs lacking microparticles at all time points examined, with a total cumulative 
release of 55.1 ± 3.9 ng of BMP-2. Constructs containing BMP-2 alone and 0.1 mg of 
BMP-2-loaded microparticles exhibited similar release profiles, releasing nearly double 
the amount of BMP-2 as constructs containing 1 mg of microparticles, with a total release 
of 111.1 ± 1.7 ng and 102.2 ± 11.2 ng of BMP-2, respectively. Overall, only a small 
fraction of the BMP-2 initially incorporated into the constructs was released into the 
surrounding solution over one week (2-5%), indicating the need to evaluate BMP-2 
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release over a longer period of time in vitro. The relatively low BMP-2 amounts observed 




Figure 6.1. BMP-2 Release from Alginate/PCL Constructs Containing 0, 0.1, or 1 mg of 
Heparin Microparticles. 2.5 µg of BMP-2 per 150 µL construct was either mixed directly into 
the 2% alginate solution (No MPs), loaded onto 0.1 mg of microparticles overnight prior to being 
mixed into the alginate solution (0.1 mg MPs), or loaded onto 1 mg of microparticles overnight 
prior to being mixed into the alginate solution (1 mg MPs). 150 µL of alginate was injected into 
each PCL mesh tube and allowed to set for 10 minutes prior to addition of 1 mL of 0.1% BSA in 
PBS. The entire volume of PBS was removed and replaced at each time point over a period of 7 
days. Constructs containing 1 mg of BMP-2-loaded microparticles retained more BMP-2 at each 
time point than constructs lacking microparticles or containing 0.1 mg of microparticles. (* = p < 
0.05 compared to No MPs and 0.1 mg MPs at each time point) 
	
6.3.2 BMP-2 Retention in Subcutaneous Implants 
 
BMP-2 retention in alginate/PCL constructs was also evaluated in vivo to 
complement in vitro BMP-2 release data. 150 µL alginate hydrogels were fabricated with 
2.5 µg of fluorescently labeled (VS750) BMP-2 alone or with 0.1 or 1 mg of heparin 
microparticles that were pre-loaded with 2.5 µg of fluorescently labeled BMP-2. 
Constructs were assembled immediately prior to subcutaneous implantation in the backs 
of rats and imaged in vivo using an IVIS® platform on Day 0, 1, 4, 7, 14, and 21, and ex 
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vivo at 21 days after explanting. Representative fluorescence images taken between Day 
0-7 demonstrated somewhat higher retention of fluorescence signal in constructs 
containing 1 mg of heparin microparticles compared to constructs containing 0.1 mg of 
heparin microparticles (Figure 6.2A-D); however, all constructs exhibited a decrease in 
fluorescent signal over time. All groups displayed an overall decrease in fluorescent 
signal over time, when fluorescence from the constructs was quantified within 7 cm2 
regions of interest and normalized to Day 0 values (Figure 6.2E). Although no 
differences were observed between groups at each time point due to animal-to-animal and 
construct position variability, BMP-2 retention profiles appeared to be similar between 
constructs lacking microparticles and containing 0.1 mg of microparticles, while 
constructs containing 1 mg of microparticles exhibited more gradual BMP-2 release at 
early time points (Day 1-7). When this data was fit to an exponential decay curve, 
constructs containing 1 mg of microparticles exhibited a lower average decay constant 
than constructs without microparticles and with 0.1 mg of microparticles, indicating 
prolonged BMP-2 retention (Figure 6.2F). These results corresponded with BMP-2 
release results obtained in vitro, which also demonstrated similar BMP-2 release profiles 
between constructs without microparticles and with 0.1 mg of microparticles, while 
BMP-2 release from constructs containing 1 mg of microparticles was lower than that of 
other groups. However, unlike in vitro BMP-2 release results, all constructs exhibited 
similar amounts of BMP-2 retention after 21 days in vivo (16-23%). Interestingly, when 
these constructs were explanted and imaged ex vivo, the final radiant efficiency measured 
in constructs containing 1 mg of microparticles was ~15% higher than that of constructs 
containing 0.1 mg of microparticles and ~20% higher than that of constructs lacking 
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microparticles (Figure 6.2G). These data suggest that the higher dose of microparticles 
altered the release profile of BMP-2 from the construct implantation site compared to 




Figure 6.2. Longitudinal BMP-2 Tracking in Subcutaneously Implanted Alginate/PCL 
Constructs Containing 0, 0.1, or 1 mg of Heparin Microparticles. 2.5 µg of VS750-labeled 
BMP-2 (alone or loaded onto 0.1 or 1 mg of microparticles) were mixed into 150 µL of 2% RGD-
alginate. Alginate/PCL constructs were implanted subcutaneously in the backs of rats for 3 weeks 
(n=8) and imaged on an IVIS® platform periodically after surgery. A-D) Representative 
fluorescence IVIS® images of subcutaneous implants at Day 0, 1, 4, and 7. E) Quantification of in 
vivo VS750 fluorescence over time (normalized to Day 0 fluorescence) revealed somewhat faster 
loss of BMP-2 signal from constructs lacking microparticles and containing 0.1 mg of 
microparticles; however, these data were not statistically different. F) BMP-2 retention data fit to 
an exponential decay curve revealed differences in average decay constants of constructs treated 
with No MPs and 1 mg MPs. (* = p < 0.05) G) Quantification of ex vivo VS750 fluorescence 
from explanted constructs 21 days post-surgery. (* = p < 0.01 between No MPs and 1 mg MPs) 
	
6.3.3 Spatial Distribution of Mineralization in Femoral Defects 
 
We next attempted to alter the spatial distribution of bone formation and reduce 
heterotopic ossification by including BMP-2-loaded heparin microparticles in 
alginate/PCL constructs used to treat femoral defects with high dose BMP-2. Femoral 
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defects were treated with constructs containing 30 µg of BMP-2, 30 µg of BMP-2 loaded 
onto 0.1 mg of heparin microparticles, or 30 µg of BMP-2 loaded onto 1 mg of heparin 
microparticles. Longitudinal radiographs revealed progressive mineralization in and 
around the bone defect site in all groups over time (Figure 6.3), resulting in robust bony 
bridging in almost all samples after 12 weeks (12/14 defects treated with BMP-2 alone, 
12/13 defects treated with 0.1 mg of BMP-2-loaded microparticles, and 13/14 defects 
treated with 1 mg of BMP-2-loaded microparticles). Some degree of heterotopic 
ossification outside of the defect area was observed in all groups as early as 2 weeks post-
surgery and persisted through 12 weeks; however, the amount of heterotopic ossification 
apparent in constructs containing microparticles was visibly decreased in comparison to 
constructs without microparticles. Constructs without microparticles also induced a more 
variable distribution of mineralization in and around the defect space, and thus two sets 
of representative radiographs demonstrating relatively lower and higher amounts of 
heterotopic bone were chosen. 
Longitudinal in vivo micro-CT scans provided quantification of total bone volume 
and bone mineral density over time; furthermore, contouring around the entire thigh and 
within the 6 mm diameter of the PCL mesh allowed for determination of heterotopic and 
defect bone volumes (Figure 6.4A). Total bone volume increased in all groups over 12 
weeks post-surgery. Although no differences were observed in total bone volume (Figure 
6.4B) or overall mineral density (Figure 6.4C) between groups, when total bone volume 
was divided into heterotopic (Figure 6.4D) and defect bone volumes (Figure 6.4E), 
constructs containing 0.1 mg or 1 mg of heparin microparticles reduced the percentage of 
bone formed outside the defect space and increased the percentage formed within the 
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defect. In femurs treated with BMP-2 alone, 65.8 ± 5.3% of the total bone volume was 
located outside of the defect space after 4 weeks post-surgery, whereas this amount was 
decreased to 39.4 ± 5.9% and 44.8 ± 7.9% with treatment with 0.1 mg and 1 mg of 
heparin microparticles, respectively. While heterotopic bone volume decreased in all 
groups over time, femurs treated with BMP-2 alone still displayed almost twice as much 
heterotopic bone than femurs treated with BMP-2-loaded microparticles at the end of the 
study (40.3 ± 6.8% compared to 21.9 ± 2.8% and 21.0 ± 3.4%).  The percentage of bone 
formed within the defect increased in all groups over time; however, defect bone volumes 
were highest in femurs treated with loaded microparticles.  
 
Figure 6.3. Representative Radiographs of Femoral Defects Treated with BMP-2 and BMP-
2-Loaded Microparticles. Femoral defects were treated with alginate/PCL constructs containing 
30 µg of BMP-2, 0.1 mg of microparticles loaded with 30 µg of BMP-2, or 1 mg of 
microparticles loaded with 30 µg of BMP-2 (n=13-14). Representative radiographs of femurs at 
2, 4, 8, and 12 weeks post-surgery depicted variable amounts of heterotopic ossification in defects 
treated with BMP-2 alone, while femurs treated with BMP-2-loaded microparticles exhibited less 
heterotopic bone. Complete bony bridging was achieved in 12/14 defects treated with BMP-2 
alone, 12/13 defects treated with 0.1 mg of BMP-2-loaded microparticles, and 13/14 defects 





Figure 6.4. Quantitative Assessment of Bone Regeneration and Distribution in Femoral 
Defects Treated with BMP-2 and BMP-2-Loaded Microparticles. Femoral defects were 
treated with alginate/PCL constructs containing 30 µg of BMP-2, 0.1 mg of microparticles loaded 
with 30 µg of BMP-2, or 1 mg of microparticles loaded with 30 µg of BMP-2 (n=13-14). A) 
Representative micro-CT slice depicting 6 mm contours chosen to separate heterotopic mineral 
volume from defect mineral volume. Micro-CT quantification of B) total bone volume, C) 
mineral density, D) heterotopic bone volume as a percentage of total bone volume, and E) defect 
bone volume as a percentage of total bone volume in bone defects at 4, 8, and 12 weeks post-




Affinity-based growth factor delivery systems aim to improve growth factor 
retention in vivo in order to localize the healing response. In this study, we demonstrated 
that the addition of ≥0.1 mg of BMP-2-laden heparin microparticles in alginate/PCL 
constructs used for high dose BMP-2 delivery in a bone defect could effectively alter the 
spatial distribution of bone formed in and around the defect site and reduce the amount of 
heterotopic ossification observed. In vitro BMP-2 release profiles and in vivo BMP-2 
retention profiles from alginate/PCL constructs revealed differences in BMP-2 
localization within the construct with the addition of a higher dose of microparticles (1 
mg), whereas the addition of a lower dose of microparticles (0.1 mg) had a minimal 
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effect on BMP-2 retention. Despite this, both doses of microparticles reduced the 
incidence of heterotopic ossification around the femoral defect and increased the volume 
of bone formed within the boundary of the PCL nanofiber mesh, suggesting that heparin 
microparticles may improve localized delivery of clinically relevant doses of BMP-2. 
Previous studies that have investigated the delivery of high doses of BMP-2 in 
preclinical animal models have reported varying results. In studies employing collagen 
sponge and PLGA delivery vehicles, cyst-like bone voids and soft tissue swelling were 
observed at higher BMP-2 doses [284, 285]; conversely, BMP-2 delivery using a 40-fold 
range of BMP-2 doses (0.005-0.25 mg BMP-2/kg body weight) in a poly-lactic acid 
scaffold in a canine spinal fusion model did not demonstrate any dose-dependent changes 
in bone distribution or adverse events [287]. Thus far, the majority of studies that have 
investigated high dose BMP-2 delivery have aimed to characterize dose responses in 
animal models in an attempt to better understand BMP-2 dose effects in humans. 
However, this study and our recent study comparing the efficacy of the alginate/PCL 
delivery vehicle to the clinical collagen sponge (Krishnan and Priddy, et al. In review.) 
represent some of the first investigations into improving BMP-2 localization at higher, 
clinically relevant doses. 
As expected based on release profiles presented in Chapters 3 and 4 and predicted 
by the computational model presented in Chapter 5, in vitro and in vivo BMP-2 release 
from alginate/PCL constructs was attenuated in the presence of 1 mg of heparin 
microparticles, likely due to the excess of unoccupied BMP-2 binding sites available. 
Interestingly, although the computational model also predicted a reduction of BMP-2 
release in alginate/PCL constructs containing 0.1 mg of microparticles, experimental data 
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revealed similar release/retention profiles between constructs lacking microparticles and 
constructs containing 0.1 mg of microparticles. The idealized in vivo environment 
simulated by the model did not capture all of the elements of the system that could 
influence BMP-2 release kinetics, including degradation of the alginate hydrogel, 
interstitial fluid flow, and competitive binding of numerous other proteins and soluble 
factors to heparin microparticles in the in vivo injury environment. Furthermore, since 
individual heparin microparticles contained a large number of concentrated BMP-2 
binding sites, reducing the number of microparticles by 10-fold (from 7.0E15 to 7.0E14 
sites) may have also decreased the probability of BMP-2 molecules (3.5E14 total 
molecules) rebinding to other heparin microparticles while diffusing through the alginate 
hydrogel. Finally, the conditions under which BMP-2 release from constructs was 
evaluated differed drastically from the femoral bone defect environment. BMP-2 release 
from alginate/PCL constructs was measured in PBS in vitro, which may have accelerated 
dissociation of the ionically cross-linked alginate [274, 288], while BMP-2 release in vivo 
was observed subcutaneously, which may have led to hydrogel leaking out of the 
flexible, open-ended PCL mesh cylinder [212-214]. While both of these experiments 
provided valuable information, it is important to note that the distinct cellular and 
molecular makeup of the tissue injury site likely contributed to an altered BMP-2 release 
profile. Further model development could attempt to account for competitive protein 
binding and BMP-2 diffusion through degrading alginate and alginate cross-linked with 
microparticles, in order to more accurately predict BMP-2 release in the bone defect. 
Despite the limitations of the computational model used, it provided a theoretical 
basis for the microparticle concentrations chosen for the in vivo study; the BMP-2 release 
	 158 
profiles generated in silico correctly suggested that order of magnitude changes in the 
number of microparticles used could change BMP-2 localization within the bone defect, 
allowing for much fewer conditions to be tested in vivo. We observed considerable 
heterotopic bone formation in femoral defects treated with alginate/PCL constructs 
containing high dose BMP-2 without microparticles, similar to what had been reported 
previously in this model (Krishnan and Priddy, et al. In review.). The inclusion of heparin 
microparticles in this tissue engineering construct reduced heterotopic ossification; 
however, the outer boundary of bone formation, characterized by a densely mineralized 
shell, still largely formed outside of the PCL mesh boundary, resulting in this mineral 
being considered heterotopic and calling into question the chosen segmentation of defect 
and heterotopic cross-sectional areas. As a result, the average polar moment of inertia of 
each sample could also be calculated from micro-CT scans of explanted 12-week femurs, 
as previously described [289], in order to complement current bone volume data with an 
unbiased evaluation of the spatial distribution of mineralization. 
Another goal of incorporating varying amounts of heparin microparticles into 
alginate/PCL constructs was the investigation of tissue engineering constructs with 
tunable growth factor affinity [240]. BMP-2 release could be tuned both in vitro and in 
vivo using heparin microparticles, although the range of release profiles observed was not 
as wide as what was predicted in silico. Surprisingly, we found that, while incorporating 
different amounts of microparticles could alter the BMP-2 release profiles of these 
constructs, the spatial distribution of regenerated bone was ultimately the same between 
both microparticle-containing groups. This could be due to a variety of reasons that 
warrant future investigation, including the fact that different amounts of microparticles 
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could influence the cross-linking of the alginate gel and that the density of BMP-2 per 
microparticle may effect its presentation to cells, which has been previously observed in 
vitro [107]. Histological analysis of alginate gels formed ex vivo and femurs treated with 
alginate/PCL constructs for 2 and 12 weeks will reveal the structure of microparticle-
containing gels before and after implantation and provide valuable information about the 
interactions of infiltrating cells with microparticles in vivo. In the future, in order to 
control for differences in alginate cross-linking, microparticles with different heparin 
content, such as 1% and 10% heparin-PEG microparticles [120], could be incorporated 
into alginate/PCL constructs, so that equivalent numbers of microparticles with varying 




In this study, we investigated the incorporation of different doses of heparin 
microparticles (0.1 mg, 1 mg) into alginate/PCL constructs to examine the effects on 
localization of high dose BMP-2 delivery to a critically sized rate femoral defect. We 
demonstrated that BMP-2 release from the alginate/PCL constructs could be tuned using 
varying amounts of microparticles based on in vitro BMP-2 release and in vivo retention 
of BMP-2 fluorescent signal. Alginate/PCL constructs containing both doses of BMP-2-
loaded microparticles reduced heterotopic ossification and increased defect bone volume 
compared to alginate/PCL constructs containing BMP-2 alone, suggesting that, above a 
certain threshold concentration, heparin microparticles may have utility in localizing 
growth factor delivery in systems containing higher, clinically relevant doses of BMP-2. 
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CHAPTER 7: COMPETITIVE PROTEIN BINDING INFLUENCES HEPARIN-




In Chapter 6, we demonstrated that heparin microparticles could be used as an 
effective delivery vehicle for high doses of BMP-2 in a rat femoral defect, resulting in the 
majority of bone regeneration occurring within the defect site. The positive results of this 
study suggested that the affinity of heparin microparticles for BMP-2 may be better 
suited to controlling the spatial distribution of higher, clinically relevant doses of BMP-2 
(30 µg/defect), rather than prolonging the effect of low doses of BMP-2 (2.5 µg/defect). 
Despite the prevalence of BMP-2-associated side effects in the clinic, such as 
inflammation, seroma, and heterotopic ossification, the majority of animal models thus 
far have focused on lowering BMP-2 doses instead of mitigating the negative effects of 
clinical doses, which are most likely due to the inability of the collagen sponge delivery 
vehicle to retain high local concentrations of BMP-2. Although a number of clinical 
studies have reported appreciable rates of heterotopic ossification in patients [43, 45, 
283], few studies have attempted to replicate and alleviate heterotopic ossification in 
preclinical animal models. Studies undertaken to systematically investigate the effects of 
high doses of BMP-2 in animal models have yielded mixed results. Delivery of BMP-2 
doses ranging between 58-2300 µg (0.005-0.25 mg BMP-2/kg body weight) in a poly-
lactic acid scaffold resulted in no differences in bone volume in a canine spinal fusion 
																																																								
3 Modified from Hettiaratchi MH, et al. Competitive protein binding influences heparin-based modulation 
of BMP-2 delivery for bone regeneration. Submitted to J Tissue Eng Regen Med. 
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model with a noted lack of adverse events [287], while delivery of 150-2500 µg of BMP-
2 in collagen sponges resulted in improved mineralization at lower doses (150-600 µg) 
and the occurrence of large heterotopic bone cysts at higher doses (>600 µg) [290]. 
Evaluation of an apatite-coated poly(lactic-co-glycolic) acid (PLGA) scaffold in a rat 
femoral defect model revealed that a lower BMP-2 dose (2.25 µg) induced bony bridging 
over 8 weeks, but higher BMP-2 doses (11.25-45 µg) resulted in the formation of 
abnormal bone and soft tissue swelling [291].  
As mentioned previously, our laboratory has recently investigated high, clinically 
relevant doses of BMP-2 (0.12 mg BMP-2/kg body weight) in a rat femoral defect model, 
and recapitulated the incidence of heterotopic bone observed using a collagen sponge 
delivery vehicle (Krishnan and Priddy, et al. In review.); delivery of 0.12 mg BMP-2/kg 
body weight resulted in >50% of total bone regenerate forming outside of the intended 
defect space. Herein, we examined an alternative method of reducing heterotopic 
ossification in the rat femoral defect model using the high BMP-2 loading capacity of 
heparin microparticles. Instead of delivering BMP-2 within heparin microparticles, we 
physically entrapped heparin microparticles within an electrospun polycaprolactone 
nanofiber mesh tube in an attempt to create a barrier to rapid BMP-2 diffusion from the 
clinical collagen sponge. Unlike the studies in Chapters 4 and 6, which utilize an alginate 
hydrogel for BMP-2 delivery, this design could allow clinicians the choice of current 
delivery methods (i.e. collagen sponge), thus lowering perceived adoption barriers, while 
harnessing the high affinity of heparin microparticles for BMP-2 to improve patient 
safety in BMP-2 therapeutics. 
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Histology was used to ascertain the distribution of heparin microparticles 
deposited in the nanofiber meshes at two densities (0.05 mg MP/cm2 and 0.10 mg 
MP/cm2), followed by in vitro evaluation of BMP-2 loading and release. Our hybrid 
mesh barrier system was then evaluated in vivo in a critically sized rat femoral defect 
model using a supraphysiological dose of BMP-2 (30 µg) delivered within the clinically 
used collagen sponge; remineralization of the defect space and the extent of heterotopic 
ossification were evaluated. We hypothesized that heparin microparticles incorporated 
into the polycaprolactone mesh tube would act as a growth factor sink, rapidly capturing 
BMP-2 dissociating from the collagen sponge after implantation. This approach could 
potentially limit the exposure of surrounding tissues to high BMP-2 doses, thereby 
reducing heterotopic ossification, while maximizing presentation of BMP-2 within the 
defect site to promote effective bone repair. 
 
7.2 Materials and Methods 
	
7.2.1 Polycaprolactone Mesh Fabrication  
 
Polycaprolactone (PCL; Sigma Aldrich) was dissolved overnight in a 90:10 
solution of hexafluoro-2-propanol (HFP; Sigma Aldrich) and dimethylformamide (DMF; 
Sigma Aldrich) with gentle stirring, and a clear polymer solution of 12% (w/v) PCL in 
organic solvent was obtained. 5 mL of solution was loaded into a 5 mL syringe (Becton 
Dickinson, Franklin Lakes, NJ) with a 22-gauge 1” blunt tip needle (Howard Electronic 
Instruments, El Dorado, KS), bubbles were removed, and the syringe was mounted onto a 
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PHD2000 Infusion syringe pump (Harvard Apparatus, Holliston, MA). For the 
electrospinning setup, the syringe pump was placed so that the needle tip was ~19 cm 
away from a rectangular copper collection plate covered with aluminum foil for PCL 
nanofiber deposition. The syringe pump was set to a constant infusion rate of 0.75 mL/hr, 
and a high voltage supply (HV Power Supply, Gamma High Voltage Research, Ormond 
Beach, FL) provided a voltage difference of ~15-20 kV between the needle and copper 
collection plate. The voltage was periodically adjusted to maintain a Taylor cone at the 
needle tip during electrospinning [292]. A total of 3.6 mL of PCL solution was infused 
through the syringe pump, creating a circular mesh with an area of ~100 cm2 and 
thickness of ~500 µm, as measured with digital calipers.  
Heparin microparticles were sprayed onto the meshes in two batches, after 1.2 mL 
and 2.4 mL of PCL had been electrospun (Figure 7.1A) and physically entrapped into the 
meshes. 2.5 or 5 mg of microparticles suspended in ethanol were sprayed evenly across 
the mesh using an airbrush (Iwata Medea Inc., Portland, OR) driven by an air pump 
(Master Airbush, TCP Global Co., San Diego, CA). The ethanol was allowed to 
evaporate briefly before continuing the electrospinning process. Spraying each 
suspension twice entrapped microparticles in two layers between polymer fibers and 
created 0.05 mg MP/cm2 and 0.10 mg MP/cm2 meshes. 0.05 mg MP/cm2 meshes 
containing 4-µm diameter polystyrene microparticles (Polysciences Inc., Warrington, PA) 
were also fabricated similarly to serve as an uncharged microparticle control. Meshes 
without microparticles received two empty ethanol sprays after 1.2 and 2.4 mL of PCL 
had been electrospun. 12 mm by 19 mm sheets with or without twenty-three 0.9 mm 
diameter perforations were laser cut from the circular meshes (Universal Laser Systems, 
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Scottsdale, AZ), rolled into tubes (diameter 5 mm, length of 12 mm), and glued using UV 
cure adhesive (1187-M MD Medical Device Adhesives & Coatings, BlueWave LED 
Prime UVA Spot Curing System, DYMAX, Torrington, CT). Mesh tubes underwent 
100% ethanol evaporation overnight, followed by disinfection in 70% ethanol for 4 
hours, and finally immersion in sterile PBS until surgery. 
 
7.2.2 Microparticle-containing Polycaprolactone Mesh Characterization  
	
6-mm diameter discs from representative meshes were embedded in cryomedium, 
and 5 µm cross-sections were taken along the disc diameter for histological analysis. 
Sections were stained with Safranin O and Fast Green to visualize heparin microparticle 
distribution within each mesh. Images of meshes were taken on a Zeiss Axio Observer 
Z.1 inverted microscope with Zeiss AxioVision software (Zeiss, Oberkochen, Germany). 
	
7.2.3 In Vitro BMP-2 Loading and Release from Meshes 
 
To evaluate in vitro BMP-2 loading and release, 6-mm diameter discs from each 
mesh were incubated in a solution of 100 ng of BMP-2 (Pfizer, New York, NY) in 1 mL 
of 0.1% (w/v) bovine serum albumin (BSA, Sigma Aldrich) in PBS with gentle mixing 
(Tube Revolver/Rotator, Thermo Fisher Scientific) for 16 hours at 4°C. Meshes were 
then removed and the remaining solution was evaluated for BMP-2 content using an 
enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN). The 
mass of BMP-2 entrapped within the meshes was determined by normalizing unbound 
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BMP-2 to a solution of 100 ng of BMP-2 incubated for 16 hours at 4°C without 
microparticles. BMP-2-loaded meshes were then placed in 1 mL of fresh solution and 
incubated at 37°C for a period of 21 days to measure passive BMP-2 release from the 
meshes. After 0.25, 1, 4, 7, 10, 14, and 21 days, the entire solution was removed and 
replaced with 1 mL of fresh 0.1% BSA in PBS.  
	
7.2.4 Rat Femoral Defect Surgical Procedure 
	
Surgeries were performed on 13-week-old female SASCO Sprague Dawley rats 
(~250 g) as previously described [293], using procedures approved by the Georgia 
Institute of Technology Institutional Animal Care and Use Committee. Briefly, using an 
anterior approach and blunt dissection of the overlaying muscles, a radiolucent fixation 
plate (polysulfone) with two stainless steel risers at the ends was attached directly onto 
the femur for stabilization. An oscillating saw was used to create an 8-mm long, full 
thickness mid-diaphyseal defect. Each defect was treated with a collagen sponge (L = 10 
mm, D = 5 mm; Kensey Nash, Exton, PA) soaked with 30 µg of BMP-2 in 150 µL of 
0.1% (w/v) rat serum albumin (RSA) in 4 mM hydrochloric acid, inserted into a PCL 
nanofiber mesh tube (L = 12 mm, D = 5 mm), and gently fit into the defect. The 
following PCL mesh formulations were tested in vivo: (1) no heparin microparticles, (2) 
meshes with 0.05 mg MP/cm2 (0.11 mg heparin microparticles total), (3) meshes with 
0.10 mg MP/cm2 (0.23 mg microparticles total), (4) meshes with 0.9 mm perforations 
without heparin microparticles, and (5) meshes with 0.9 mm perforations and 0.10 mg 
MP/cm2 (0.23 mg heparin microparticles total, prior to perforation).  
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7.2.5 In Vivo Faxitron and Micro-computed Tomography 
	
Longitudinal in vivo radiographs were obtained at 2, 4, 8, and 12 weeks post-
surgery (Faxitron MX-20, Faxitron Bioptics LLC, Tucson, AZ) at a voltage of 23 kV and 
exposure time of 15 seconds; radiographs were used to qualitatively assess mineralized 
bridging across the defect space and the presence of heterotopic bone outside of the 
defect. In vivo micro-CT was conducted at 4, 8, and 12 weeks post-surgery (Viva CT, 
Scanco, Brüttisellen, Switzerland) to quantify total bone volume, bone mineral density, 
and spatial distribution of mineral inside and outside of the defect space. Animals were 
scanned at a voxel size of 38.5 µm, voltage of 55 kVp, current of 109 µA, and medium 
resolution. Mineral was quantified within the central ~6 mm (160 scan slices) of each 8 
mm defect, and three different volumes of interest (VOIs) were identified: (1) total 
mineral volume of the thigh within the region of interest, (2) mineral volume within the 
defect space, as defined by 5 mm diameter circular contours corresponding to the 
diameter of the nanofiber mesh, and (3) heterotopic mineral volume, which fell outside of 
the 5 mm diameter circular contours. A global threshold for newly regenerated bone was 
set at 50% of the mineral density of native cortical bone. 
	
7.2.6 Biomechanical Testing 
	
Femurs harvested from animals at 12 weeks were wrapped in saline-soaked gauze 
and stored at -20oC.  For mechanical testing, samples were thawed to room temperature, 
and soft tissue and polysulfone fixation plates were removed, leaving the metal risers 
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attached to the bone. The bone ends (including part of the metal risers) were potted in 
molten Wood’s metal (Alfa Aesar, Haverhill, MA) in custom metal holders, allowed to 
solidify, and mounted in the test clamps. Torsion was applied at a rate of 3º per second 
until failure on a uniaxial torsion testing system (Bose EnduraTEC ELF200; Bose 
Electroforce Systems Group, Eden Prairie, MN), allowing for the determination of 
maximum torque and calculation of torsional stiffness, using the slope of the linear 
segment of the torque-rotation curve. 7-8 samples from each treatment group and 5 
contralateral intact femurs were tested.  
	
7.2.7 Histological Analysis of Microparticle Retention and Bone Regeneration 
	
One femur from each treatment group demonstrating representative bone 
formation (as evaluated by radiography) was isolated for histology at 12 weeks post-
surgery. After harvesting, the femurs were fixed in 10% neutral buffered formalin at 4°C 
for 48 hours, followed by decalcification at room temperature (Cal Ex-II, Fisher 
Scientific, Pittsburgh, PA) with gentle agitation for 14 days. Samples were then 
dehydrated through submersion in a series of alcohol and xylene solutions and vacuum-
embedded in paraffin wax at 60°C; 5-7 µm mid-sagittal sections of the defects were 
obtained for histological analysis using Safranin O/Fast Green staining, primarily for 
identification of heparin microparticles within the mesh. Images of sections were taken 
on a Zeiss Axio Observer Z.1 inverted microscope with Zeiss AxioVision software 
(Zeiss, Oberkochen, Germany). 
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7.2.8 In Vitro BMP-2 Loading and Release from Heparin Microparticles 
 
a) Contact time required for BMP-2 loading onto heparin microparticles: In vitro 
evaluation of BMP-2 loading and release from heparin microparticles was performed as 
previously described [107]. 0.1 mg of microparticles were incubated with 100 ng of 
BMP-2 in 0.1% BSA in PBS at 4°C for various periods of time between 0-16 hours, to 
establish the minimum contact time required for BMP-2 loading onto microparticles.  
b) Competitive binding/adsorption of serum components to heparin 
microparticles: To determine whether the presence of serum borne biomolecules 
interfered with BMP-2 loading onto microparticles, 10 µg samples of heparin 
microparticles were incubated with a range of BMP-2 concentrations (3-3000 ng/mL) in 
1 mL of fetal bovine serum (FBS; Hyclone – GE Healthcare Life Sciences, Logan, UT) 
or 0.1% BSA in PBS for 16 hours at 37°C. BMP-2 content of microparticle-containing 
samples were normalized to samples containing BMP-2 alone in 0.1% BSA in PBS or 
FBS and incubated for 16 hours at 37°C. BMP-2 release (100 ng) from heparin 
microparticles (0.1 mg) was also evaluated in both 0.1% BSA/PBS and FBS at 37°C over 
21 days. At each time point, the entire solution was removed and replaced with 1 mL of 
fresh solution. All samples were evaluated for BMP-2 content via ELISA. 
	
7.2.9 Polyacrylamide Gel Electrophoresis (PAGE) Analysis 
 
Binding and adsorption of serum proteins to heparin microparticles was 
confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
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followed by silver staining for all protein bands.  0.1 mg of heparin microparticles were 
incubated in PBS, 30 ng of BMP-2 in 0.1% BSA in PBS, FBS, or 30 ng of BMP-2 in 
FBS at 4°C for 16 hours. Heparin microparticles were then centrifuged, washed once 
with PBS, and resuspended in SDS-PAGE loading buffer. 30 ng of soluble BMP-2 in 
0.1% BSA in PBS and diluted FBS (1:25, 1:50) were also resuspended in loading buffer 
as additional controls. All solutions were heated to 95°C for 10 minutes prior to loading 
onto a 12% Mini-PROTEAN TGX gel (Bio-Rad Laboratories, Hercules, CA). Gel 
electrophoresis was performed in SDS/PAGE running buffer under reducing and 
denaturing conditions using a Mini-PROTEAN Tetra Cell system (Bio-Rad) set at a 
constant voltage (200 V) for 40 minutes. A 10-250 kDa protein ladder (Precision Plus 
Kaleidoscope, Bio-Rad) was used as a molecular weight reference. Silver staining of 
SDS-PAGE gels was performed using the Silver Staining Plus Kit (Bio-Rad) as per the 
manufacturer’s instructions, rinsed, and imaged using a CanoScan LiDE 220 Flatbed 
Scanner (Canon USA, Melville, NY). 
	
	
7.2.10 Mass Spectrometry of Heparin Microparticle Samples 
	
	
In order to identify serum proteins bound to heparin microparticles, mass 
spectrometry analysis was conducted on 1 mg of microparticles loaded with 5 mL of FBS 
or 5 mL of FBS and 8 µg BMP-2 together using aforementioned techniques. The 
microparticles were centrifuged, washed with PBS, and proteins bound to microparticles 
were digested with 2 units of Glu-C (EMD Millipore, Darmstadt, Germany) for 16 hours 
and 10 units of Lys-C (Wako Chemicals USA, Richmond, VA) for 3.5 hours in 50 mM 
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HEPES (pH=7.9). Digestion was quenched with formic acid (FA) until samples reached a 
final pH of 2.  Samples were then purified using the stage tip method [294], dried and 
resuspended in 10 µL solvent containing 5% acetonitrile (ACN) and 4% formic acid. 
For mass spectrometry (MS) analysis, an WPS-3000(T)PLRS autosampler 
(Thermostatted Pulled Loop Rapid Separation Nano/Capillary Autosampler; Dionex, 
Sunnyvale, CA) loaded 4 µL of each sample onto a microcapillary column packed with 
C18 beads (Magic C18AQ, 5 µm, 200 Å, 100 µm x 16 cm).  Peptides were separated by 
reversed-phase chromatography using an UltiMate 3000 binary pump with a 15 minute 
gradient of 5-60% ACN and detected in a hybrid dual-cell quadrupole linear ion trap – 
Orbitrap mass spectrometer (LTQ Orbitrap Elite, Thermo Scientific, with Xcalibur 3.0.63 
software) using a data-dependent Top 15 method.  Each cycle included one full MS scan 
(resolution: 60,000) in the Orbitrap at 106 AGC target, followed by up to 20 tandem mass 
spectra (MS/MS) for the most intense ions. Ions with a single or unassigned charge were 
not fragmented for MS/MS. For each full MS scan the maximum ion accumulation time 
was 1000 ms, and for each MS/MS scan the maximum time was 50 ms. 
MS/MS fragmentation precursors were checked for incorrect monoisotopic peak 
assignments while refining precursor ion mass measurements [295]. The SEQUEST 
algorithm (version 28) [296] was used to search all MS/MS spectra by matching against a 
database encompassing sequences of all proteins in the UniProt Bovine database 
(downloaded March 2014) and common contaminants. To estimate the false discovery 
rate (FDR) of peptide identifications, each protein sequence was listed in forward and 
reversed orientations. The following parameters were used for database searching: 20 
ppm precursor mass tolerance, 1.0 Da product ion mass tolerance, Lys-C and Glu-C 
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digestion, up to 3 missed cleavage sites. The modifications included in the search were 
oxidation of methionine (+15.9949) and carbamidomethylation of cysteine (+57.0215). 
To further control the FDRs of peptide identification, the target-decoy method was 
employed [297, 298]. Linear discriminant analysis (LDA) was employed to distinguish 
correct and incorrect peptide identifications [295, 299]. Peptides containing less than six 
amino acids were discarded and peptide spectral matches were filtered to a less than 1% 
FDR based on the final number of decoy sequences in the dataset. 
	
	
7.2.11 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. In vitro experiments 
were run with a minimum of three replicates for each experimental group. For BMP-2 
loading and release from nanofiber meshes, three samples were obtained from each mesh, 
and a total of 3-10 meshes were analyzed from each group. For in vivo bone defect 
experiments, longitudinal micro-CT was conducted on 8-9 femurs per group, and 
biomechanical testing was conducted on 7-8 femurs per group. Statistical significance 
was determined using one-way or two-way ANOVA as appropriate, followed by 
Bonferroni’s post hoc analysis (Graphpad Prism, Version 5.0, La Jolla, CA). For data that 
did not satisfy the assumptions of equal variances and Gaussian distributions, the 







7.3.1 Polycaprolactone Mesh Characterization 
	
Safranin O/Fast Green staining of representative 5 µm thick cross-sections of PCL 
nanofiber meshes revealed two distinct layers of heparin microparticles (red) entrapped 
between PCL layers (gray) in both the 0.05 mg MP/cm2 meshes (Figure 7.1C, F) and 0.10 
mg MP/cm2 meshes (Figure 7.1D, G). In contrast, meshes without heparin microparticles 
consisted of a single continuous PCL layer (Figure 7.1B, E). Some mesh delamination 
and microparticle loss was observed in the 0.10 mg MP/cm2 meshes, demonstrated by 
separation of the mesh layers and presence of microparticles at the mesh surface (Figure 
7.1D, G); this may have been caused by the intervening ethanol spray step in the 
fabrication technique or histology processing. Meshes that exhibited delamination during 
manipulation prior to in vivo implantation were excluded from the study; however, this 
did not eliminate the possibility of in vivo mesh delamination, which was qualitatively 




Figure 7.1. Fabrication and Characterization of Heparin Microparticle-Containing 
Polycaprolactone Nanofiber Meshes. A) Schematic of microparticle-containing mesh 
fabrication. B, C, D) Low magnification images of mesh cross-sections stained with Safranin O 
and Fast Green demonstrated microparticles distributed throughout two layers in microparticle-
containing meshes. E, F, G) High magnification images of mesh cross-sections stained with 
Safranin O/Fast Green. All scale bars = 100 µm. H) 6-mm diameter meshes loaded with 100 ng of 
BMP-2 demonstrated higher BMP-2 loading in the presence of heparin microparticles compared 
to no microparticles and polystyrene microparticles. (* = p < 0.05 as indicated.) I) Cumulative 
mass of BMP-2 released over 21 days was similar between meshes without microparticles and 
with heparin microparticles. J) Cumulative BMP-2 release as a percentage of initial loading was 
higher for meshes without microparticles compared to meshes with microparticles. (# = p < 0.05 
compared to 0.05 mg MP/cm2 and 0.10 mg MP/cm2 meshes at each time point.) 
	
7.3.2 BMP-2 Loading and Release from Meshes 
	
PCL nanofiber meshes containing 0.05 and 0.10 mg/cm2 of heparin microparticles 
depleted more BMP-2 from solution (58.7% ± 1.1%, 56.0% ± 3.0%, respectively) than 
meshes without heparin microparticles or with 0.05 mg/cm2 of uncharged 4 µm 
polystyrene microparticles that lacked similar electrostatic affinity for BMP-2 (30.9% ± 
2.0%, 39.7% ± 4.3%, respectively; n=4-10, p<0.05) when loaded with 100 ng of BMP-2 
(Figure 7.1H). Meshes with and without heparin microparticles exhibited similar BMP-2 
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release profiles in 0.1% BSA in PBS at 37°C, releasing 25-27 ng of BMP-2 after 21 days 
in vitro (Figure 7.1I). However, when BMP-2 release was evaluated as a percentage of 
initial BMP-2 loading, meshes without microparticles released almost all of the bound 
BMP-2 (88.6% ± 10.3%), compared to meshes with 0.05 and 0.10 mg/cm2 of heparin 
microparticles, which released less than half of the bound BMP-2 over 21 days (44.1% ± 
5.1% and 47.2% ± 4.0%, respectively; n=3, p<0.001) (Figure 7.1J). 
	
7.3.3 In Vivo Faxitron and Micro-Computed Tomography 
 
Longitudinal radiographs revealed progressive mineralization in and around the 
bone defect area in all groups over time (Figure 7.2A), resulting in robust bony bridging 
in almost all samples after 12 weeks (9/9 of No MP, 8/9 of 0.05 mg MP/cm2, 8/8 of 0.10 
mg MP/cm2, 8/8 of Perforated No MP, 8/9 of Perforated 0.10 mg MP/cm2). Heterotopic 
ossification outside of the defect was observed in all groups at 2 weeks post-surgery and 
persisted through 12 weeks. Overall, no qualitative reduction in heterotopic ossification 
was observed with the inclusion of heparin microparticles in meshes (Figure 7.2A). 
Micro-CT reconstructions confirmed radiographic observations, revealing 
heterotopic ossification in all treatment groups with no reduction associated with 
microparticle-containing meshes (Figure 7.2B). Quantitative micro-CT analysis of bone 
regeneration within the defect site revealed increased mineralization over time, with no 
differences in total bone volume between groups at each time point. Furthermore, when 
the thigh region was divided (axially) into defect bone volume (corresponding to the 5 
mm diameter of the nanofiber mesh tube) and heterotopic bone volume (outside of the 
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diameter of the mesh tube) as pictured in Figure 6.4, bone volume between groups 
remained comparable (Figure 7.3A). The spatial distribution of newly formed bone from 
the central axis of the femur was also quantified by calculating the polar moment of 
inertia for each sample from micro-CT reconstructions, and did not exhibit differences 
between the groups with time (Figure 7.3B). Similarly, no notable morphological 
differences in the regenerated bone could be detected between groups by micro-CT 




Figure 7.2. Representative Radiographs and Three-dimensional Micro-CT Reconstructions 
of Femoral Bone Defects. A) Radiographs and B) micro-CT reconstructions (full reconstructions 
and cross-sections) of defects treated with No MP, 0.05 mg MP/cm2, and 0.10 mg MP/cm2, No 
MP (Perforated), and 0.10 mg MP/cm2 (Perforated) meshes. Bridging was achieved in 9/9 of No 
MP, 8/9 of 0.05 mg MP/cm2, 8/8 of 0.10 mg MP/cm2, 8/8 of No MP (Perforated), 8/9 of 0.10 mg 





Figure 7.3. Quantitative Micro-CT Analysis of Bone Defects After 4 and 12 Weeks. A) 
Defect bone volume (solid bars), heterotopic bone volume (diagonal line bars), and total bone 
volume (combined bars) were not different between treatment groups. Bone volume in each 
group increased over time (* = p < 0.05 as indicated). B) Polar moment of inertia was calculated 
to determine distribution of newly formed bone from the central axis of the femur and was also 




Figure 7.4. Micro-CT Analysis of Bone Morphology Parameters. Micro-CT analysis on 
regenerated bone at 4 and 12 week post-surgery demonstrated no differences in A) bone mineral 
density and B) trabecular number between groups. 
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7.3.4 Biomechanical Properties of Regenerated Femurs  
	
Torsion testing was used to determine the strength of the regenerated bone after 
12 weeks post-surgery. Maximum torque (Figure 7.5A) and torsional stiffness (Figure 
7.5B) were comparable between all groups and did not differ from the properties of age-




Figure 7.5. Maximum Torque and Torsional Stiffness of Regenerated Bone at 12 Weeks. 
Regenerated femurs underwent torsion testing to failure after 12 weeks post-surgery. Both 
maximum torque and torsional stiffness were not different between groups or compared to that of 
intact femurs of age-matched rats. Dashed line represents properties of intact femurs. 
	
7.3.5 Histological Analysis of Femurs 
	
Sections from representative femurs stained with Safranin O and Fast Green 
revealed that heparin microparticles remained entrapped within the mesh after 12 weeks 
in vivo (Figure 7.6; indicated by red arrows). Mesh integrity was better maintained in the 
0.05 mg MP/cm2 meshes, which exhibited two distinct layers of heparin microparticles 
and were comparable in appearance to intact meshes prior to implantation (Figure 7.6B, 
E). However, some areas of mesh disintegration were observed and were 
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indistinguishable from processing artifacts. The 0.10 mg MP/cm2 meshes displayed 
greater mesh delamination, as illustrated by large gaps within the meshes and an overall 
expansion of mesh area. Some heparin microparticles were located in close proximity to 
the 0.10 mg MP/cm2 meshes (indicated by red arrow, Figure 7.6C) or entrapped within 
them (Figure 7.6F), but overall fewer microparticles were retained in the 0.10 mg 
MP/cm2 meshes compared to 0.05 mg MP/cm2 meshes. Notably, heparin microparticles 
were not observed outside of the nanofiber mesh boundary (indicated by black arrows), in 
the defect region, or surrounding muscle. Overall, the regenerated bone in each of the 
groups demonstrated a trabecular structure (indicated by red arrowheads) interspersed 
with areas of loose fibrous tissue, as has been previously demonstrated with collagen 
sponge-mediated delivery of BMP-2 in this model [300]. 
 
Figure 7.6. Safranin O and Fast Green Staining of Bone Defects at 12 weeks. Safranin O and 
Fast Green staining was performed on defects treated with A, D) No MP meshes, B, E) 0.05 mg 
MP/cm2 meshes, and C, F) 0.10 mg MP/cm2 meshes. Black arrows denote the mesh boundary, 
and red arrowheads denote areas of new bone. Heparin microparticles, which are denoted by red 
arrows, were found entrapped within 0.05 mg MP/cm2 and 0.10 mg MP/cm2 meshes; however, 
0.10 mg MP/cm2 meshes demonstrated greater delamination. All scale bars = 100 µm. 
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7.3.6 Effect of Incubation Time on BMP-2 Loading onto Microparticles 
	
Since the presence of heparin microparticles in the nanofiber meshes did not 
appear to have an impact on bone regeneration in vivo, the minimal contact time required 
for BMP-2 loading onto heparin microparticles was evaluated in vitro by repeating BMP-
2 depletion experiments with microparticle samples collected at time points between 0 
and 16 hours. Analysis of BMP-2 remaining in solution following incubation with 
heparin microparticles and normalized to solutions containing BMP-2 alone revealed that 
64.1 ± 6.5% of the BMP-2 was depleted by the microparticles immediately after contact, 
and increased to 83.3 ± 4.3% within the first hour (Figure 7.7A). BMP-2 loading 
continued to increase over the next 4 hours before reaching a plateau of ~90% BMP-2 






Figure 7.7. Effect of Contact Time and Presence of Serum on BMP-2 Loading and Release 
from Heparin Microparticles. A) 0.1 mg of microparticles loaded with BMP-2 over different 
periods of time exhibited >60% BMP-2 loading immediately upon contact and a maximum 
loading of ~90% after 4 hours. B) 10 µg of microparticles loaded with 3-3000 ng of BMP-2 over 
16 hours at 37°C demonstrated reduced loading in the presence of FBS compared to 0.1% BSA in 
PBS. (* = p < 0.01 as indicated.) C) When 0.1 mg of heparin microparticles were loaded with 100 
ng of BMP-2 and allowed to release BMP-2 into 0.1% BSA in PBS or FBS, cumulative release of 
BMP-2 was higher in FBS after 4 days. (# = p < 0.05 between 0.1% BSA in PBS and FBS at 
indicated time points.) D) Gel electrophoresis followed by silver staining was completed on the 
following samples: 1 – Ladder, 2 – Unloaded MPs, 3 – MPs loaded with 30 ng of BMP-2, 4 – 
MPs loaded with FBS, 5 – MPs loaded with FBS + 30 ng of BMP-2, 6 – 30 ng of soluble BMP-2, 
7 – FBS diluted 1:25, 8 – FBS diluted 1:50. Blue dashed box indicates BSA bands, and red 
dashed boxes indicate BMP-2 monomer and dimer bands. 
	
	
7.3.7 Competitive Binding of Serum Proteins to Microparticles 
	
Because contact between BMP-2 and heparin microparticles embedded within 
nanofiber meshes in vivo occurred at 37°C in the presence of numerous blood borne 
soluble factors, in vitro BMP-2 loading and release experiments were performed in the 
presence of FBS, as a substitute for rat serum, and compared to results obtained in 0.1% 
	 181 
(w/v) BSA in PBS. Overall, heparin microparticles loaded less BMP-2 in the presence of 
FBS when incubated in BMP-2 concentrations between 3-3000 ng/mL (corresponding to 
0.3-300 µg of BMP-2 per mg of microparticles) (Figure 7.7B). Heparin microparticles 
incubated with BMP-2 in 0.1% BSA in PBS depleted ~75% of the BMP-2 at lower doses, 
while loading was reduced to 39.3 ± 9.3% at the highest dose (300 µg BMP-2/mg MPs); 
the BMP-2 loading efficiencies obtained in 0.1% BSA in PBS at higher growth factor 
concentrations were similar to results documented in Chapter 3 [107]. In contrast, heparin 
microparticles incubated with BMP-2 in the presence of FBS depleted less BMP-2 at 
each dose, with the highest loading percentage at the lowest dose (63.0 ± 3.9% compared 
to 82.8 ± 3.3% in BSA/PBS; p < 0.01) and lowest loading percentage at the highest dose 
(14.7 ± 2.2% compared to 39.3 ± 9.3% in BSA in PBS, p < 0.01). Similarly, the presence 
of FBS during BMP-2 release from heparin microparticles increased the amount of BMP-
2 released after 4 days of incubation (Figure 7.7C). Over 21 days in vitro, BMP-2-loaded 
microparticles incubated at 37°C in 0.1% BSA in PBS released 22.3 ± 4.6 % of the 
loaded BMP-2, whereas BMP-2-loaded microparticles incubated in FBS released double 
this amount (44.4 ± 8.4%; p < 0.05). 
Gel electrophoresis and mass spectrometry were performed to identify the serum 
proteins interfering with BMP-2 loading and increasing BMP-2 release. Silver staining of 
SDS-PAGE gels revealed BMP-2 monomer and dimer bands (red boxes) in the soluble 
BMP-2 lane (#6) at ~13 kDa and ~26 kDa, respectively, as well as a BSA band (blue 
box) at ~63 kDa (Figure 7.7D). The BMP-2 monomer (red box) and BSA (blue box) 
bands were also visible in the BMP-2-loaded microparticle lane (#3), although no BMP-2 
dimer band was observed and the bands were considerably less intense, indicating, as 
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expected, incomplete capture of BMP-2 by the microparticles. When the BSA bands in 
the FBS-loaded microparticle lanes (#4, #5) and the diluted FBS lanes (#7, #8) were 
compared, the BSA bands in the FBS-loaded microparticle lanes were found to be similar 
in size to that of the 1:50 diluted FBS lane (#8), demonstrating that only a fraction of the 
BSA in FBS was entrapped by heparin microparticles. Interestingly, several distinct 
bands emerged in the FBS-loaded microparticle lanes between 15-37 kDa, which were 
not present in the diluted FBS lanes, suggesting the concentration of multiple proteins 
within this molecular weight range. When heparin microparticles were loaded with BMP-
2 in the presence of FBS (#5), similar protein bands were observed compared to FBS 
loading alone; however, the BMP-2 monomer band was faint in comparison, suggesting 
that serum proteins were preferentially captured by the microparticles in much higher 
abundance than BMP-2. 
Mass spectrometry-based proteomics analysis was used to identify proteins on 
FBS-loaded heparin microparticles. All proteins detected on FBS-loaded microparticles 
are listed in Table 7.2. Proteins identified based on only two or fewer unique peptides 
were excluded from the analysis. Out of 33 total proteins identified, 20 were known 
heparin-binding proteins, including several apolipoproteins and thrombospondins. 
Selected peptides identified from these heparin-binding proteins are highlighted in Table 
7.1. The extracellular matrix protein fibronectin, which has a known heparin binding site 
and specific affinity for heparin [301], was confidently identified based on 26 unique 
peptides. For example, one peptide from fibronectin, SLPLVGQQSTVSDVPRDLE, was 
very confidently identified with an XCorr of 4.2 and mass accuracy of 0.04 ppm. XCorr 
signifies the correlation between the experimental mass spectra and theoretical mass 
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spectra of the peptide; higher XCorr values indicate higher confidence in the peptide 
identification. Similarly, the mass accuracy of each peptide demonstrates how closely the 
theoretical mass of the peptide matches the experimentally measured mass. High mass 
accuracy (less than 3 ppm) is another good indication of confident peptide identifications. 
On microparticles loaded with both FBS and BMP-2, BMP-2 was only identified based 
on one unique peptide and thus was not included in the list of detected proteins. This 
further suggests that FBS borne proteins were entrapped by the microparticles in larger 
quantities than BMP-2 and corroborates the results obtained from gel electrophoresis. 
 
Table 7.1. Selected Peptides from Known Heparin Binding Proteins Identified on FBS-
Incubated Heparin Microparticles. Ppm indicates mass accuracy and XCorr indicates 
correlation between experimental and theoretical mass spectra for each peptide. 
 
Protein Peptide ppm XCorr 
Apolipoprotein-A1 D.NWDTLASTLSK.V 1.03 3.3 
 
E.TLRQQLAPYSDD.L 0.63 2.9 
 
E.QLGPVTQE.F 0.27 2.6 
Apolipoprotein-B E.TSRSLPYAQNIQDQLSGLQE.L 1.30 5.9 
 
K.VSDSLIGVTQGYSVTVK.H -0.28 4.5 
 
E.ITVPASQLTVSQFTLPK.S 0.77 4.1 
Apolipoprotein-C2 K.TYLPAVDEK.I 0.55 2.4 
 
D.QVFSVLSGKD.- 0.71 2.0 
 
E.SLLGYWDTAK.A 0.83 2.9 
Apolipoprotein-E E.LQAAQARLGSDME.D 0.64 4.6 
 
D.YLRWVQTLSDQVQE.E -0.06 4.3 
 
E.QGQSRAATLSTLAGQPLLE.R 0.73 3.8 
Thrombospondin-1 K.DHSGQVFSVISNGK.A -0.37 4.8 
 
K.FQDLVDAVRAE.K 0.45 3.6 
 
K.GPDPSSPAFRIE.D 0.83 3.1 
Thombospondin-4 E.FQTQNFDRLD.K -0.13 2.4 
 
K.SSATIFGLYSSADHSK.Y 0.70 2.3 
 
K.SSATIFGLYSSADHSK.Y 0.04 3.8 
Fibronectin-1 K.LGVRPSQGGEAPRE.V 0.62 4.4 
 
E.SLPLVGQQSTVSDVPRDLE.V 0.04 4.2 
 





Table 7.2. Complete List of Proteins Identified on FBS-Incubated Heparin Microparticles. 
Known heparin binding proteins are italicized. Unique peptides represent the number of unique 
peptides identified from each protein, while total peptides indicates the total number of peptides 
identified for each protein. Average XCorr was calculated from all peptides.   
	





APOB Apolipoprotein B 62 66 2.9 
FN1 Embryo-specific fibronectin 1  26 29 2.9 
TLN1 Talin 1 21 22 2.9 
POSTN Periostin 16 19 2.9 
APOE Apolipoprotein E  14 14 3.1 
SERPINA1 Alpha-1-antiproteinase  12 13 2.8 
ALB Serum albumin  10 12 2.6 
ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 10 10 2.8 
THBS1 Thrombospondin-1  9 9 2.8 
APOA1 Apolipoprotein A-I  9 9 2.5 
HBA Hemoglobin subunit alpha  8 10 2.7 
AHSG Alpha-2-HS-glycoprotein  8 9 3.0 
FGA Fibrinogen alpha chain 8 9 2.9 
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 7 8 2.7 
AFP Alpha-fetoprotein  7 8 2.4 
FGG Fibrinogen gamma-B chain  6 8 3.2 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  6 6 2.8 
C3 Complement C3  6 6 2.6 
A2M Alpha-2-macroglobulin  5 6 3.0 
FGB Fibrinogen beta chain  4 10 2.9 
KNG1 Kininogen-1  4 5 3.3 
MYH9 Myosin heavy chain 9 (non-muscle) 4 4 2.9 
VTN Vitronectin 4 4 2.3 
THBS4 Thrombospondin-4  3 4 2.7 
COL18A1 Collagen type XVII alpha 1 3 3 3.0 
SERPINA Serpin A3-2  3 3 2.8 
TF Serotransferrin  3 3 2.7 
FETUB Fetuin-B  3 3 2.5 
APOC2 Apolipoprotein C-2 3 3 2.4 





Poor BMP-2 localization and rapid release following delivery is a limiting factor 
in the widespread use of BMP-2 therapy for bone healing applications. Most delivery 
approaches have focused on controlled release of growth factors from scaffolds either 
through non-specific electrostatic binding, which may result in rapid growth factor 
dissociation, or covalent localization, which may reduce growth factor bioactivity [302, 
303]. In this study, we designed a hybrid nanofiber mesh barrier system containing 
entrapped heparin microparticles with the goal of creating a growth factor sink to impede 
BMP-2 diffusion outside of the site of interest and subsequently reduce the incidence of 
heterotopic ossification in vivo. We incorporated heparin-based microparticles in order to 
increase the BMP-2 loading capacity of PCL nanofiber mesh tubes and localize the 
delivered growth factor within the bone defect. The novel airbrush technique that we 
employed to incorporate heparin microparticles resulted in uniform meshes with a 
reproducible distribution of microparticles. Furthermore, the addition of heparin 
microparticles into the nanofiber meshes resulted in increases in BMP-2 loading capacity 
and decreases in BMP-2 release from the meshes. Despite promising results achieved in 
vitro, the microparticle-containing meshes did not perform as hypothesized in vivo, since 
no impact was observed on heterotopic ossification, regenerated bone volume, or 
mechanical properties.  
With its high affinity for BMPs, heparin has been previously incorporated into a 
number of biomaterial scaffolds to reversibly bind BMP-2 through electrostatic 
interactions and provide sustained delivery in vivo to induce mineralization in both 
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ectopic and orthotopic sites [101, 116, 178, 227, 304-306]. These include heparin-
functionalized alginate microparticles [178], heparin-conjugated PLGA nanoparticles and 
bulk scaffolds [227, 307], and poly-ethylene glycol (PEG) hydrogels modified with 
heparin chains [172]. Unlike most heparin-containing biomaterials, which are typically 
used to deliver BMP-2 to bone defects, we employed heparin microparticles entrapped 
within PCL nanofiber meshes as a composite material to localize BMP-2 release from a 
primary biomaterial (collagen sponge) with a lower BMP-2 affinity. This biomimetic 
concept of using heparin as both a physical barrier to diffusion as well as a growth factor 
sink resembles the natural role played by other GAGs (heparan sulfate and chondroitin 
sulfate) during development, in which areas of high GAG content sequester cell-secreted 
growth factors, such as fibroblast growth factors (FGFs) and BMPs, in order to provide 
spatial localization of mitogenic and morphogenic cues [308]. While a few other studies 
have used empty heparin-based materials to sequester cell-secreted growth factors [309, 
310], to our knowledge, this is the first study that demonstrates the use of an empty 
heparin-based biomaterial to locally sequester co-delivered BMP-2 in vivo. 
The fact that the hybrid mesh system exhibited favorable BMP-2 loading and 
release kinetics in vitro, but could not spatially control bone distribution in vivo, could be 
due to a number of reasons. Inadequacies in the physical mesh barrier itself (irrespective 
of the presence of microparticles) may have contributed to the patterns of bone formation 
observed. Firstly, the mesh tubes did not fit tightly around the bone ends, such that there 
was a reduced barrier to diffusion at the bone ends, potentially allowing BMP-2 to exit 
the collagen sponge without contacting the embedded microparticles; secondly, the 
possible delamination of these meshes in vivo may have further disrupted the intended 
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barrier. Despite these scaffold limitations, radiographic images and micro-CT 
reconstructions demonstrated that heterotopic ossification was not limited to the bone 
ends alone (Figure 7.2), and was also evident in femurs treated with 0.05 mg MP/cm2 
meshes, which remained intact with localized heparin microparticles throughout the 12 
week study (Figure 7.6). Furthermore, even with the loss of mesh integrity observed in 
the 0.10 mg MP/cm2 meshes, microparticles were observed within the mesh region, 
accessible to diffusing BMP-2. Lastly, mesh perforations, which accelerated early 
mineralization at a lower BMP-2 dose (5 µg) in an alginate delivery vehicle [234], did not 
impact early bone formation in this study, potentially due to the increased BMP-2 dose 
and use of a collagen sponge delivery vehicle with low BMP-2 affinity. 
To further explain the in vivo results, we also sought to investigate the conditions 
under which the heparin microparticles entrapped within the mesh tubes would contact 
and capture BMP-2 released from the collagen sponge and how this differed from our 
initial in vitro investigation. Insufficient contact time between BMP-2 and heparin 
microparticles in vivo and impaired BMP-2-microparticle interactions in the presence of 
competing biomolecules may have reduced the ability of entrapped heparin 
microparticles to impede BMP-2 diffusion. Contact time between heparin microparticles 
and BMP-2 did not appear to play an important role in vitro, as >60% of the BMP-2 in 
solution was captured by the microparticles immediately upon contact and only 4 hours 
of incubation were required for >90% loading. This further suggested that the hybrid 
mesh could readily capture BMP-2 diffusing from the collagen sponge following 
implantation in vivo. On the other hand, the presence of bovine serum decreased the 
BMP-2 loading capacity of the heparin microparticles and promoted BMP-2 release.  
	 188 
In our previous publication, heparin microparticles displayed a maximum loading 
capacity of ~300 µg BMP-2 per mg of microparticles in 0.1% BSA in PBS [107]. Based 
on this loading capacity, the density of microparticles embedded in the meshes (0.11-0.23 
mg MPs per mesh) should have been sufficient to capture the entire mass of BMP-2 
loaded into the collagen sponge (30 µg). However, given the reduced BMP-2 loading 
capacity of heparin microparticles in the presence of FBS in vitro (~120 µg BMP-2/mg 
MPs), it is possible that the loading capacity of the microparticles in vivo may have also 
been somewhat reduced in the presence of serum borne soluble factors in the bone defect 
environment. At the highest BMP-2 dose evaluated in vitro (300 µg BMP-2/mg MPs), the 
BMP-2 loading capacity of the microparticles was reduced by >60% in the presence of 
FBS. Moreover, BMP-2 release from the microparticles in the presence of serum was 
double that of BMP-2 release in 0.1% BSA in PBS over 21 days. Additionally, mass 
spectrometry analysis of the serum proteins bound to heparin microparticles incubated in 
FBS revealed a number of known heparin binding proteins that display affinity for native 
heparin, including fibronectin (KD = 4 µM) [311], thrombospondins (KD = 4-14 nM) 
[312], and apolipoproteins (KD = 22-4000 nM) [313, 314]. Since the dissociation constant 
of heparin and BMP-2 is on a similar order of magnitude (KD = 20 nM) [3] to fibronectin, 
thrombospondins, and apolipoproteins, it is possible that these serum proteins may 
competitively bind to heparin and may interfere with BMP-2 loading or increase its 
release in vivo. Others have also observed the binding of serum borne and endogenously 
added fibronectin to heparin-containing materials in vitro [127, 315]. Since fibronectin 
also contains heparin-like growth factor binding domains [316, 317], this ECM molecule 
may out-compete heparin for protein binding. Growth factor binding to fibronectin has 
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been demonstrated extensively using both native fibronectin and purified fibronectin 
fragments containing integrin and growth factor binding domains, which have 
demonstrated enhanced binding of BMP-2 and other growth factors both in vitro and in 
vivo [136, 318, 319]. 
Since incorporating more heparin microparticles into the nanofiber mesh appeared 
to increase the risk of mesh delamination, linear heparin chains could be alternatively 
incorporated into the meshes to provide a more dispersed network of BMP-2 binding 
sites. Several studies have investigated the addition of varying amounts of heparin into 
PCL scaffolds using electrospinning [320], covalent immobilization [321], or 
electrostatic assembly [322]. These methods could also be used to more evenly disperse 
heparin on the surfaces of the mesh tubes in order to facilitate more immediate contact 
between the immobilized heparin and diffusing BMP-2. Finally, since the promiscuity of 
heparin’s binding sites may be responsible for the potential saturation of binding sites 
with serum components, the use of BMP-2-specific binding domains may help to 
circumvent some of the potential issues caused by serum adsorption and binding to 
microparticle-containing meshes. A more nuanced approach could include engineered 
protein-specific binding ligands [10] and derivatives of extracellular matrix molecules 
that possess a high affinity for specific proteins, such as fibronectin [318, 319]. 
Ultimately, the incorporation of specific affinity molecules into biomaterials may 







While significant research has focused on developing materials for growth factor 
delivery, our approach to spatially control local BMP-2 diffusion presents a novel 
strategy to address clinical concerns of supraphysiological growth factor dose exposure. 
The mismatch between in vitro and in vivo results observed in this study also highlights 
an important caveat in developing biomaterials for in vivo applications. While growth 
factor loading and release performed in vitro provides valuable information about a 
biomaterial’s ability to function as a delivery vehicle, it does not necessarily recapitulate 
the in vivo injury environment, and can lead to an overestimation of a material’s growth 
factor loading capacity and underestimation of its growth factor release. Thus, the results 
of this study may provide insight into the development of other heparin-based protein 
delivery systems by demonstrating the importance of evaluating materials in serum-
containing environments, to better mimic the complex in vivo environment and take 





CHAPTER 8: SEQUESTRATION AND DELIVERY OF STEM CELL 




Stem cells are functionally defined as cells that possess the ability to self-renewal 
and differentiate into a variety of mature cell types, making them a promising cell source 
for many regenerative medicine applications. Current tissue engineering research has 
expanded beyond the initial premise of using stem cells as a means of directly replacing 
diseased and damaged cell populations, resulting in a broadened interest in their utility. 
The unique properties of stem cells have led to their more widespread use for other 
applications, such as in vitro screening platforms for pharmaceutical testing and models 
of predictive toxicology [323, 324]. Furthermore, recent research has also revealed that 
complex mixtures of stem cell-secreted soluble factors can exert beneficial paracrine 
effects on other cell populations, thereby enabling transplanted stem cells to serve as 
reservoirs of secreted factors in vivo that can influence endogenous cell populations to 
repair and regenerate damaged tissues through a variety of mechanisms [79]. This is 
contrary to the traditional notion that transplanted stem cells directly contributed to tissue 
repair through stable engraftment and differentiation and represents a paradigm shift in 
the way researchers consider applying stem cells for regenerative medicine, placing 
emphasis on both the viability of the cells themselves and duration, amount, and efficacy 
of soluble factors they secrete. 
Pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced 
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pluripotent stem cells (iPSCs), which were described in more detail in Chapter 2, are 
particularly promising candidates for exploiting paracrine factor secretion, since concerns 
of tumorigenicity and low cell engraftment often impede their in vivo transplantation 
[325]. Moreover, ESCs are known to secrete a number of growth factors and other 
biomolecules that play key roles in development [50, 79, 235], and subsequently may 
also be harnessed for tissue regeneration. 
Previous studies have used mass spectrometry and antibody-based approaches to 
identify a myriad of soluble factors that make up the ESC secretome, including a number 
of fibroblast growth factors (FGFs), transforming growth factors (TGF-βs), insulin-like 
growth factors (IGFs), Wnts, insulin-like growth factor binding proteins (IGFBPs), bone 
morphogenetic proteins (BMPs), vascular endothelial growth factors (VEGFs), and 
growth differentiation factors (GDFs), as well as stromal cell-derived factor-1 (SDF-1) 
and stem cell factor (SCF) [48-51]. Many of these growth factors have been implicated in 
tissue development and regeneration, and several studies have attributed positive 
outcomes observed in vivo following ESC transplantation to various stem cell-secreted 
factors. For example, transplantation of ESCs following myocardial infarction resulted in 
improvements in heart function, potentially due to ESC-secreted VEGF, IGF-1, and IL-
10 [80], while injection of ESCs into an embryonic mouse model of cardiac defects, 
rescued a normal cardiac phenotype through increased Wnt5a and IGF-1 secretion and 
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without cell engraftment [326]. Similar results have also been demonstrated in vitro, in 
studies wherein ESC-conditioned media elicited proliferation and migration of progenitor 
cells and terminally differentiated cells, including muscle satellite cells, neural progenitor 
cells, fibroblasts, endothelial cells, and hematopoietic progenitor cells [7, 8, 51, 52]. 
Despite the promising results that have been attributed to ESC paracrine effects 
thus far, few researchers have attempted to deliver stem cell secreted factors without 
transplanting the cells themselves [8, 82]. The short half-life and high diffusivity of 
soluble factors in vivo coupled with the dilute nature of these molecules in ESC-
conditioned media present significant technical challenges to developing paracrine-based 
tissue regeneration strategies. Consequently, we aimed to develop a robust biomaterial 
approach for concentrating ESC-derived morphogens and providing their enhanced 
delivery both in vitro and in vivo. 
We have previously developed heparin-based microparticles that demonstrate a 
high capacity for BMP-2 (>1000 times greater than other heparin-based materials), as 
well as a number of other heparin binding proteins [107]. These microparticles can be 
used to locally concentrate large amounts of growth factor, while maintaining growth 
factor bioactivity and ability to induce functional cellular responses. Heparin-based 
biomaterials have been used extensively for the sequestration and delivery of various 
growth factors, including BMP-2, VEGF, and FGF-2 [112, 173, 327-329], due to 
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heparin’s natural ability to strongly and reversibly bind positively charged proteins with 
its negatively charged sulfate groups [91]. However, heparin biomaterials have not 
previously been used to sequester and concentrate multiple proteins of interest from a 
complex mixture of biomolecules such as conditioned media. 
In this first proof-of-concept study, we aimed to harness the promiscuous growth 
factor binding ability of heparin to selectively enrich a number of potent stem cell-
derived morphogens from ESC-conditioned media, while excluding cellular wastes and 
metabolites. Conditioned media was collected from ESC aggregates undergoing 
differentiation and analyzed via proteomics analysis such as SDS-PAGE and mass 
spectrometry to demonstrate that multiple proteins from conditioned media could be 
sequestered by heparin microparticles. Morphogen-laden microparticles were then 
delivered to multiple cell types in vitro to assess their ability to induce functional cellular 
responses, such as cell proliferation and differentiation. Finally, since stem cell paracrine-
based strategies may eventually be used in conjunction with existing growth factor 
delivery therapies, the ability to co-deliver the potent osteogenic protein BMP-2 with 
ESC-derived morphogens from conditioned media was also investigated in vitro to 




8.2 Materials and Methods 
	
8.2.1 Embryonic Stem Cell Culture 
 
Undifferentiated murine embryonic stem cells (mESCs, D3 cell line; ATCC) were 
maintained and expanded on tissue culture polystyrene plates (Corning) coated with 0.1% 
gelatin (Millipore), in high glucose Dulbecco’s Modified Eagle Medium (DMEM; 
Corning Mediatech) containing 16% fetal bovine serum (FBS; Thermo Scientific – 
Hyclone), 1X Minimal Essential Media (MEM) non-essential amino acid solution 
(Corning Mediatech), 2 mM of L-glutamine (Corning Mediatech), 100 units/mL of 
penicillin (Corning Mediatech), 100 µg/mL of streptomycin (Corning Mediatech), 0.25 
µg/mL of amphotericin (Corning Mediatech), 0.1 mM of β-mercaptoethanol (Sigma 
Aldrich), and 100 units/mL of leukemia inhibitory factor (LIF; Millipore), as previously 
described [330]. Media was completely exchanged every two days, and cells were 
passaged after reaching ~80% confluence. 
 
8.2.2 Embryoid Body Formation, Culture, and Conditioned Media Collection 
 
Embryoid bodies (EBs) were formed from undifferentiated mESCs using a forced 
aggregation technique, as previously described [330-332]. mESCs were trypsinized using 
0.05% trypsin-EDTA (Thermo Fisher Scientific) and plated at a density of 1.2 million 
cells/well in 24-well 3% agarose inserts containing ~1200 individual 400 µm x 400 µm 
pyramidal microwells, in order to create ~1200 uniform embryoid bodies containing 
	 196 
~1000 cells each. 500 µL of 16% FBS in DMEM were added to the microwell inserts, 
which were centrifuged at 3000 rcf for 5 minutes to remove air bubbles; 500 µL of 
mESCs at a density of 2.4 million cells/mL were then added to the microwells, allowed to 
settle for 5 minutes, and centrifuged at 200 rcf for 3 minutes. Embryoid bodies were 
maintained in microwell inserts in serum-containing media without LIF for 
approximately 20 hours to promote aggregation and then removed from the microwells 
and suspended in non-adherent, bacteriological grade polystyrene Petri dishes at a density 
of ~1200 EBs per 10 mL of media. 
Embryoid bodies (EBs) were cultured on a rotary orbital shaker set to 45 rpm in 
serum free media, consisting of 1X N2 and B27 supplements (Thermo Fisher Scientific), 
1X MEM non-essential amino acid solution, 2 mM of L-glutamine, 100 units/mL of 
penicillin, 100 µg/mL of streptomycin, 0.25 µg/mL of amphotericin, and 0.1 mM of β-
mercaptoethanol in KnockOutTM DMEM (Thermo Fisher Scientific). Media was 
completely exchanged and collected after 4, 7, 9, 10, 11, 12, 13, and 14 days of culture; 
the frequency of media exchanges increased over time as the total number of cells in 
culture increased, and media became exhausted more quickly. Collected conditioned 
media was centrifuged at 3000 rcf for 10 minutes to remove any cellular debris and 
stored at -20°C until use. Unconditioned media was generated by incubating serum free 
media without cells in Petri dishes at 37°C on rotary culture for 48 hours prior to use, in 
order to permit protein adsorption and degradation similar to that which would occur in 




8.2.3 Embryoid Body Characterization 
 
Phase images were taken of EBs before and after initial formation in microwells 
and at Day 4, 7, 10, 12 and 14 of differentiation in Petri dishes. EBs were also collected 
at each of these time points for histological analysis as previously described [330]. EBs 
were sampled from Petri dishes, washed once in PBS, and fixed in 10% neutral buffered 
formalin at 4ºC for 30 minutes, before being washed in 1% polysorbate 20 and 1% BSA 
in PBS. Fixed EBs were then embedded in 2% (w/v) agarose in PBS at 4ºC overnight, 
dehydrated through submersion in a series of alcohol and xylene solutions, and embedded 
in paraffin wax at 60°C. 5 µm sections were obtained and stained with Safranin O/Fast 
Green and Hematoxylin/Eosin (H&E). 
 
8.2.4 Analysis of Conditioned Media Protein Content 
	
Total protein content of EB conditioned media samples was determined using a 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific) according to 
manufacturer’s instructions and normalized to the protein content of unconditioned media 
samples. Specific growth factors of interest in conditioned media samples were evaluated 
using enzyme linked immunosorbent assay (ELISA) kits for BMP-2, BMP-4, VEGF, and 





8.2.5 Loading Heparin Microparticles with EB Conditioned Media 
	
Heparin microparticles were loaded with EB conditioned media similar to loading 
with a single growth factor solution [107]. 0.2 mg of microparticles were incubated with 
either 1 mL or 5 mL of conditioned media collected from each aforementioned time point 
and rotated at 4ºC for 16 hours. The microparticles were then centrifuged at 3000 rcf for 
5 minutes, washed once in PBS to remove any loosely bound media components, and 
used for SDS-PAGE analysis, mass spectrometry, or functional cellular assays. Day 1-4 
EB conditioned media depleted of microparticle-binding components were also assayed 
for remaining BMP-4 and VEGF using ELISA.  
For loading with both conditioned media and BMP-2, microparticles were either 
(1) incubated in 30 ng of BMP-2 in 1 mL of 0.1% BSA in PBS for 16 hours first, 
followed for 16 hours of incubation in conditioned media, (2) incubated in conditioned 
media first, followed by incubation in BMP-2, or (3) BMP-2 was added directly to the 
conditioned media and microparticles were incubated in both simultaneously. BMP-2 
loading efficiency from conditioned media was evaluated using ELISA.  
 
8.2.6 Removal of Proteins from Heparin Microparticles 
	
It was necessary to elute proteins bound to heparin microparticles for SDS-PAGE 
and mass spectrometry analysis, and these methods are described in the respective 
sections below. Removal of proteins was confirmed using a fluorescamine binding assay 
[333], since fluorescamine fluoresces in the presence of free amines and can be used to 
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determine the amount of protein remaining on a sample of heparin microparticles. 0.01% 
(w/v) fluorescamine (Sigma Aldrich) in acetone was added to 0.1 mg of heparin 
microparticles in a 1:3 fluorescamine to sample volume ratio, and the solution was read 
on a microplate reader (Biotek) at an excitation of 390 nm and emission of 475 nm. The 
fluorescent signal intensity was compared to that of a glycine standard curve (0.05-8 
µg/mL). 0.1 mg of heparin microparticles were loaded with PBS (no protein control), 1 
mg of BSA in PBS, 150 ng of BMP-2 in PBS, and 1-5 mL of Day 1-4 EB conditioned 
media. Microparticles were washed once with PBS, treated for SDS-PAGE analysis, or 
treated for mass spectrometry analysis (trypsin treatment) to determine the efficacy of 
each of these protein removal methods; results were compared to that of untreated, 
protein-loaded microparticles and unloaded microparticles. 
 
	
8.2.7 Gel Electrophoresis and Silver Staining 
 
In order to characterize the proteins in EB conditioned media samples that bound 
to heparin microparticles, eluted proteins from microparticles were analyzed via sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver 
staining for all proteins bands [334], as well as protein mass spectrometry. For SDS-
PAGE analysis, 0.2 mg of heparin microparticles were incubated in solutions as indicated 
in Table 8.1 and Table 8.2 at 4°C, prepared as mentioned above, and resuspended in 
SDS-PAGE loading buffer, containing a mixture of SDS, Tris-HCl, glycerol, 
bromophenol blue, and β-mercaptoethanol. Soluble BMP-2 was also suspended in SDS-
PAGE loading buffer and run on the gel as an additional control. All solutions were 
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heated to 95°C for 10 minutes prior to loading onto a 12% Mini-PROTEAN TGX gel 
(Bio-Rad Laboratories, Hercules, CA). Gel electrophoresis was performed in SDS/PAGE 
running buffer under reducing and denaturing conditions using a Mini-PROTEAN Tetra 
Cell system (Bio-Rad) set at a constant voltage (200 V) for 30 minutes. A 10-250 kDa 
protein ladder (Precision Plus Kaleidoscope, Bio-Rad) was used as a molecular weight 
reference. Silver staining of SDS/PAGE gels was performed using a Silver Staining Plus 
Kit (Bio-Rad) as per the manufacturer’s instructions, rinsed, and imaged using a 
CanoScan LiDE 220 Flatbed Scanner (Canon USA, Melville, NY). 
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8.2.8 Mass Spectrometry 
	
Mass spectrometry was also used to further characterize a) proteins in Day 1-4 EB 
conditioned media samples and b) proteins bound to heparin microparticles from Day 1-4 
EB conditioned media. For conditioned media samples, 100 µL of each sample were 
digested with 2 units of Glu-C (16 hours) and 10 units of Lys-C (3.5 hours) in 50 mM 
HEPES (pH=7.9). For protein-loaded microparticle samples, 0.2 mg of microparticles 
were incubated in 5 mL of conditioned media overnight, then centrifuged, washed once 
with PBS, and digested with 2 units of Glu-C (16 hours) and 10 units of Lys-C (3.5 
hours) in 50 mM HEPES (pH=7.9). Peptides from all samples were then purified, dried, 
and resuspended in 5% acetonitrile and 4% formic acid for liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis. Detailed mass spectrometry methods 
can be found in Chapter 7 and in the listed references [294, 296, 335]. 
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8.2.9 C2C12 Alkaline Phosphatase Activity and DNA Assays 
	
Mouse skeletal myoblasts (C2C12; ATCC) were cultured in growth media 
consisting of DMEM (Corning) supplemented with 16% FBS and maintained at 37ºC in a 
5% CO2 humidified incubator. Alkaline phosphatase (ALP) and DNA content assays 
were performed as previously described [107]. C2C12 cells were seeded in 96-well plates 
at an initial density of 20,000 cells per well and allowed to attach for 6 hours under 
growth conditions (16% FBS in DMEM). Cells were then switched to low serum media 
(1% FBS in DMEM), and the following treatments were added: 0.1 mg of unloaded 
heparin microparticles, EB conditioned media, 0.1 mg of microparticles loaded with 0.5 
mL of EB conditioned media (1x MPs), 0.1 mg of microparticles loaded with 2.5 mL of 
EB conditioned media (5x MPs), and EB conditioned media depleted of microparticle-
binding components. Conditioned media collected after 4, 7, 10, 12, and 14 days of EB 
differentiation were tested. Low serum (1% FBS) and high serum (16% FBS) media were 
used as controls. After 72 hours of treatment, cells were washed with PBS and lysed 
using 100 µL of CelLytic M (Sigma Aldrich). Cell lysate was stored at -80ºC prior to 
analysis.  
ALP activity of C2C12 cultures was measured by incubating 50 µL of cell lysate 
with 50 µL of CelLytic M and 100 µL of a substrate solution consisting of 3.33 mM 
MgCl2 (VWR), 500 mM 2-amino-2-methyl-1-propanol (Sigma Aldrich), and 6.67 mM p-
nitrophenyl phosphate (pNPP; Sigma Aldrich). The reaction was terminated with 0.2 M 
NaOH after one hour, and absorbance measured at 405 nm on a microplate reader. A 
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standard curve for total ALP activity was generated using graded concentrations of the 
ALP product, 4-nitrophenol (0-1 nmol/µL; Sigma Aldrich). 
DNA content of C2C12 cultures was measured using the QuantiFluor dsDNA kit 
(Promega). Briefly, 20 µL of cell lysate was incubated with 80 µL of the assay buffer and 
100 µL of the fluorescent DNA-binding dye for five minutes, protected from light. 
Fluorescence was measured on a microplate reader, using an excitation wavelength of 
504 nm and emission wavelength of 519 nm. Total DNA content was correlated to 
fluorescence by comparison to a lambda DNA standard curve (48.5 kb). Fold-change in 
DNA was determined by dividing the final DNA content after 72 hours of culture by 
DNA content after 6 hours of initial cell attachment (Day 0). 
	
8.2.10 NIH/3T3 DNA and Cell Proliferation Assays 
	
Mouse embryonic fibroblasts (NIH/3T3; ATCC) were cultured in growth media 
consisting of DMEM (Corning) supplemented with 16% FBS and maintained at 37ºC in a 
5% CO2 humidified incubator. DNA content assays were performed as previously 
published [107] and were described for C2C12 cells in the preceding section. NIH/3T3 
cells (20,000 cells/well) were treated with the following for 72 hours: 0.1 mg of unloaded 
heparin microparticles, EB conditioned media, 0.1 mg of microparticles loaded with 0.5 
mL of EB conditioned media (1x MPs), 0.1 mg of microparticles loaded with 2.5 mL of 
EB conditioned media (5x MPs), and EB conditioned media depleted of microparticle-
binding components. Conditioned media collected after 4, 7, 10, 12, and 14 days of EB 
differentiation were tested. Low serum and high serum media were used as controls. 
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EdU (5-ethynyl-2’-deoxyuridine) incorporation was used to evaluate active DNA 
synthesis as an indication of cell proliferation [336]. Since Day 1-4 EB conditioned 
media had a greatest effect on NIH/3T3 DNA content, treatment with 0.2 mg of 
microparticles loaded with 1 mL of Day 1-4 EB conditioned media was compared to 
treatment with 0.2 mg of unloaded microparticles, low serum medium, and high serum 
medium. The Click-iT® Edu Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific) was 
used according to manufacturer’s instructions and previously established protocols [336]. 
10,000 cells were plated in a 25 mm x 75 mm well of a glass chamber slide (NuncTM 
Lab-TekTM II Chamber SlideTM System, Thermo Fisher Scientific) and allowed to attach 
in 16% FBS in DMEM overnight. Media was then removed and replaced with low serum 
(1% FBS) media for the next 8 hours to slow cell proliferation. Following this, cells were 
subjected with the aforementioned treatments for a total of 24 hours, in which 10 µM of 
EdU was added to the cultures for the last 6 hours. EdU was allowed to incorporate into 
cellular DNA over this period of time, after which cells were fixed in 3.7% 
paraformaldehyde in PBS for 30 minutes, permeabilized with 0.5% Triton-X in PBS for 
20 minutes, and stained with Hoechst 33342 (1:2000 dilution) for cell nuclei and Alexa 
Fluor 488 hydrazide for EdU detection via a copper-catalyzed click reaction. 
 
8.2.11 Analysis of C2C12 and NIH/3T3 Cell Morphology 
 
Morphological differences in C2C12 cultures caused by treatment with Day 1-4 
EB conditioned media-loaded microparticles were analyzed using rhodamine-conjugated 
phalloidin staining for visualizing filamentous actin (Thermo Fisher Scientific). 10,000 
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cells were plated in a 25 mm x 75 mm well of a glass chamber slide, allowed to attach in 
16% FBS in DMEM overnight, and treatments were added. After 24 hours of treatment, 
cells were fixed in 3.7% paraformaldehyde in PBS, permeabilized with 0.5% Triton-X in 
PBS, and stained with rhodamine-conjugated phalloidin (165 nM) and Hoechst 33342 
(1:2000 dilution). 
	
8.2.12 Statistical Analysis 
 
All data are reported as mean ± standard error of the mean. Experiments were run 
with a minimum of four replicates for each experimental group. Statistical significance 
was determined using one-way or two-way ANOVA as appropriate, followed by 
Bonferroni’s post hoc analysis (Graphpad Prism, Version 5.0, La Jolla, CA). P < 0.05 




8.3.1 Embryoid Body Characterization 
 
Embryonic stem cells were aggregated into 1000-cell embryoid bodies in agarose 
microwells over 20 hours and cultured on a rotary orbital shaker at a density of 1200 EBs 
per 10 mL of serum-free media for 14 days (Figure 8.1). Phase images before and after 
initial formation (Figure 8.1) and at 4, 7, 10, 12, and 14 of rotary suspension culture 
(Figure 8.2A-E) depict EBs increasing in size from ~200 µm in diameter initially to >750 
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µm in diameter at Day 14. Images of EBs stained with Hematoxylin/Eosin (Figure 8.2F-
J) and Safranin O/Fast Green (Figure 8.2K-O) demonstrate that this increase in EB area is 
due mainly to an increase in cell number, as indicated by the number of hematoxylin-
stained cell nuclei. Histology images also demonstrate areas of extracellular matrix 
deposition at later time points (indicated by arrows), as well as tightly packed, epithelial-





Figure 8.1. Schematic of Embryoid Body Culture. Undifferentiated embryonic stem cells were 
formed into embryoid bodies in agarose microwells overnight using a forced aggregation 
technique and then cultured in suspension for 14 days on a rotary orbital shaker. Images depict 
cells in microwells following centrifugation, after ~20 hours of formation, and in rotary 




Figure 8.2. Size and Morphology of Differentiating Embryoid Bodies. A-E) Phase images of 
EBs in rotary suspension culture at Day 4, 7, 10, 12, and 14 of differentiation depict EBs 
increasing in size over time. EBs were also fixed, embedded in paraffin, and sectioned for 
histological analysis at the aforementioned time points. F-J) Images of EBs stained with 
Hematoxylin/Eosin and K-O) Safranin O/Fast Green depict aggregates that increased in size and 
cell number over time and contained areas of extracellular matrix (black arrows) at later time 
points. ESCs within EBs demonstrated both epithelial-like and mesenchymal-like morphologies 
(yellow arrowheads and black arrowheads, respectively). All scale bars = 500 µm. 
	
8.3.2 Conditioned Media Characterization 
 
A BCA protein assay was used to determine the protein content of media 
conditioned by EBs during Day 1-4, Day 4-7, Day 9-10, and Day 11-12, and Day 13-14 
of differentiation, and normalized to the protein content of unconditioned media. EB 
conditioned media was found to contain between 200-500 µg/mL of secreted protein with 
higher protein content in Day 1-4 EB conditioned media compared to media from later 
time points (Day 9-10, Day 13-14) (Figure 8.3A). Individual ELISAs for proteins in Day 
4-7, Day 7-10, and Day 10-12 EB conditioned media revealed variable levels of BMP-4 
and VEGF, consistent levels of IGF-2, and no detectable BMP-2 (Figure 8.3B). 
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8.3.3 Characterization of Microparticle-Bound Conditioned Media Proteins 
 
The abundance of proteins in cell conditioned media makes analysis of individual 
protein types difficult. We have previously demonstrated that heparin microparticles can 
be used to sequester specific heparin-binding proteins from both fetal bovine serum 
(Chapter 7) and conditioned media [337], resulting in a reduction in bovine serum 
albumin content, which can mask other less abundant proteins, and an enrichment in 
smaller, 15-37 kDa proteins, enabling easier protein detection. Consequently, ESC and 
EB conditioned media samples from multiple time points of differentiation were 
incubated with heparin microparticles, and the loaded proteins were eluted and 
qualitatively assessed via SDS-PAGE following by silver staining (Figure 8.3C).	
SDS-PAGE revealed a prominent BSA band in the unconditioned media lane (red 
box) followed by minimal staining for additional proteins. On the other hand, lanes 
containing EB conditioned media proteins exhibit both a reduced presence of BSA (red 
box) and increased staining for a number of protein bands within the 10-20 kDa and 25-
37 kDa molecular weight ranges (blue boxes). Furthermore, the protein content in these 
samples appeared to be dependent on the stage of EB differentiation from which the 
conditioned media was taken, as multiple dark bands were evident at earlier time points 
of differentiation (Day 1-4, Day 4-7, and Day 9-10 EB conditioned media). 
Microparticles loaded with conditioned media from undifferentiated ESCs demonstrated 
fewer protein bands with less intense staining than that of EB conditioned media. 
Select ELISAs were also performed on Day 1-4 EB conditioned media and 
depleted conditioned media following overnight incubation with heparin microparticles. 
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Based on the amount of growth factor remaining in solution, heparin microparticles 
bound 47.6 ± 7.5% of VEGF and 88.6 ± 2.8% of BMP-4 contained in EB conditioned 
media (Figure 8.4A), demonstrating that sequestration of specific heparin-binding 




Figure 8.3. Characterization of Protein Content of EB Conditioned Media and Conditioned 
Media Loaded Microparticles. A) A BCA protein assay was used to determine total protein 
content of EB conditioned media. Media contained ~200-500 µg/mL of additional secreted 
protein, when normalized to unconditioned media protein content. Day 1-4 EB conditioned media 
contained more secreted protein than conditioned media collected from Day 9-10 and Day 13-14. 
(* = p < 0.05 as indicated) B) ELISAs for BMP-4, VEGF, and IGF-2 content in Day 4-7, Day 7-
10, and Day 12-14 EB conditioned media revealed that EB conditioned media collected from 
different time points contained varying amounts of BMP-4 and VEGF, and consistent amounts of 
IGF-2. BMP-2 was not detected. (% = p < 0.05 compared to BMP-4 content at other time points, 
# = p < 0.05 compared to VEGF content at other time points.) C) SDS-PAGE gel stained with 
silver stain to non-specifically detect all proteins eluted from heparin microparticles. 0.2 mg of 
microparticles were loaded overnight with 5 mL of unconditioned media, undifferentiated ESC 
conditioned media, and conditioned media from Day 1-4, Day 4-7, Day 9-10, Day 11-12, and 
Day 13-14 of EB differentiation. Proteins were eluted from microparticles in SDS-PAGE loading 
buffer after being heated for 10 minutes at 95ºC. Red dashed box represents BSA band, and blue 
dashed boxes represent proteins within the 10-20 kDa and 25-37 kDa ranges that were detected in 














































































































































8.3.4 Depletion of Conditioned Media Components by Heparin Microparticles with or 
without Exogenous BMP-2 Addition 
 
Future in vivo applications of heparin microparticles as delivery vehicles for EB 
conditioned media may require the addition of other potent proteins to help stimulate 
initial cellular responses. Since BMP-2 was not detected in conditioned media, additional 
recombinant BMP-2 would likely be necessary to develop this tissue engineering strategy 
for bone regeneration. Thus, the ability of heparin microparticles to deplete both 
conditioned media and exogenously added BMP-2 from solution was evaluated. 
Heparin microparticles depleted ~90% of BMP-2 from solution when added prior 
to conditioned media incubation, following conditioned media incubation, or together 
with conditioned media (Figure 8.4B). This depletion of BMP-2 from solution was 
similar to what has been observed previously in a single growth factor solution 
containing BMP-2 alone [107] and multiple growth factor solution containing BMP-2 
and VEGF (Figure 3.6), indicating minimal interference of conditioned media 
components on BMP-2-heparin microparticle interactions. BMP-2 loading onto heparin 
microparticles in the presence of 0.1% BSA in PBS, unconditioned media, and Day 1-4 
EB conditioned media was confirmed via SDS-PAGE followed by silver staining and 
compared to protein staining in the soluble BMP-2 lane (Figure 8.4C); blue dashed boxes 
indicate BMP-2 bands. Similar to Figure 8.3C, the BSA bands in most microparticle-
eluted samples were reduced compared to the BSA band in the soluble BMP-2 lane (red 
dashed boxes). Furthermore, when microparticles loaded with five times the volume of 
media (0.2 mg microparticles in 5 mL media vs. 1 mL media) were treated and run on the 
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gel, the densities of the protein bands increased, indicating that the total amount of 
protein bound to the microparticles also increased. This increase in the intensity of other 
protein bands was accompanied by a similar increase in the intensity of the BSA band. 
 
Figure 8.4. Analysis of Microparticle-Mediated Protein Depletion from Conditioned Media 
With or Without Exogenous BMP-2 Addition. A) Heparin microparticles incubated with Day 
1-4 EB conditioned media overnight at 4ºC depleted 47.6 ± 7.5% of VEGF and 88.6 ± 2.8% of 
BMP-4 from solution. B) Microparticles bound ~90% of BMP-2 from solution when 30 ng of 
BMP-2 was added prior to conditioned media incubation, following conditioned media 
incubation, or when BMP-2 and conditioned media were added to microparticles simultaneously. 
C) SDS-PAGE gel stained with silver stain to detect all proteins eluted from microparticles. 0.2 
mg of microparticles were loaded overnight with the solutions described in Table 8.2. Before 
running SDS-PAGE, proteins were eluted from microparticles in SDS-PAGE loading buffer. 30 
ng of soluble BMP-2 were also heated in loading buffer and run on the gel as an additional 
control. Red dashed box indicates BSA band, and blue dashed boxes indicate BMP-2 bands. 
 
8.3.5 Dissociation of Proteins from Heparin Microparticles 
	
Dissociation of proteins from heparin microparticles was required for both SDS-
PAGE and mass spectrometry analysis. A fluorescamine assay was conducted on protein-
loaded microparticles treated for SDS-PAGE (10 min at 95ºC in SDS-PAGE loading 
buffer) and mass spectrometry (overnight trypsin digestion) and compared to protein-
loaded microparticles that were washed once in PBS without any additional treatment. 
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Analysis of untreated microparticles revealed that 1296 ± 8 ng of BSA/mg microparticles 
bound from a 1 mg/mL BSA solution (~0.01%), 1349 ± 60 ng of BMP-2/mg 
microparticles bound from a 150 ng/mL BMP-2 solution (~90%), 461 ± 35 ng of 
protein/mg microparticles bound from 1 mL of conditioned media, and 631 ± 49 ng of 
protein/mg microparticles bound from 5 mL of conditioned media (Figure 8.5). The high 
efficiency of BMP-2 loading further corroborated a strong affinity between heparin 
microparticles and BMP-2 compared to the weak interactions between heparin 
microparticles and BSA. Additionally, loading heparin microparticles with increased 
amounts of conditioned media (5 mL vs. 1 mL) resulted in higher protein loading. 
Despite the different amounts and types of proteins captured by heparin microparticles, 
both SDS treatment and trypsin treatment resulted in removal of proteins from 
microparticles loaded with BSA, BMP-2, and conditioned media. There were no 
differences in efficacy between the two protein removal methods, and residual protein 






Figure 8.5. Protein Loading and Removal from Heparin Microparticles Based on 
Fluorescamine Assay. Microparticles were loaded with 1 mg of BSA in 1 mL of PBS, 150 ng of 
BMP-2 in 1 mL of PBS, or 1-5 mL of Day 1-4 EB conditioned media. Microparticles were then 
washed once with PBS (No Treatment), washed with PBS and digested with trypsin overnight 
(Trypsin Treatment), or washed once in PBS and heated for 10 minutes at 95ºC in SDS-PAGE 
loading buffer (SDS Treatment). Microparticles incubated in 1 mL of PBS overnight served as a 
“No Protein” control. Fluorescamine was used to evaluate the protein content of microparticles 
based on fluorescence microplate readings and compared to a glycine standard curve (0.05-8 
µg/mL). (# = p < 0.05 compared to microparticles with no protein, * = p < 0.01 as indicated) 
 
8.3.6 Mass Spectrometry Analysis of EB Conditioned Media and Microparticles 
Loaded with EB Conditioned Media 
 
Mass spectrometry proteomic analysis was used as an unbiased approach to 
identify proteins in EB conditioned media and proteins bound to heparin microparticles 
after incubation in EB conditioned media. Prior to investigating this approach with 
conditioned media, heparin microparticles were loaded with single growth factor 
solutions of BMP-2 and TGF-β1 for mass spectrometry analysis; positive identification 
of these proteins confirmed that this method could identify microparticle-bound proteins.  
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Day 1-4 EB conditioned media was analyzed, due to the variety of protein bands 
displayed when Day 1-4 EB conditioned media was loaded onto heparin microparticles 
and run on SDS-PAGE (Figure 8.3). Proteins from conditioned media and loaded heparin 
microparticles were digested overnight using trypsin, which effectively removed proteins 
bound to microparticles (Figure 8.5). All proteins detected in EB conditioned media and 
media-loaded microparticles are listed in Table B.1 and Table B.2 in Appendix B. Human 
contaminants, such as keratins, and proteins identified based on two or fewer unique 
peptides were removed from the dataset.  
Overall, mass spectrometry analysis identified 35 proteins in EB conditioned 
media and 169 proteins on conditioned media-loaded microparticles. Clustering of 
microparticle-bound proteins according to cellular compartment (Table 8.3) and 
biological process (Table 8.4) revealed that most proteins identified were intracellular 
and involved in metabolic processes and cellular component assembly. Heat shock 
proteins, as well as histones and ribosomal proteins, which were more frequently 
identified on microparticles, contributed largely to the clustering results. Some notable 
secreted proteins that were identified included left-right determination factor-2 (LEFTY-
2), fibronectin, and osteopontin, as well as several thrombospondins, secreted frizzled 
related proteins (SFRPs), and apolipoproteins. Both thrombospondins and 
apolipoproteins are known heparin binding proteins [93]. The molecular weights of these 
proteins ranged from 10-400 kDa, with many in the 10-37 kDa range of interest identified 




Table 8.3. Cellular Compartment Clustering of Peptides Identified via Mass Spectrometry 
from Heparin Microparticles Loaded with Day 1-4 EB Conditioned Media 
Cellular Compartment Number of Identified Peptides 
Percentage of Total 
Peptides (%) P Value 
Intracellular 163 96.6 1.52E-10 
Cytoplasm 138 81.4 1.24E-10 
Membrane-bounded organelle part 109 64.4 2.79E-03 
Macromolecular complex 97 57.6 6.93E-13 
Nucleus 90 47.5 8.93E-04 
Non-membrane-bounded organelle part 72 42.4 1.17E-08 
Ribonucleoprotein complex 54 32.2 1.80E-14 
Ribosome 46 27.1 1.39E-16 
Nuclear part 26 15.3 7.47E-02 
Vesicles 20 11.9 1.06E-02 
Protein-DNA complex 8 5.08 2.98E-02 
 
Table 8.4. Biological Process Clustering of Peptides Identified via Mass Spectrometry from 
Heparin Microparticles Loaded with Day 1-4 EB Conditioned Media 
Biological Process Number of Identified Peptides 
Percentage of Total 
Peptides (%) P Value 
Cellular metabolic process 126 74.6 4.53E-07 
Protein metabolic process 86 50.8 1.66E-08 
Gene expression 83 49.2 5.38E-08 
Translation 54 32.2 1.21E-16 
RNA processing 28 16.9 4.73E-05 
Cellular component biogenesis 28 16.9 6.35E-04 
Organelle organization 26 15.3 5.91E-02 
Cellular component assembly 20 11.9 1.58E-02 
Macromolecular complex assembly 17 10.2 1.04E-02 
Protein-DNA complex assembly 11 6.78 3.32E-03 
Ribosome biogenesis 11 6.78 9.74E-03 






8.3.7 Response of C2C12 Cells to EB Conditioned Media Delivery 
 
In order to determine whether cell-secreted factors in EB conditioned media were 
capable of inducing functional cellular responses, C2C12 myoblasts were cultured in (1) 
conditioned media delivered solubly, (2) low serum with conditioned media-loaded 
microparticles, or (3) microparticle-depleted conditioned media for 72 hours. C2C12 
DNA content, ALP activity, and morphology were evaluated in response to conditioned 
media exposure. As expected, cells cultured in high serum (16% FBS) media exhibited a 
higher fold increase in DNA content over 72 hours compared to cells cultured in low 
serum (1% FBS) media (11.4 ± 0.1 vs. 3.0 ± 0.1; Figure 8.6A). The addition of unloaded 
heparin microparticles to low serum media decreased the fold change in DNA slightly, 
but not significantly (2.0 ± 0.2), similar to previously observed results [107].   
C2C12 cells cultured in unconditioned serum-free media exhibited a similar fold 
increase in DNA to cells cultured in high serum media, demonstrating that the nutrients 
available in media formulated for ESCs was also sufficient for myoblast growth. 
However, while both unconditioned media-loaded microparticles and depleted 
unconditioned media also resulted in increased growth compared to low serum media, 
this increase was attenuated in comparison to soluble unconditioned media, suggesting 
that only some beneficial factors from unconditioned media were loaded onto heparin 
microparticles and removed from depleted media.  
Conversely, soluble addition of conditioned media from all time points of EB 
differentiation (Day 1-4, Day 4-7, Day 9-10; Day 11-12, Day 13-14 not shown) resulted 
in poor cell growth, with fold increases in DNA lower than that of low serum culture. 
	 217 
This was likely due to the decrease in nutrients and increase in cellular metabolites 
associated with cell-conditioned media. Furthermore, microparticle-depleted conditioned 
media also resulted in poor cell growth, with DNA fold changes somewhat lower than 
that of conditioned media treatment, potentially indicating a removal of beneficial soluble 
factors by microparticle depletion. Lastly, C2C12 culture in low serum media with the 
addition of conditioned media-loaded microparticles had variable outcomes depending on 
the stage of EB differentiation from which the media was collected. Conditioned media-
loaded microparticles from the earliest stage of EB differentiation (Day 1-4) induced 
increases in DNA content over that of low serum media alone. In fact, when the same 
amount of microparticles (0.1 mg) were loaded with five times the volume of conditioned 
media and added to C2C12 cells, the fold change in DNA content almost doubled (from 
6.6 ± 0.6 to 12.2 ± 1.2), such that it was comparable to the culturing cells in high serum 
media (i.e. typical myoblast growth media). This suggests that heparin microparticles 
may be used to concentrate soluble factors from large volumes of conditioned media for 
in vitro delivery. 
Despite positive effects observed using Day 1-4 EB conditioned media, 
conditioned media from other time points did not result in DNA content increases, even 
when conditioned media was loaded onto heparin microparticles. Although the use of 
microparticles to concentrate conditioned media biomolecules resulted in small increases 
in cell growth, these increases were not different from that soluble conditioned media 
treatment or low serum culture. EB conditioned media from Day 11-12 and Day 13-14 
EBs yielded similar results to Day 4-7 EB conditioned media, but these results were 
excluded for simplicity. 
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ALP activity of C2C12 cultures was also investigated under these same 
conditions (Figure 8.7). It has been previously documented that C2C12 cells begin to 
express ALP and other osteogenic markers the presence of BMPs, such as BMP-2 and 
BMP-4, as early as 24 hours after exposure [101]; thus, ALP activity served as a means 
of identifying the osteogenic potential of C2C12 cells in the presence of EB conditioned 
media as well as a means of detecting active BMPs in solution. C2C12 cells incubated in 
low serum, high serum, unconditioned, and conditioned media did not exhibit any 
detectable ALP activity (data not shown). Additionally, cells treated with unloaded 
microparticles did not express ALP, despite previous results that demonstrated an 
increase in ALP activity with unloaded microparticle treatment [107].  
On the other hand, when unconditioned and conditioned media were loaded onto 
heparin microparticles and delivered, C2C12 cells exhibited a positive ALP activity 
response (Figure 8.7A). More specifically, while microparticles loaded with 
unconditioned media and Day 11-12 EB conditioned media induced low levels of 
detectable ALP activity, microparticles loaded with Day 1-4, Day 4-7, Day 9-10, and Day 
13-14 EB conditioned media induced higher ALP activity in comparison. Interestingly, a 
concentration effect similar to that observed with DNA content was observed with ALP 
activity, in which loading larger volumes of Day 1-4 and Day 13-14 EB conditioned 
media onto heparin microparticles (5x MPs) also induced higher ALP activity. 
Furthermore, phalloidin staining for F-actin in C2C12 cultures revealed a reduction in 
multi-nucleated, myoblast-like cells (white arrows) following treatment with Day 1-4 
conditioned media-loaded microparticles (Figure 8.7C, E) compared to low serum media 
alone (Figure 8.7B, D). Taken together, these data suggest that the concentration of 
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Figure 8.6. Effect of EB Conditioned Media on C2C12 and NIH/3T3 DNA Content. C2C12 
myoblasts and NIH/3T3 fibroblasts were plated at an initial density of 20,000 cells/well in a 96-
well plate for 72 hours in low serum media, high serum media, EB conditioned media, and 
microparticle-depleted EB conditioned media, as well as low serum media supplemented with 0.1 
mg of unloaded microparticles and 0.1 mg of microparticles loaded with 0.5 mL or 2.5 mL of EB 
conditioned media overnight. A) Fold change in DNA content of C2C12 cultures after 72 hours 
of treatment. B) Fold change in DNA content of NIH/3T3 cultures after 72 hours of treatment. 
DNA content was normalized to initial Day 0 DNA content. Dashed lines indicate fold change in 
DNA content of cell cultures treated with low serum media and high serum media. (* = p < 0.05 





Figure 8.7. Effect of EB Conditioned Media on C2C12 ALP Activity and Morphology. A) 
For analysis of ALP activity, C2C12 cells were plated at 20,000 cells/well in a 96-well plate for 
72 hours in low serum media, high serum media, EB conditioned media, and microparticle-
depleted EB conditioned media, as well as low serum media supplemented with 0.1 mg of 
unloaded microparticles and 0.1 mg of microparticles loaded with 0.5 mL or 2.5 mL of EB 
conditioned media overnight. Treatment with EB conditioned media and microparticle depleted 
conditioned media did not induce detectable ALP activity, while treatment with conditioned 
media-loaded microparticles induced varying levels of ALP activity. (* = p < 0.05 as indicated, # 
= p < 0.05 compared to unloaded microparticles, % = p < 0.05 compared to microparticles loaded 
with unconditioned media) For F-actin staining, C2C12 cells were plated at an 10,000 cells/well 
in a chamber slide and treated for 24 hours in A, D) low serum media or C, D) low serum media 
supplemented with 0.2 mg of Day 1-4 conditioned media-loaded microparticles. Cells were then 
fixed and stained with rhodamine-conjugated phalloidin and Hoechst. 
  
8.3.8 Response of NIH/3T3 Cells to EB Conditioned Media Delivery 
 
Growth of NIH/3T3 fibroblasts in response to EB conditioned media was also 
evaluated, since fibroblasts are often employed to investigate cell proliferation and have 
been used previously to assess the mitogenic potential of EB conditioned media [7]. 
Similar to C2C12 experiments described above, NIH/3T3 fibroblasts were cultured in (1) 
conditioned media, (2) low serum with conditioned media-loaded heparin microparticles, 
or (3) microparticle-depleted conditioned media for 72 hours. NIH/3T3 cells cultured in 
high serum media also displayed increased DNA content at the end of the culture period 
compared to cells cultured in low serum media (5.6 ± 0.1 fold change vs. 1.5 ± 0.6 fold 
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change; Figure 8.6B); moreover, exposure of NIH/3T3 cells to unconditioned serum-free 
media similarly increased cell growth, although this increase was only significant when 
unconditioned media were loaded on heparin microparticles. 
NIH/3T3 cells exposed to EB conditioned media responded comparably to C2C12 
myoblasts, exhibiting poor cell growth regardless of time point of conditioned media 
collection, especially in the case of the later stages of EB differentiation (Day 4-7, Day 9-
10; Day 11-12, Day 13-14 not shown). However, when EB conditioned media were 
loaded onto heparin microparticles, increases in DNA content were observed in response 
to media from all stages of EB differentiation (Day 11-12, Day 13-14 not shown for 
simplicity). Although delivering microparticles loaded with five times the volume of Day 
1-4 EB conditioned media resulted in a dramatic concentration effect in C2C12 cultures, 
this was not observed in NIH/3T3 cultures; instead, this concentration effect was more 
evident at later conditioned media time points of Day 9-10 and onwards, in which 5x 
MPs induced greater cell growth than 1x MPs. 
EdU staining, demonstrating cell proliferation, further supported the increases in 
DNA content observed in NIH/3T3 cultures. As expected, treatment with low serum 
media resulted in few proliferating cells (Figure 8.8A), while treatment with high serum 
media induced higher cell proliferation (Figure 8.8D). In the case of cultures treated with 
unloaded microparticles, images of cells adhered to the glass slide surface (Figure 8.8B) 
and the microparticles themselves (Figure 8.8E), revealed a low proportion of 
proliferating cells; however, when cultures were treated with Day 1-4 EB conditioned 
media-loaded microparticles, more cells stained positively with EdU on both the glass 
slide surface (Figure 8.8C) and attached to the microparticles (Figure 8.8F). Interestingly, 
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more proliferating cells were found on the microparticles than adhered to the glass slide, 
potentially due to the presence of conditioned media proteins and other ECM molecules 
on the microparticles, promoting cell attachment and subsequent growth. 
 
 
Figure 8.8. Effect of Conditioned Media-Loaded Microparticles on NIH/3T3 Proliferation. 
NIH/3T3 cells were plated in chamber slides at an initial density of 10,000 cells/well, serum 
starved for 8 hours, and treated for 24 hours with A) low serum media, D) high serum media, or 
B, E) low serum media supplemented with 0.2 mg of unloaded heparin microparticles or C, F) 0.2 
mg of Day 1-4 EB conditioned media-loaded microparticles. Cells were pulsed with EdU for 6 
hours before being fixed and stained. Since cells adhered to the microparticles during culture, 
images were taken of both cells adhered to glass slide surfaces (B, C) and cells adhered to 




In this study, we demonstrated that heparin microparticles could be used to 
sequester and deliver a variety of soluble biomolecules from EB conditioned media. 
Microparticles loaded with conditioned media from different stages of EB differentiation 
were analyzed for protein content using a wide variety of proteomic methods, including 
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BCA and fluorescamine assays, ELISA, SDS-PAGE, and mass spectrometry. When 
morphogen-laden microparticles were delivered to in vitro cultures of NIH/3T3 
fibroblasts and C2C12 myoblasts, increases in cell proliferation and alkaline phosphatase 
activity were observed that were absent in cultures treated with conditioned media alone, 
indicating the ability of concentrated ESC-secreted factors to induce functional cellular 
responses. While several studies have previously examined the effects of ESC 
conditioned media on cell phenotype, this study investigates a unique approach to 
conditioned media delivery in which ESC-derived proteins are concentrated and 
delivered in a localized manner via a biomaterial platform.   
One major hurdle in using cell-secreted products for tissue engineering 
applications is the difficulty of characterizing the complex mixture of biomolecules 
present in conditioned media. In this study, we used SDS-PAGE and silver staining to 
visualize the profile of proteins concentrated by heparin microparticles during different 
stages of EB differentiation. We demonstrated that proteins of various molecular weights 
could be concentrated to detectable levels using the protein depletion capacity of heparin, 
while simultaneously reducing the signal of BSA, which does not specifically bind 
heparin but is abundant in cell culture media. Many of the proteins observed were also in 
the expected molecular weight range of a number of heparin binding proteins [93, 94]. 
This method provides a significant advantage in visualizing conditioned media proteins 
on SDS-PAGE gels, as our previous work has demonstrated that when soluble 
conditioned media is run on a gel, the BSA protein band typically floods the gel, 
obscuring other proteins, while more dilute species cannot be detected [337]. Most 
importantly, this technique allowed visualization of clear differences in the heparin-
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bound fraction of proteins secreted by differentiating EBs over time, corroborating results 
which indicate that the ESC secretome changes during differentiation [50, 338].  
Previous analysis of ESC and EB conditioned media using mass spectrometry 
techniques has also revealed a variety of proteins, including a number of secreted growth 
factors and intracellular components [48-50]; thus, we sought to use mass spectrometry to 
further analyze the heparin-bound fraction of the differentiating ESC secretome. Based 
on clustering analysis of 169 proteins found on loaded microparticles, the majority of the 
proteins identified were intracellular and involved in general metabolic processes. Farina, 
et al. previously reported similar results from clustering of ESC proteomic data, as well 
as the presence of a number of comparable proteins, including heat shock proteins (i.e. 
endoplasmin) and ribosomal subunits [50]. Furthermore, Farina, et al. highlighted the 
secretion of isoforms of thrombospondin and Lefty – both of which were also identified 
in our dataset. Several of the proteins we identified in our analysis are also known 
heparin binding proteins, such as thrombospondin-1, thrombospondin-3, apolipoprotein 
B, and apolipoprotein E [93]. 
The abundance of intracellular components identified in EB conditioned media 
was likely due to cell lysis following cell death. However, ELISA analysis of conditioned 
media revealed that growth factors such as BMP-4, VEGF, and IGF-2 were also present 
in relatively dilute concentrations on the order of 10-60 pg/mL. Although we expected 
heparin microparticles to concentrate these growth factors from conditioned media over 
the limit of detection of several proteomics analyses, none of these growth factors were 
identified in mass spectrometry analysis, suggesting that they were present in much lower 
quantities than the intracellular components identified. In future studies, additional 
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upstream processing techniques, such as fractionation, or downstream analysis methods, 
such as iterative elusion of identified proteins, may be employed to improve the 
sensitivity of mass spectrometry for dilute protein species. We have previously separated 
protein fractions using SDS-PAGE followed by in-gel digestion prior to mass 
spectrometry analysis and have obtained similar results to direct digestion of proteins 
from microparticles. Iterative elusion of abundantly identified proteins has been 
successfully used by others to characterize ESC and embryonic fibroblast conditioned 
media samples, resulting in the identification of a number of morphogenic proteins [48]. 
Thus, more sophisticated analysis tools may be required in the future to improve mass 
spectrometry-based approaches to identifying proteins bound to heparin microparticles. 
In addition to characterizing EB conditioned media and its heparin binding 
fraction, the effects of soluble conditioned media and protein-laden microparticles on cell 
phenotype were investigated using two different cell lines. Morphogen-laden 
microparticles induced increases in cell number in cultures of NIH/3T3 fibroblasts and 
C2C12 myoblasts, as well as increases the ALP activity and osteogenic differentiation of 
C2C12 myoblasts. Interestingly, the effects observed were dictated by both the cell type 
and stage of EB differentiation during conditioned media collection. Microparticles 
loaded with conditioned media from the earliest time points of EB differentiation elicited 
the greatest cell proliferation responses, presumably due to the presence of mitogenic 
biomolecules in the media, secreted by EBs that were growing rapidly between Day 4-10. 
Although growth effects were only observed on C2C12 cells with microparticles loaded 
with media collected from Day 1-4 of EB differentiation, growth effects were observed 
on NIH/3T3 cells with microparticles loaded with media collected from all time points, 
	 226 
suggesting different interactions with heparin-presented biomolecules. Similarly, modest 
increases in muscle progenitor cell proliferation have been achieved using the heparin 
binding fraction of human ESC conditioned media, although no biomaterial delivery 
platform was employed [8]. While FGFs and PDGFs both stimulate C2C12 and NIH/3T3 
proliferation [339-341], C2C12 growth is also largely regulated by myostatin and IGF-1 
[342-344]. However, since none of these proteins were detected in our proteomic 
analyses, more information is required to explain the proliferation responses observed.  
One advantage of evaluating conditioned media effects on C2C12 myoblasts is 
that it enables simultaneous investigation of proliferation and differentiation towards 
osteogenic and myogenic lineages. In this study, we found that, although soluble delivery 
of conditioned media did not induce any detectable ALP in cell lysates, conditioned 
media delivery using heparin microparticles resulted in robust ALP induction. More 
specifically, ALP activity was dependent on stage of EB differentiation, and was 
observed following treatment with microparticles loaded with Day 1-4 4-7, 9-10, and 12-
14 EB conditioned media, with Day 1-4 EB conditioned media eliciting the greatest 
response. These data suggest that the heparin binding fraction of conditioned media may 
push C2C12 cells towards a more osteogenic phenotype – a conclusion that was also 
supported by the lack of multinucleated, myogenic-like cells observed in these cultures. 
Although no BMP-2 was detected in conditioned media, appreciable levels of BMP-4 
were detected via ELISA. BMP-4 has been previously shown to induce C2C12 ALP 
activity [104], and thus heparin microparticles may be enriching and presenting BMP-4 
to the cells in a similar manner to BMP-2 delivery [107]. 
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It is important to note that the effects on cell proliferation and ALP activity that 
were observed following treatment of cell cultures with morphogen-laden microparticles 
were not observed with soluble delivery of conditioned media alone. Moreover, in several 
cases, incubating microparticles in an increased volume of conditioned media stimulated 
greater cell responses, suggesting that this approach to conditioned media delivery may 
enrich growth factors responsible for cell proliferation and osteogenic differentiation 
and/or remove cellular wastes and biomolecules that inhibit these processes.  
Ultimately, this study provides initial proof of concept that heparin-based 
microparticles can be used to sequester and subsequently deliver ESC-derived 
morphogens from cell conditioned media. Few other studies have attempted to use 
biomaterial-based platforms for conditioned media delivery, with the most notable of 
these being self-assembling peptide nanofibers that can be soaked in conditioned media 
to form a hydrogel [345, 346] and heparin-containing hyaluronic acid hydrogels that can 
enhance the effects of morphogens secreted by encapsulated cells [125, 126]. Despite 
some positive effects, challenges still exist in identifying the proteins that were 
sequestered by these materials and contributed to the results observed. Herein, we used 
several methods of proteomic analysis to further investigate the components of the ESC 
secretome captured by heparin microparticles, revealing differences in the profiles of 
proteins secreted at various stages of EB differentiation; however, additional studies are 
required to identify the biomolecules that were responsible for the proliferation and 
differentiation effects. 
These experiments were completed using a non-degradable form of heparin 
microparticles that allows for long-term entrapment of proteins for analysis and delivery 
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and has previously exhibited enhanced growth factor (BMP-2) presentation when 
cultured in vitro in direct contact with cells [107]. Future studies may be conducted using 
degradable heparin-PEG microparticles [120], which may be better suited to morphogen 
delivery for in vivo studies. Degradable heparin microparticles would allow for the 
delivery of highly concentrated molecular cargo while also providing enhanced release of 
bioactive proteins, such that these proteins can influence more cells throughout the tissue 
of interest. Furthermore, as this platform for conditioned media delivery is developed, the 
sequestration of proteins from other cell conditioned media can be considered. For 
example, similar mass spectrometry analysis of microparticles loaded with media 
conditioned by adherent human mesenchymal stem cells (MSCs) revealed fewer 
intracellular proteins than EB conditioned media (47% clustered as extracellular space) 
and a number of heparin binding proteins, including fibronectin, collagen, 
apolipoproteins, and thrombospondins, and IGFBPs (Tables B.3 and B.4 in Appendix B). 
Thus, MSC-conditioned media may also be investigated in the future as a source of 
potent morphogens.  
Finally, in the context of this thesis work, we demonstrated that the potent 
osteogenic morphogen BMP-2 could be co-sequestered with EB conditioned media using 
heparin microparticles. Since the bone healing cascade involves a series of events 
characterized by a wide variety of morphogens and cell phenotypes [1], the co-delivery of 
a complex mixture of cell secreted morphogens, including VEGF, BMP-4, and IGF-2 
identified in EB conditioned media, may target multiple stages of the bone healing 
cascade and enhance typical BMP-2-induced bone healing. Future work in this area will 
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involve developing this biomaterial platform for in vivo conditioned media delivery and 




In this study, we demonstrated a novel method to sequester and deliver ESC-
secreted morphogens using a heparin-based biomaterial. This approach enables the 
concentration of desired proteins, without collecting cellular metabolites that may have 
detrimental effects on target cell populations. By exploiting the growth factor binding 
properties of heparin in a biomaterial platform, these concentrated growth factors can be 
delivered to cell cultures and tissue injury sites in a more localized manner than a bolus 
injection of soluble conditioned media. Future work in this area will involve further 
characterization of the key heparin-bound proteins responsible for the positive effects 










CHAPTER 9: CONCLUSIONS AND FUTURE DIRECTIONS 
	
9.1 Contributions to the Field 
 
This innovative two-fold approach aimed to improve current growth factor 
delivery strategies by both creating a heparin-based affinity biomaterial for clinically 
approved BMP-2 delivery and investigating heparin-bound PSC morphogens as a source 
of growth factors for the treatment of bone injuries. Thus, this work presents significant 
contributions to bone tissue engineering, affinity-based biomaterial design, and the 
translation of stem cell-based therapeutics, as outlined below.  
 
9.1.1 Fabrication of a Novel Affinity-Based Biomaterial 
 
Heparin-based materials have thus far demonstrated an inconsistent ability to 
improve osteogenesis and bone regeneration within critically sized bone defects [101, 
105, 106, 116]. This work resulted in the creation of a novel microparticle-based delivery 
vehicle, which consists purely of heparin, and thus can incorporate and retain large 
amounts of growth factor. The spatial concentration of molecular cargo that can be 
achieved using heparin microparticles enabled highly localized delivery of BMP-2 doses 
needed to stimulate endogenous repair mechanisms, while minimizing rapid growth 
factor diffusion and spatially limiting bone formation. As a result, heparin microparticles 
may provide more effective delivery of clinically relevant doses of BMP-2 than the 
clinical collagen sponge delivery system in humans, thereby improving outcomes and 
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reducing adverse events. Furthermore, given that heparin exhibits promiscuous binding 
for a number of different growth factors, this biomaterial presents a versatile delivery 
system that may be used for other protein delivery applications in the future.  
 
9.1.2 Development of a Computational Model Describing In Vivo BMP-2 Diffusion 
 
Since heparin microparticles can be dose-dependently incorporated into tissue 
engineering constructs, they enable truly tunable growth factor delivery systems. 
Computational modeling of affinity-based biomaterials provides a significant advantage 
for developing these systems with the appropriate features to attain desired protein 
release profiles. The computational model of BMP-2 release developed within this work 
predicted BMP-2 release kinetics for different BMP-2 and microparticle doses, as well as 
different microparticle loading regimes, following in vivo implantation in the bone defect 
site; this information drastically reduced the number of conditions that required in vivo 
testing and highlighted potential reasons for the differences in in vivo outcomes observed 
with microparticle-mediated delivery. While several other computational models of 
affinity-based growth factor delivery have been reported [248, 257, 258, 260], this model 
is one of the few that attempts to describe BMP-2 release in vivo within the implantation 
site of interest. The COMSOL-based framework of this model also enables easy 
adjustment of diffusion coefficients of the biomaterial and surrounding tissue, or the 
interactions between the protein and affinity ligand, such that this model can be widely 
applied to a number of affinity-based growth factor delivery systems.   
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9.1.3 Ability to Enrich and Deliver Cell-Secreted Morphogens as a Cell-Free Therapy 
 
Heparin microparticles can also be used to selectively enrich growth factors from 
a complex mixture of biomolecules found in cell-conditioned media, thereby enabling 
concentration of desired proteins, without collecting cellular metabolites that may have 
detrimental effects on target cell populations. By exploiting the growth factor binding 
properties of heparin in a biomaterial platform, we demonstrated that concentrated 
growth factors could be delivered to multiple mature cell types in vitro, resulting in 
higher potency than the delivery of dilute conditioned media components alone. In the 
future, heparin microparticles could serve as a platform to sequester, concentrate, and 
deliver complex mixtures of morphogens to tissue injury sites in a more localized manner 
than a bolus injection of conditioned media itself. The long term goal of this approach is 
to one day eliminate the need for stem cell transplantation by harnessing the regenerative 
potential of PSCs through their secreted proteins. 
	
9.2 Future Directions 
	
The work completed within the scope of thesis has broadened the current 
understanding of affinity-based delivery systems for bone tissue engineering and stem 
cell paracrine factor delivery.  The promising results achieved within this work motivate 
further development of this growth factor delivery platform and present new 
opportunities to investigate the effects of growth factor delivery on in vitro cell fate and 
in vivo tissue regeneration. 
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9.2.1 Tunable Affinity-based Delivery Systems 
 
Perhaps the most recognizable new avenue of research stemming from this work 
is the investigation of degradable heparin-based delivery systems. The pure heparin 
microparticles developed and evaluated within this thesis were fabricated from 
methacrylamide-modified, covalently cross-linked heparin [128], which did not facilitate 
hydrolytic degradation and reduced susceptibility to heparinase-mediated degradation. 
Heparin microparticles delivered to in vitro cell cultures remained visibly intact 
throughout the entire culture period [107], while heparin microparticles delivered in vivo 
to the femoral bone defect were likely taken up by phagocytic cells or swept into the 
bloodstream, although a portion of these microparticles were also found in the defect site 
after 12 weeks post-surgery (Chapter 4). Despite being non-degradable and releasing 
<20% of bound BMP-2, BMP-2-loaded heparin microparticles still induced BMP-2 
signaling events in skeletal myoblasts, which were enhanced when microparticles and 
cells were cultured in direct contact [107]. BMP-2-loaded microparticles also stimulated 
considerable mineralization in the femoral defect site using both low and high doses of 
BMP-2, further confirming the maintenance of microparticle-bound BMP-2 bioactivity. 
These findings corroborated previous results that demonstrated the enhancement of BMP-
2 bioactivity in the presence of soluble GAGs [101, 104] and supported the theory that 
growth factor presentation enabled by ECM molecules may be as influential as growth 
factor release. 
More recently, efforts have been led to fabricate degradable heparin-based 
microparticles, which offer greater tunability in heparin content and subsequent growth 
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factor release kinetics. Temenoff and colleagues reported the fabrication of heparin-
functionalized PEG microparticles and bulk hydrogels, in which heparin content could be 
varied from 1-10% of the total dry hydrogel weight [120, 347, 348], and degradable or 
non-degradable cross-linkers could be employed via Michael Type addition [120, 348]. 
Degradable heparin microparticles may increase the bioavailability of delivered growth 
factors by facilitating greater release. These materials also offer the additional advantage 
of incorporating both native and selectively desulfated heparin, allowing further 
manipulation of growth factor affinity and reducing heparin’s anticoagulant effects [144, 
349]. Other groups have also fabricated similar degradable heparin-containing materials, 
including heparin-functionalized alginate and PEG hydrogels [187, 350]. 
While we successfully modulated the properties of our bulk alginate/PCL 
constructs by changing the total number of 100% heparin microparticles incorporated 
into the system, the use of 1-10% heparin-functionalized microparticles and selectively 
desulfated heparin species may provide alternative methods of easily changing the 
heparin content (and subsequent affinity ligand density) of the system. The use of 
heparin-functionalized alginate could also be used to more directly alter the heparin 
content of the system without drastically changing the cross-linking density of the bulk 
alginate hydrogel. These approaches represent more advanced engineering strategies for 
modulating the growth factor sequestration properties of heparin-based materials and 
warrant further investigation in the future. 
On the other hand, given that heparin is a naturally occurring affinity molecule, 
the ability to manipulate its growth factor binding properties is limited. While timed 
material degradation and modification of electrostatic binding affinity provide tunability 
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for heparin-based systems, “bottom-up,” modular creation of synthetic affinity-based 
delivery systems may offer an alternative method of controlling growth factor release. 
Several groups have developed ligands with high affinity for specific therapeutic proteins 
of interest using naturally occurring biomolecules as templates. Hubbell and colleagues 
demonstrated that the fused growth factor and integrin binding domains of fibronectin 
(FN III9-10/12-14) exhibited increased affinity for a number of heparin-binding growth 
factors [134, 135], while Murphy, et al. developed specific protein-binding ligands for 
VEGF by isolating its receptor (VEGFR2) [272, 334]. Conversely, proteins with 
heightened affinity for specific ligands have also been engineered. These include modular 
peptides with bioactive BMP-2 domains fused to mineral binding domains, which enable 
binding to calcium phosphate coatings [351], and growth factors containing Src 
homology 3 (SH3) domains, which can be differentially captured by low and high affinity 
SH3 binding ligands [260, 352]. 
Synthetic ligands with specific protein affinity have the additional advantage of 
circumventing issues caused by non-specific protein binding, which may reduce the 
overall loading capacity of a material for the protein of interest and accelerate its release. 
In Chapter 7, we demonstrated that competitive binding of serum components, such as 
fibronectin, apolipoproteins, and thrombospondins, for heparin could interfere with BMP-
2 binding and release from heparin microparticles; we expect that a similar phenomenon 
may also occur following in vivo implantation of heparin-based materials into protein-
rich injury environments, and may result in off-target effects. Conversely, when materials 
containing specific protein binding ligands, such as VEGF receptor ligands, were 
investigated in the presence of serum, VEGF binding was not reduced in the presence of 
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whole serum, serum-borne heparin, or exogenously added heparin, indicating strong and 
specific affinity for VEGF [334]; interestingly, VEGF release from VEGFR-containing 
microparticles was increased in the presence of serum due to competitive binding of 
proteins to VEGF and not the affinity ligand [256]. These studies highlight both the 
utility of specific affinity ligands and the challenges of creating ligands with the 
characteristics needed for sustained release in different environments. 
The ability to create synthetic affinity ligands for proteins of interest using a 
variety of methods has dramatically increased the potential of affinity-based protein 
delivery vehicles. A number of technologies have emerged that can be used to better 
design affinity ligands for particular applications [10], such as screening affinity ligands 
using cell-surface display methods, selecting high affinity ligands using competitive 
binding and directed evolution of peptides, and designing desired protein-ligand 
interactions computationally. These methods may enable the selection of ligands with 
well-defined dissociation constants and highly specific binding affinities for a single 
protein. In the context of protein delivery for tissue regeneration, these technologies 
could generate of a range of affinity ligands that provide precise, customizable protein 
release, allowing for more systematic investigation into the effect of protein release on 
tissue healing and creation of delivery vehicles with more optimal release kinetics. 
 
9.2.2 Multiple Growth Factor Delivery 
 
Despite the drawbacks of the promiscuous binding nature of heparin for effective 
single growth factor delivery, it is important to note that this characteristic can also be 
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harnessed for other applications. There are several instances in this work in which we 
utilize the non-specific protein sequestration abilities of heparin-based microparticles for 
the entrapment and delivery of multiple growth factors. In Chapter 3, we demonstrated 
that heparin microparticles could be used for the sequential delivery of BMP-2 and 
VEGF, while in Chapter 8, we used heparin microparticles to capture multiple stem cell-
derived factors from embryonic stem cell conditioned media.  
The use of heparin-based materials for the delivery of numerous other 
biomolecules has been reported in literature [163-165, 348]; additionally, we have 
recently published on the use of these same heparin methacrylamide microparticles for 
the sustained delivery of interferon gamma (IFN-γ) to modulate the behavior of 
mesenchymal stem cell aggregates [353]. Thus, it should be unsurprising that the high 
protein loading capacity of heparin can be harnessed to deliver multiple growth factors 
simultaneously from heparin-containing materials. A number of previous studies have co-
delivered BMP-2 and VEGF using other biomaterials in an attempt to improve 
revascularization of large bone defects in concert with remineralization [194, 195, 354]. 
It has been hypothesized that preceding remineralization with a revascularization phase, 
similar to the natural bone healing cascade, may accelerate healing by increasing local 
exposure to circulating biomolecules and cells [193]. However, previous dual delivery 
approaches have required the fabrication of complex delivery systems with multiple 
materials to provide sequential growth factor release. We have demonstrated the 
fortuitous sequential release of VEGF followed by BMP-2 using heparin microparticles 
as a single delivery vehicle, likely due to natural differences in affinity to heparin. Future 
work may focus on investigating the dual delivery of VEGF and BMP-2 from heparin 
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microparticles in vivo, as a strategy to target both vascular and mineral deficits in large 
bone defects. Previously, in our femoral defect model, we have demonstrated that 
multiple growth factor delivery (BMP-2, TGF-β3, VEGF) results in modest gains in 
mineral volume [239, 355]; thus, this approach may be better suited to tissue defect 
models with compromised vasculature, such as composite models of muscle and bone 
injuries, which have also been developed in our laboratory [356]. 
The delivery of multiple recombinant growth factors represents a “bottom up” 
modular approach to tissue regeneration, which limits the investigation to 2-3 
recombinant growth factors at a time. Conversely, the use of ESC morphogens presents a 
“top down” biomimetic approach to tissue regeneration, in which the effects of a complex 
mixture of growth factors from cells with high regenerative capacity can be explored. 
This initial work examining the sequestration and delivery of ESC-derived morphogens 
using heparin microparticles was the first step in developing a platform to harness the 
paracrine effects of pluripotent stem cells to enhance tissue regeneration. Our initial goal 
was to develop ESC morphogen-laden microparticles as an alternative strategy for bone 
repair; however, while morphogen-laden microparticles induced ALP activity in C2C12 
myoblasts, this was the only indicator of osteogenic potential observed throughout these 
studies, and no osteogenic proteins were detected in mass spectrometry analyses. In the 
future, directed osteogenic differentiation of embryoid bodies may be employed to 
increase the secretion of osteogenic growth factors [357]. In vivo studies may be 
conducted in the rat femoral defect model to evaluate stem cell morphogen-laden 
microparticles as a method to supplement BMP-2 delivery, thereby decreasing 
supraphysiological BMP-2 doses in favor of the mitogenic effects of stem cell 
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morphogens demonstrated in this work. Additionally, stem cell morphogen-based 
therapies are currently being applied to other tissue regeneration applications in our 
laboratory, including dermal wound healing and hindlimb ischemia. Taken together, 
these approaches may eventually provide new insight into the synergistic, regenerative 
effects of stem cell morphogens on mature mammalian tissues.   
We expect that the work completed on complex protein delivery using heparin 
microparticles will also open doors to other sequestration-based approaches to tissue 
regeneration. The ability to capture and concentrate numerous cell-secreted and serum-
borne morphogens using biomaterials may provide novel, facile means of analyzing cell-
secreted products and potentiating cell growth and differentiation through dynamic 
feedback between cells and biomolecules. Because many morphogens are heparin 
binding growth factors, GAG-based biomaterials are prime candidates for sequestering 
cell-secreted proteins. In a recent study by Yousef, et al., heparin-coated Sepharose beads 
were used to concentrate stem cell-derived, heparin binding growth factors for in vivo 
delivery [8]. However, thus far, no study has attempted to deliver soluble stem cell-
derived factors via heparin materials. 
Heparin-based morphogen sequestration is not limited to the collection of 
morphogens from cell conditioned media alone. In the future, heparin materials may also 
be used for the in vivo sequestration of circulating biomolecules to enhance their effect 
within a site of interest. This concept has been recently explored in a study by Liu, et al., 
in which empty chitosan hydrogels delivered following myocardial infarction increased 
both local SDF-1 concentrations and c-kit+ cell recruitment [358]. This mechanism of 
action may have also been responsible for some of the recent results reported by Healy 
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and colleagues, in which heparin-containing hyaluronic acid hydrogels containing cardiac 
progenitor cells (CPCs) and TGF-β1 sequestered CPC-secreted soluble factors in vitro 
and induced a neovascular response in vivo [125, 126]. As a long term goal, in vivo 
morphogen capture could be combined with the material-based mass spectrometry 
techniques we have developed within this work, such that heparin microparticles could be 
explanted and purified following implantation in the femoral defect site to provide 
valuable information about the proteins sequestered in vivo. 
As a final future avenue of research stemming from complex protein 
sequestration, heparin microparticles could also be developed as a platform to concentrate 
and capture dilute biomolecules from complex solutions for proteomic analysis. We have 
begun to demonstrate this concept in the proteomic analysis reported in Chapter 8; 
however, additional work is required to ensure that proteins of interest are concentrated 
beyond their levels of detection. A similar platform has been recently reported using the 
thermosensitive polymer, poly-nisopropylacrylamide (pNIPAm), which can easily 
absorbing proteins from in vitro cell cultures and protein-rich body fluids [359, 360]. 
pNIPAm hydrogels are highly porous, charged materials with tunable mesh sizes, which 
allow them to act as molecular sieves to capture biomolecules of specific sizes while 
excluding others. Consequently, pNIPAm microparticles have been successfully used as 
molecular sieves to separate and concentrate dilute proteins of interest such as insulin, 
SDF-1, and myoglobin from complex protein mixtures, while excluding more abundant 
proteins such as albumin and immunoglobins on the basis of size [361]. pNIPAm has also 
been used to isolate proteins biomarkers for diseases from body fluids. The most notable 
of these is PDGF, which can be captured and concentrated 10-fold from a large volume 
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of human serum into a small volume of pNIPAm microparticles and subsequently 
shielded from proteolytic degradation prior to analysis [361]. Given that heparin binds 
and similarly protects proteins on the basis of electrostatic interactions, heparin 
microparticles engineered with different mesh sizes could be used to concentrate 
positively charged, heparin binding proteins of specific molecular weights. Using SDS-
PAGE analysis, we have demonstrated in this work that heparin microparticles can 
concentrate less abundant proteins from both serum and cell conditioned media, while 
reducing BSA capture. This characteristic of heparin microparticles lends itself to further 
development for somewhat selective protein capture. Furthermore, since both SDF-1 and 
PDGF are known heparin binding growth factors [347, 362], heparin microparticles could 
be used to concentrate these biomarkers in a manner similar to pNIPAm microparticles. 
Although the promiscuous binding nature of heparin may reduce its ability to very 
precisely capture single proteins from solution, heparin microparticles could still be used 
to drastically reduce the complex nature of protein rich solutions. 
 
9.2.3 Clinical Application 
 
The eventual goal of designing a novel growth factor delivery system for tissue 
regeneration is clinical application. Since BMP-2 has already been approved for clinical 
use via a absorbable collagen sponge [4], improving current BMP-2 delivery strategies 
ideally involves the creation of readily translatable delivery vehicles with low adoption 
barriers for orthopedic surgeons. The alginate/PCL construct described throughout this 
work consists of clinically approved biomaterials [363, 364] with BMP-2 or BMP-2-
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containing heparin microparticles pre-loaded into the injectable hydrogel phase. Despite 
its ease of use, the method for implantation of this tissue engineering construct differs 
considerably from current methods for collagen sponge implantation, in which the sponge 
is typically soaked in BMP-2 solution and press-fit into the bone defect [6, 365]. In 
Chapter 7, we incorporated empty heparin microparticles into a PCL nanofiber mesh tube 
to serve as a barrier to BMP-2 diffusion from the collagen sponge; this approach was 
designed for use with standard clinical procedures to facilitate easy adoption in the future. 
However, the lack of success demonstrated in vivo with this system encourages the 
development of other methods of incorporating heparin microparticles into BMP-2 
delivery vehicles.  
Perhaps the most clinically relevant method of delivering heparin microparticles 
that has not yet been investigated in this work is the incorporation of microparticles into 
the absorbable collagen sponge. Several groups have fabricated porous collagen sponges 
and collagen sponge composites by physically entangling or chemically cross-linking 
collagen fibers into hydrogels and lyophilizing them to create sponges [116, 261, 366-
369]. Furthermore, soluble GAG chains [116, 367] and alginate, chitosan, and glass 
microparticles [370-372] have been successfully integrated into collagen sponges using 
these methods. We have conducted some preliminary studies to attempt to incorporate 
heparin microparticles into collagen hydrogels at a density of 1 mg of microparticles per 
150 µL of collagen gel, which was the highest microparticle density used in alginate 
hydrogels used throughout this work. Since heparin microparticles can be lyophilized for 
long term storage, much like the collagen sponge, the heparin microparticle/collagen 
hydrogel composite material can similarly be lyophilized until use. Moreover, in Chapter 
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3, we demonstrated that BMP-2-loaded microparticles could be lyophilized, while 
maintaining BMP-2 bioactivity. This gives us the choice of two BMP-2 loading regimes, 
in which composite sponges could come pre-loaded with a fixed concentration of BMP-2, 
simply requiring re-hydration upon implantation, or unloaded composite sponges could 
be soaked in BMP-2 solution immediately prior to delivery. It is expected that the 
presence of high affinity heparin microparticles would greatly increase the BMP-2 
loading capacity of the low affinity collagen sponge and significantly attenuate the 
detrimental burst release of BMP-2 from this material. Future studies in this area could 
investigate incorporation of heparin microparticles into both collagen hydrogels and 
collagen sponges at various densities, following by in vivo comparison to the clinically 
used collagen sponge in the rat femoral defect model. Overall, we expect that the 
development of multiple biomaterial platforms in which heparin microparticles can be 
















% Specify the bounds for the diffusion coefficient in cm^2/s 
lowbound = 10e-15;                             
upbound = 10e-4;  
  
% Set options for running the fmincon 
% Enable plotting of the results 
options = optimset('PlotFcns',{@optimplotfval,@optimplotstepsize}); 
pmin = 10e-6; 
[pminf,Smin,exitflag,output]=fmincon(@MarianData_ToMinimize,... 
    pmin,[],[],[],[],lowbound,upbound,[],options); 
 
 
FUNCTION TO MINIMIZE 
  




% Parameter to solve for: diffusion of protein 
D_eff = p; % cm^2/s 
  
% Time in seconds for each image 
t = 60*time; % s 
  
% Convert distance to centimeters 
  
x = 10^-4*(Data_X); %cm 
  
% Calculate the value to plug into our erfc, defined in Clauss, et al. 1990 
  
% First, create empty vectors 
y = zeros(length(t),length(x)); % Value to plug into the equation 
C = zeros(length(t),length(x)); % Calculated concentration, as fcn of time and position 
  
% Step through each time point to calculate the input variable, y 
% And the resulting concentration, C 
for i = 1:length(t) 
    y(i,:) = x./(2*sqrt(D_eff.*t(i))); 










ax = gca; 
ax.LineWidth = 1; 







ax = gca; 
ax.LineWidth = 1; 
ax.FontSize = 14; 
  
% Error Function 
S = 0; 
for i = 1:length(x) 
     
    S = S + sum(((C(:,i) - Data_M(:,i))./Data_M(:,i)).^2); 














APPENDIX B: MASS SPECTROMETRY RESULTS 
 
Table B.1. Mass Spectrometry Results for Day 1-4 EB Conditioned Media 







Hsp90aa1 90 kDa Heat shock protein α 84.73 15 12 3.3937 
Hspa8 71 kDa Heat shock protein 70.83 12 11 3.371 
Ncl Nucleolin 76.68 12 8 2.8017 
Hsp90ab1 90 kDa Heat shock protein β (Endoplasmin) 83.23 11 8 3.4602 
Actb Actin, cytoplasmic 1 41.71 10 9 3.2182 
Eno1 α-enolase 47.11 10 8 3.6471 
Serpinc1 Antithrombin-III 51.97 8 6 2.8124 
Aldoa Fructose-bisphosphate aldolase A 39.33 7 4 4.2843 
Prdx1 Peroxiredoxin-1 22.16 7 3 2.9617 
Eef1a1 Elongation factor 1-α 1 50.08 6 6 2.841 
Pkm Pyruvate kinase 57.81 6 5 3.4992 
Eef2 Elongation factor 2 95.25 5 5 2.9917 
Pfn1 Profilin-1 14.95 5 5 2.8193 
Hist1h4a Histone H4 11.36 5 4 2.7632 
Ppia Peptidyl-prolyl cis-trans isomerase A 17.96 4 4 2.5761 
Ywhaz 14-3-3 protein ζ/δ 27.75 4 3 4.4702 
Ybx1 Nuclease-sensitive element-binding protein 1 35.71 4 3 2.9704 
Hspa4 70 kDa Heat shock protein 4 94.07 4 3 2.9065 
Tubb4b Tubulin β-4B chain 49.8 4 3 2.8342 
Hpx Hemopexin 51.29 4 2 2.3923 
Cat Catalase 59.76 3 3 4.0551 
Hspd1 60 kDa Heat shock protein 60.92 3 3 4.0264 
Tkt Transketolase 67.59 3 3 3.8275 
Fkbp4 Peptidyl-prolyl cis-trans isomerase 51.54 3 3 3.0905 




ribonucleoproteins A2/B1 37.38 3 3 2.6214 
Fn1 Fibronectin 272.37 3 3 2.3814 
Kpnb1 Importin subunit β-1 97.12 3 3 2.1949 
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Table B.1. Mass Spectrometry Results for Day 1-4 EB Conditioned Media (Contd) 
	







Hnrnpab Heterogeneous nuclear ribonucleoprotein A/B 30.81 3 2 3.626 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 35.79 3 2 2.9579 
Rps18 40S ribosomal protein S18 17.71 3 2 2.414 
Spp1 Osteopontin 32.44 3 2 4.129 
Hspg2 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
398.04 3 2 3.4984 


































Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles 
	







Iqgap1 Ras GTPase-activating-like protein IQGAP1 188.62 32 34 3.6 
Hsp90aa 90 kDa Heat shock protein α 84.73 22 24 3.2 
Ncl Nucleolin 76.68 20 23 2.9 
Mybbp1 Myb-binding protein 1A 151.94 17 19 3.5 
Apoe Apolipoprotein E 35.84 15 17 3.6 
Hsp90ab 90 kDa Heat shock protein β (Endoplasmin) 83.23 14 17 3.1 
Eef1a1 Elongation factor 1-α 1 50.08 13 18 3.4 
Eif2a Eukaryotic translation initiation factor 2A 64.36 12 14 3.4 
Rpl5 60S ribosomal protein L5 34.38 12 14 2.8 
Ipo5 Importin-5 123.51 12 13 3.5 
Kpnb1 Importin subunit β-1 97.12 12 13 3.5 
Ssb Lupus La protein homolog 47.73 12 13 3.0 
Rps3 40S ribosomal protein S3 26.66 12 12 3.3 
Npm1 Nucleophosmin 32.54 11 14 3.8 
Actb Actin, cytoplasmic 1 41.71 11 14 2.9 
Sf3b1 Splicing factor 3B subunit 1 145.72 11 12 3.9 
Rpl7 60S ribosomal protein L7 31.4 11 12 2.5 
Rps3a 40S ribosomal protein S3a 29.87 10 14 2.8 
Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein 44.69 10 12 3.3 
Fn1 Fibronectin 272.37 10 12 3.0 
Tuba1b Tubulin α-1B chain 50.12 9 11 3.6 
Eno1 α-enolase 47.11 9 10 3.3 
Rpl6 60S ribosomal protein L6 33.49 9 10 3.1 
Rps2 40S ribosomal protein S2 31.21 9 10 2.8 
Pxdn Peroxidasin homolog 165 9 9 3.4 
Rpl13a 60S ribosomal protein L13a 23.45 9 9 2.0 
Tubb4b Tubulin β-4B chain 49.8 8 8 3.5 
Rps4x 40S ribosomal protein S4 29.58 8 8 2.9 
Rps19 40S ribosomal protein S19 16.08 8 8 2.8 
Serpine2 Glia-derived nexin 44.18 8 8 2.8 
Rpl13 60S ribosomal protein L13 24.29 8 8 2.6 
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Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles (Contd) 
	







Rpl23a 60S ribosomal protein L23a 17.68 8 8 2.4 
Rps10 40S ribosomal protein S10 18.9 7 10 2.4 
Hist1h2b Histone H2B type 1-F/J/L 13.93 7 9 2.9 
Top2a DNA topoisomerase 2-α 172.68 7 8 3.7 
Rps6 40S ribosomal protein S6 28.66 7 8 3.0 
Pkm Pyruvate kinase PKM 57.81 7 7 3.8 
Cct4 T-complex protein 1 subunit δ 58.03 7 7 3.3 
Dhx9 ATP-dependent RNA helicase A 149.38 7 7 3.1 
Rps18 40S ribosomal protein S18 17.71 7 7 2.9 
Rps9 40S ribosomal protein S9 22.58 7 7 2.6 
Rpl4 60S ribosomal protein L4 47.12 7 7 2.6 
Hist1h4a Histone H4 11.36 6 11 3.2 
Ybx1 Nuclease-sensitive element-binding protein 1 35.71 6 9 3.9 
Lamb1 Laminin subunit β-1 196.96 6 8 4.4 
Rpl10a 60S ribosomal protein L10a 24.9 6 8 2.8 
Rpl27 60S ribosomal protein L27 15.79 6 8 2.7 
Vcp Transitional endoplasmic reticulum ATPase 89.27 6 7 3.6 
Rpl35a 60S ribosomal protein L35a 12.55 6 7 2.0 
Eif3a Eukaryotic translation initiation factor 3 subunit A 161.84 6 6 3.6 
Lama1 Laminin subunit α-1 337.95 6 6 3.3 
Eef2 Elongation factor 2 95.25 6 6 3.2 
Hnrnpk Heterogeneous nuclear ribonucleoprotein K 50.94 6 6 3.1 
Rsu1 Ras suppressor protein 1 31.53 6 6 3.1 
Rpl7a 60S ribosomal protein L7a 29.96 6 6 2.7 
Fus RNA-binding protein FUS 52.64 5 7 2.9 
Acly ATP-citrate synthase 119.65 5 6 4.0 
Rps15 40S ribosomal protein S15 17.03 5 6 3.9 
Set Protein SET 33.36 5 6 3.8 
Naca Nascent polypeptide-associated complex subunit α, muscle-specific 220.36 5 6 3.7 
Ldha L-lactate dehydrogenase A chain 36.48 5 6 3.3 
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Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles (Contd) 
	







Rpl12 60S ribosomal protein L12 17.79 5 6 2.9 
Psmd3 26S proteasome non-ATPase regulatory subunit 3 60.68 5 5 3.8 
Tubb5 Tubulin β-5 chain 49.64 5 5 3.7 
Api5 Apoptosis inhibitor 5 56.75 5 5 3.6 
Rplp0 60S acidic ribosomal protein P0 34.19 5 5 3.6 
Eif3l Eukaryotic translation initiation factor 3 subunit L 66.57 5 5 3.6 
Rps7 40S ribosomal protein S7 22.11 5 5 3.5 
Rpl18 60S ribosomal protein L18 21.63 5 5 3.5 
Tcp1 T-complex protein 1 subunit α 60.41 5 5 3.4 
Trim28 Transcription intermediary factor 1-β 88.79 5 5 3.2 
D1Pas1 Putative ATP-dependent RNA helicase Pl10 73.1 5 5 3.1 
Rbmxl1 RNA binding motif protein 42.14 5 5 3.1 
Hmgb1 High mobility group protein B1 24.88 5 5 3.1 
Map4 Microtubule-associated protein 117.36 5 5 2.8 
Pabpc1 Polyadenylate-binding protein 70.63 5 5 2.2 
Btf3 Transcription factor BTF3 22.02 4 6 4.5 
Rps17 40S ribosomal protein S17 15.51 4 6 4.3 
Kpna2 Importin subunit α-1 57.89 4 5 4.0 
Rpl3 60S ribosomal protein L3 46.08 4 5 3.1 
Rpl31 60S ribosomal protein L31 14.45 4 5 2.6 
Hnrnpab Heterogeneous nuclear ribonucleoprotein A/B 30.81 4 4 4.1 
Snrpa1 U2 small nuclear ribonucleoprotein  28.34 4 4 3.9 
G3bp1 Ras GTPase-activating protein-binding protein 1 51.8 4 4 3.8 
Rps14 40S ribosomal protein S14 16.26 4 4 3.8 
Eif4a2 Eukaryotic initiation factor 4A-2 46.37 4 4 3.6 
Ilf2 Interleukin enhancer-binding factor  43.04 4 4 3.3 
Rps8 40S ribosomal protein S8 24.19 4 4 3.3 
Aldh2 
Aldehyde dehydrogenase, 
mitochondrial 56.5 4 4 3.2 
Rpl24 60S ribosomal protein L24 17.77 4 4 3.1 
Rif1 Telomere-associated protein RIF1 266.06 4 4 3.1 
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Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles (Contd) 
	







Cct7 T-complex protein 1 subunit 59.61 4 4 3.1 
Eef1d Elongation factor 1-δ 31.27 4 4 3.0 
Cand1 Cullin-associated NEDD8-dissociated protein 1 136.24 4 4 3.0 
Glud1 Glutamate dehydrogenase 1, mitochondrial 61.3 4 4 3.0 
Rpl26 60S ribosomal protein L26 17.25 4 4 3.0 
Ran GTP-binding nuclear protein Ran 24.41 4 4 2.9 
Pygl Glycogen phosphorylase, liver form 97.4 4 4 2.9 
Rps23 40S ribosomal protein S23 15.8 4 4 2.7 
Rpl15 60S ribosomal protein L15 24.13 4 4 2.7 
Kars Lysine - tRNA ligase 67.8 4 4 2.7 
Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3 39.63 4 4 2.6 
Sfrp2 Secreted frizzled-related protein 2 33.45 4 4 2.6 
Snrpb2 U2 small nuclear ribonucleoprotein 25.31 4 4 2.6 
Rps15a 40S ribosomal protein S15a 14.83 4 4 2.5 
Rrbp1 Ribosome-binding protein 1 172.78 4 4 2.5 
Snrnp70 U1 small nuclear ribonucleoprotein 70 kDa 51.96 4 4 2.5 
Sf3b2 Protein Sf3b2 98.14 4 4 2.4 
Ddx5 Probable ATP-dependent RNA helicase DDX5 69.25 4 4 2.4 
Rpl30 60S ribosomal protein L30 12.78 4 4 2.3 
H3f3c Histone H3.3C 15.31 4 4 2.2 
Rplp2 60S acidic ribosomal protein P2 11.64 3 5 3.8 
Sf3b3 Splicing factor 3B subunit 3 135.46 3 4 4.3 
Eif3f Eukaryotic translation initiation factor 3 subunit F 37.96 3 4 4.0 
Fasn Fatty acid synthase 272.26 3 4 3.8 
Nap1l1 Nucleosome assembly protein 1-like  45.32 3 4 3.7 
Rpl9 60S ribosomal protein L9 21.87 3 4 3.7 
Rps24 40S ribosomal protein S24 15.41 3 4 3.6 
Sub1 Activated RNA polymerase II transcriptional coactivator p15 14.42 3 4 3.0 
Sfrp1 Secreted frizzled-related protein 1 35.39 3 4 2.8 
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Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles (Contd) 
	







Rps13 40S ribosomal protein S13 17.21 3 4 2.5 
Hspd1 60 kDa heat shock protein, mitochondrial 60.92 3 3 4.6 
Rpsa 40S ribosomal protein SA 32.82 3 3 4.5 
Lamc1 Laminin subunit γ-1 177.18 3 3 4.2 
St13 Hsc70-interacting protein 41.63 3 3 4.1 
Thumpd1 THUMP domain-containing protein  38.86 3 3 3.9 
Thbs3 Thrombospondin-3 104.05 3 3 3.8 
Cct2 T-complex protein 1 subunit β 57.44 3 3 3.8 
Psme3 Proteasome activator complex subunit 3 29.49 3 3 3.7 
Prpf4b Serine/threonine-protein kinase PRP4 homolog 116.9 3 3 3.6 
Cltc Clathrin heavy chain 1 191.43 3 3 3.6 
Xpo1 Exportin-1 123.01 3 3 3.6 
Dek Protein DEK 43.13 3 3 3.6 
Hspa8 Heat shock cognate 71 kDa protein 70.83 3 3 3.5 
Psmd2 26S proteasome non-ATPase regulatory subunit 2 100.14 3 3 3.5 
Eif3b Eukaryotic translation initiation factor 3 subunit B 91.31 3 3 3.5 
Cul1 Cullin-1 89.63 3 3 3.5 
Hspa1l Heat shock 70 kDa protein 1-like 70.59 3 3 3.5 
Pltp Phospholipid transfer protein 54.42 3 3 3.4 
Aldoa Fructose-bisphosphate aldolase 39.33 3 3 3.3 
Snrpd2 Small nuclear ribonucleoprotein Sm D2 13.52 3 3 3.3 
Vars Valine-tRNA ligase 140.13 3 3 3.3 
Parp1 Poly ADP-ribose polymerase 1 113.03 3 3 3.2 
Hnrnpc Heterogeneous nuclear ribonucleoproteins C1/C2 34.36 3 3 3.2 
Sfpq Splicing factor, proline- and glutamine-rich 75.39 3 3 3.1 
Cul4b Cullin-4B 110.63 3 3 3.1 
Rpf2 Ribosome production factor 2 35.34 3 3 3.1 
Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1 34.18 3 3 3.0 
Rps25 40S ribosomal protein S25 13.73 3 3 2.9 
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Table B.2. Mass Spectrometry Results for Day 1-4 EB Conditioned Media-Loaded 
Microparticles (Contd) 
	







H2afz Histone H2A.Z 13.54 3 3 2.8 
Hmgb2 High mobility group protein B2 24.15 3 3 2.8 
Hist1h1c Histone H1.2 21.25 3 3 2.7 
Tubb1 Tubulin β-1 chain 50.41 3 3 2.7 
Hsd17b4 Peroxisomal multifunctional enzyme type 2 79.43 3 3 2.7 
Uba1 Ubiquitin-like modifier-activating enzyme 1 117.73 3 3 2.7 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 35.79 3 3 2.7 
Rpl17 60S ribosomal protein L17 21.41 3 3 2.7 
Tnpo1 Transportin-1 102.29 3 3 2.6 
Lyar Cell growth-regulating nucleolar protein 43.71 3 3 2.6 




ribonucleoproteins A2/B1 37.38 3 3 2.5 
Rps16 40S ribosomal protein S16 16.44 3 3 2.4 
Rpl36 60S ribosomal protein L36 12.21 3 3 2.3 
Lefty2 Left-right determination factor 41.15 2 2 3.0 
Rpl22 60S ribosomal protein L22 (Heparin-binding protein HBp15) 14.75 2 2 2.8 
	
Table B.3. Cellular Compartment Clustering of MSC Conditioned Media-Loaded 
Microparticles 
 
Cellular Compartment Number of Identified Peptides 
Percentage of Total 
Peptides (%) P Value 
Intracellular 28 82.4 3.91E-02 
Organelle part 18 52.9 1.36E-03 
Extracellular space 16 47.1 9.66E-11 
Protein complex 13 38.2 3.18E-03 
Non-membrane-bounded organelle 12 35.3 1.01E-02 
Extracellular matrix 7 20.6 5.77E-05 
Vesicle 7 20.6 1.99E-03 
Insulin-like growth factor binding protein 
complex 2 5.88 8.08E-03 
Fibrinogen complex 2 5.88 1.41E-02 
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Table B.4. Mass Spectrometry Results for MSC Conditioned Media-Loaded 
Microparticles 
	







THBS1 Thrombospondin-1 129.3 25 27 3.2045 
RRBP1 Ribosome-binding protein 1 152.38 14 16 2.7645 
COL1A1 Collagen α-1 chain 138.86 11 12 2.6359 
FN1 Fibronectin 262.46 10 11 3.0034 
F5 Coagulation factor V 251.55 9 9 2.8696 
ITIH2 Inter-α-trypsin inhibitor heavy chain H2 106.4 7 7 2.6648 
GSN Gelsolin 85.64 6 8 2.8178 
ACTB Actin, cytoplasmic 1 41.71 5 6 2.9129 
EEF1A1 Elongation factor 1-α 1 50.11 5 6 2.7799 
HBA1 Hemoglobin subunit α 15.25 5 8 3.1793 
APOE Apolipoprotein E 36.13 4 5 3.284 
COL1A2 Collagen α-2 chain 129.24 4 5 2.8195 
EDF1 Endothelial differentiation-related factor 1 16.36 3 4 2.8132 
C4A Complement C4-A 192.66 3 3 2.5517 
HMGB2 High mobility group protein B2 24.02 3 4 2.8803 
IQGAP1 Ras GTPase-activating-like protein IQGAP1 189.13 3 3 2.4108 
HMGB1P
1 
Putative high mobility group protein 
B1-like 1 24.22 2 2 2.9811 
LECT2 Leukocyte cell-derived chemotaxin-2 16.38 2 3 2.224 
CHAD Chondroadherin 40.45 2 2 4.7743 
F13A1 Coagulation factor XIII A chain 83.21 2 2 2.8772 
HBD Hemoglobin subunit δ 16.05 2 2 2.7413 
AFP α-fetoprotein 68.63 2 2 2.9331 
APOB Apolipoprotein B-100 515.28 2 2 2.9615 
HMGN1 Non-histone chromosomal protein HMG-14 10.65 2 2 2.6728 
ANXA2 Annexin A2 38.58 2 3 3.752 
HMGB1 High mobility group protein B1 24.88 2 2 3.7922 
HIST1H1
E Histone H1.4 21.85 2 2 2.795 
PKM Pyruvate kinase PKM 57.9 2 4 2.411 
IGFBP3 Insulin-like growth factor-binding protein 3 31.65 2 2 2.404 
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Table B.4. Mass Spectrometry Results for MSC Conditioned Media-Loaded 
Microparticles (Contd) 
	







FLNA Filamin-A 280.56 2 3 2.8689 
IGFBP5 Insulin-like growth factor-binding protein 5 30.55 2 2 3.1013 
KIF5B Kinesin-1 heavy chain 109.62 2 3 2.6433 
RNASE4 Ribonuclease 4 16.83 2 3 3.2315 
THBS4 Thrombospondin-4 105.8 2 2 2.133 
SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 44.94 2 2 3.7359 
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